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Abstract
Colorectal cancer (CRC) patients are stratified by the Tumour, Node and Metastasis
(TNM) staging system for clinical decision making. Additional genomic markers have
a limited utility in some cases where precise targeted therapy may be available. Thus,
classical clinical pathological staging remains the mainstay of the assessment of this
disease. Surgical resection is generally considered curative for Stage II patients,
however 20-30% of these patients experience disease recurrence and disease specific
death. It is imperative to identify these high risk patients in order to assess if further
treatment or detailed follow up could be beneficial to their overall survival. The aim
of the thesis was to categorise Stage II CRC patients into high and low risk of disease
specific death through novel image based analysis algorithms.
Firstly, an image analysis algorithm was developed to quantify and assess the
prognostic value of three histopathological features through immunofluorescence:
lymphatic vessel density (LVD), lymphatic vessel invasion (LVI) and tumour budding
(TB). Image analysis provides the ability to standardise their quantification and
negates observer variability. All three histopathological features were found to be
predictors of CRC specific death within the training set (n=50); TB (HR =5.7; 95%
CI, 2.38-13.8), LVD (HR =5.1; 95% CI, 2.04-12.99) and LVI (HR =9.9; 95% CI, 3.57-
27.98). Only TB (HR=2.49; 95% CI, 1.03-5.99) and LVI (HR =2.46; 95% CI, 1 - 6.05),
however, were significant predictors of disease specific death in the validation set
(n=134). Image analysis was further employed to characterise TB and quantify intra-
tumoural heterogeneity. Tumour subpopulations within CRC tissue sections were
segmented for the quantification of differential biomarker expression associated with
epithelial mesenchymal transition and aggressive disease.
Secondly, a novel histopathological feature ‘Sum Area Large Tumour Bud’ (ALTB)
was identified through immunofluorescence coupled to a novel tissue phenomics
approach. The tissue phenomics approach created a complex phenotypic fingerprint
consisting of multiple parameters extracted from the unbiased segmentation of all
objects within a digitised image. Data mining was employed to identify the significant
x
parameters within the phenotypic fingerprint. ALTB was found to be a more
significant predictor of disease specific death than LVI or TB in both the training set
(HR = 20.2; 95% CI, 4.6 – 87.9) and the validation set (HR = 4; 95% CI, 1.5 – 11.1).
Finally, ALTB was combined with two parameters, ‘differentiation’ and ‘pT stage’,
which were exported from the original patient pathology report to form an integrative
pathology score. The integrative pathology score was highly significant at predicting
disease specific death within the validation set (HR = 7.5; 95% CI, 3 – 18.5).
In conclusion, image analysis allows the standardised quantification of set
histopathological features and the heterogeneous expression of biomarkers. A novel
image based histopathological feature combined with classical pathology allows the




There exists a subset of colorectal cancer (CRC) patients where surgery is considered
curative and where no chemotherapy or further treatment is recommended. There is,
however, a high risk subpopulation within this subset that experience disease
recurrence and die of CRC. It is important to be able to identify these high risk patients
in order to assess if further treatment or detailed follow up could be beneficial.
The literature reports that there are three microscopically observed features within
tissue which have been correlated to disease recurrence and disease specific death:
lymphatic vessel invasion, lymphatic vessel density and tumour budding. They have
not been included into official clinical guidelines for the reporting of CRC due to
variation in results between pathologists when carrying out manual quantification.
This thesis utilises computer based image analysis to help standardise the
quantification of these features and reports on their significance to categorise CRC
patients into high and low risk of disease specific death. This work was carried out on
a training set (n=50) and validation set (n=134) of patients. Although all the features
were significant in predicting disease specific death in the training set only tumour
budding and lymphatic vessel invasion were significant when assessing the larger
validation set.
Although tumour buds are significantly prognostic there is less known about their
characteristics which make them an indicator of aggressive disease. In this thesis,
image analysis is not only used to segment tumour buds for quantification but to
identify proteins displayed by them and not by other parts of the cancer. These proteins
once identified could be used as a drug target to inhibit cancer invasion.
The thesis further discovers a previously unidentified feature, through novel image
based methodology, and which predicts poor patient outcome. This novel feature is
more significant at the prediction of disease specific death than those previously
described for both the training and validation set.
xii
Novel tools within pathology will most likely not replace classical pathology but
augment it and therefore the thesis reports an integrative pathological score which is
compiled of the novel image based feature and two parameters from the original
clinical report. This integrative pathology score is highly significant at stratifying high





Cancer is amongst one of the leading causes of disease related mortality in the world
with 14 million new cases diagnosed each year and 8.2 million cancer related deaths
in 2012(1). Lung, colorectal and either prostate in men or breast in women are the most
common diagnosed cancers worldwide. Despite advances in early detection, surgery
and treatment, these numbers are likely to rise due to, among other reasons, pollution,
an aging population and poor lifestyle choices: smoking, alcohol, poor diet and lack of
exercise(1). Cancer is not one disease but an umbrella term for many diseases
originating from many tissue types and from heterotypic cells of origin. The one
common theme of all cancers is malignant neoplasia. Neoplasia, meaning a new
growth, is the unregulated and autonomous proliferation of cells outwith homeostatic
control(2).Neoplasms may be either benign or malignant and are also referred to by
their more common name of tumour. Malignant tumours, unlike benign ones, have the
capability to invade into neighbouring tissue borders and structures as well as
metastasise(3).Metastasis occurs when cancer cells obtain the ability to invade from
the primary tumour of origin and spread, usually through the vasculature, to a distant
organ where they form a new proliferating neoplastic colony(4). In around 90% of
cancer cases it is the secondary metastatic neoplasm which kills the patient(5).
Malignant tumours are usually spawned from a single cell of origin which, through
multiple steps of mutation or epigenetic aberration, termed the metastatic cascade,
creates a heterogeneous malignant tumour; where at least a subpopulation of which is
capable of metastasis(6). Metastasising adenocarcinoma cells, for example, must not
only be able to lose aspects of their epithelial phenotype in order to break contact and
migrate away from their neighbouring cells but also acquire driver mutations enabling
them to intravasate the vasculature, survive within the blood or lymphatic vessels,
extravasate into and colonise a foreign organ(5, 7). Vogelstein characterised this multi-
2
step progression to neoplasia in 1993(8) and malignancy is now characterised by a
cancer’s evolution to encompass the six major hallmarks of cancer: undergoing
uncontrolled proliferation, replicative immortality, evading growth suppressors,
resisting cell death, inducing angiogenesis and being able to invade and metastasise(9).
1.1.2 Cancer evolution
Primary tumours contain heterogeneous subpopulations of cancer cells which display
differential genotypes and phenotypes, some of which may confer proliferative and
metastatic advantages to the tumour. These subpopulations evolve through a
Darwinian natural selection process which may also be affected by a response to attack
from the host or insult by therapy(10). These populations of heterogeneous cells may
also perform differing functions within the tumour depending on their lineage and
evolutionary hierarchy. These functions could involve angiogenic, proliferative and
Extra cellular remodelling (ECM) remodelling properties to sustain neoplastic growth
and tumour survival(11). This heterogeneity may stem from several sources; clonal
evolution, cancer stem cells, the microenvironment, host interactions or a response to
the chemotherapy itself(12).
The clonal evolution theory states that cancers build up heterogeneous subpopulations
after concurrent mutations over multiple rounds of cell division due to the plasticity of
the cells through chromosomal and replicative instability or exogenous insults(6, 10).
These heterogeneous subpopulations are under the influence of natural selection where
they may acquire mutations which ultimately lead to cell death while others
accumulate a specific set of driver mutations allowing the cancer cells to metastasise.
There are multiple hypotheses on the existence of the cancer stem cell (CSC) model
and the CSCs’ multipotency. CSCs may originate from healthy tissue stem cells(5, 13)
or may have attained their stem-like phenotype through epigenetic alterations of the
genome or through stromal cell interaction from their microenvironmental niche(14).
The stem-like attributes associated with CSCs would confer a certain amount of
plasticity upon it in order for it to evade aggressive treatment regimens or commit to
the metastatic cascade(15). CSCs may have the ability to produce hierarchical
heterogeneous cell subpopulation progenies of which only some are tumourigenic and
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others differentiated(12). CSCs are thought to initiate tumourigenesis, have the ability
to propagate the cancer after chemotherapy and a cure for the patient depends on the
eradication of such self-renewing cells. CSCs also appear to be more resistant to
radiation and chemotherapeutic treatment and may incur tumour recurrence even after
a long period of remission and dormancy(13). The plasticity of CSCs also potentially
allows them not only to undergo an epithelial to mesenchymal transition (EMT) in
order to invade in the first instance, but also to revert back to an epithelial phenotype
and propagate a secondary tumour upon metastasising to a distant organ (15, 16).
1.1.2.1 Epithelial to mesenchymal transition
The epithelial to mesenchymal transition (EMT) is the first step of the metastatic
cascade for adenocarcinomas such as colorectal cancer(5). During EMT cells lose
certain characteristics of an epithelial cell and express a more mesenchymal-like
phenotype(17). This not only enables the cell to disseminate from their epithelial
neighbours through disassembly of cell-cell adhesions and loss of cell polarity, but
allows it to migrate through the extra cellular matrix(18). Loss of E-cadherin, a major
component of cell-cell adhesion complexes and cell polarity, is considered an essential
factor of the EMT (18, 19), and can occur at the invasive edge of colorectal cancer
(Figure 1)(20). The stabilisation of β-Catenin and its subsequent nuclear translocation 
is a hallmark of colorectal cancers(21). β-Catenin loss at the cell membrane, where it 
binds to E-cadherin in cell-cell adhesion complexes, further disrupts the epithelial
phenotype(19). Upon nuclear translocation β-Catenin acts as a transcription factor for 
proliferation, mesenchymal and invasion oncogenes. Zeb1, Snail and Twist proteins
transcriptionally repress E-cadherin and are associated with the mesenchymal
phenotype (15, 18, 19). These families of proteins are also activated by nuclear β-
Catenin either directly or indirectly. Zeb1 also acts as a transcriptional repressor of
EpCAM, another epithelial cell adhesion molecule, to induce EMT(22). A further
inducer of the mesenchymal phenotype is TGF-β which upregulates Snail, Zeb and 
Twist protein expression(23). Interestingly it has been shown that the source of EMT
inducers such as TGF-β and TNFα come from the stromal cells of the 
microenvironment, such as cancer-associated fibroblasts, and from inflammatory
cytokines respectively(23-25). After the cancer cells have disassociated from the
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neoplastic glands they may express enzymes involved in the remodeling of the extra-
cellular matrix (ECM) in order to migrate toward sites of invasion such as the matrix
metalloproteinases (MMPs)(26). Cancer cells may undergo a further transformation in
the form of mesenchymal to amoeboid transition, which is regulated by Rac and Rho
protein expression, whereupon they migrate through the ECM without breaking it
down through proteolysis(11).
Figure 1. Loss of E-Cadherin at the invasive front of CRC. TMA core taken from the invasive front of
a CRC patient tumour block. Neoplastic glands are visualized with antibody against panCK (green) and
counterstained with DAPI (blue). E-Cadherin (red) is not expressed in neoplastic glands at the edge of
the cancer invasion (green box) but is expressed in well differentiated glands located closer to the
tumour centre (red box). Image taken with a x10 objective.
Although the EMT process can become complicated with many interacting proteins
and pathways, it results in a cell which decreases its epithelial cell polarity, its ability
to adhere to neighbouring epithelial cells and increases cell survival and migratory
characteristics. The EMT process also adds to the intra-tumour heterogeneity. In CRC,
for example, well-differentiated neoplastic glands near the centre of the tumour may




Within the tumour and interacting with it is the cancer microenvironment. This is made
up of a heterogeneous colony of cancer cells as well as a complex milieu of non-
cancerous host cells and scaffold proteins including immune and inflammatory cells,
stroma (fibroblasts, myofibroblasts, muscle cells and extra cellular matrix) and
lymphatic and venous vasculature all of which further adds to the inherent
heterogeneous make-up of tumourigenesis(3). The stromal aspect of cancers is thought
to play a role in EMT and to induce stem-like properties in the cancer cell, where the
cancer cells at the invasive front react to mesenchymal stimuli from host cells and not
from within the tumour itself(15). A novel CRC grading system for patient prognosis
has recently been proposed which combines a tumour’s invasive pattern with stromal
desmoplastic reaction(27). Understanding the microenvironment is therefore
important to understand the cancer’s progression as its interaction with the tumour can
aid or hinder the tumour’s evolution to autonomous survival as well as its metastatic
and invasive potential(11, 24, 28). The majority of anti-cancer therapies, either
cytotoxic e.g. FOLFOX (Folinic Acid, Fluorouracil and Oxaliplatin) for colorectal
cancer(29) and CAVE (Cyclophosphamide, Adriamycin, Vincristine, Etoposide) for
lung cancer(30) or targeted trastuzumab for breast cancer(31) and gefitinib for non-
small cell lung cancer(32), are designed against the cancer cell with an attempt to stop
one of the six hallmarks stated above. As the knowledge of the tumour
microenvironment and its role in tumourigenesis grows there has been a shift in effort
within pharmaceutical strategies to target its characteristics rather than the tumour’s
(33-35) in an attempt to stifle the tumour and its invasive capacity. Examples of such
strategies are: bevacizumab(36) and sunitinib(37) which target VEGF and are anti-
angiogenic, induced apoptosis of Treg cells by agonistic anti-OX40 mAb(38) and
repolarization of macrophages by agonistic CD40 mAb(39), marimastat(40) and
neovastat(41) which block matrix metalloproteinases and inhibit the breakdown or
remodelling of ECM. Microenvironmental features such as; microvessel density and
angiogeneisis (42-44), vasculature invasion(45-47) and immune and inflammatory cell
infiltration(44, 46, 48) are being investigated for their clinical use. The prognostic
importance of the immune infiltrate in CRC is becoming ever more apparent(49, 50).
The immune response is not only being utilised as a prognostic tool but also to identify
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novel drug targets such as anti-PD1 to stimulate the anti-tumour immune response of
the patient(51).
When investigating the difference in deregulation of significant pathways involved in
CRC between the epithelium and the stroma Abba et al. showed that epithelial active
pathways were involved mainly in proliferation, while the stromal expression favoured
invasive and angiogenic related pathways(52). They state that the tumour related
stroma is the major determinant of cancer phenotype adding further weight to the
argument that the stroma as well as the primary tumour should be investigated for
prognosis and therapeutically targeted.
1.1.4 Inter-patient heterogeneity
Inter-patient heterogeneity can be classified as patients with the same cancer type but
whose disease differs in molecular, morphological and phenotypic characteristics.
Inter-patient heterogeneity is demonstrated in Figure 2 where two stage II CRC patient
samples express differential Cytokeratin 7.
Figure 2. Cytokeratin 7 inter-patient heterogeneity. TMA cores taken from blocks from 2 different
patient: core A and core B. Core B shows high expression Cytokeratin 7 (red) in the neoplastic cells
(green) and Core A shows no Cytokeratin 7 expression. Image taken with a x10 objective.
Cytokeratin 7Core A Core B
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Driver mutations leading to tumourigenesis can be somatic and sporadic or of germline
descent. They can be caused by genetic or epigenetic aberrations or from exogenous
sources such as viruses(10). Depending on the type of mutagen, morphology,
phenotype and organ or cell type of origin, cancers can be divided into subgroups.
Since the dawn of molecular pathology these subgroups can be further subdivided
depending upon specific molecular characteristics(53, 54). In theory, patients with
similar characteristics may therefore have similar prognosis and be treated with similar
therapy regimens(55, 56). Knowledge of inter-patient heterogeneity, through clinical
and molecular pathology, arms the oncologist with a much more exacting data
repertoire to consult in order to treat the patient successfully. This pathological
knowledge of the difference between patients’ cancer and treatment strategies bears a
much higher success rate in treating patients and their overall quality of life than a
“one treatment fits all”. This is eloquently exemplified in the treatment of CRC over
the last decade. Previous to targeted biological treatment, advanced colorectal patients
were commonly treated with FOLFOX or FOLFIRI (Folinic Acid, Irinotecan and
Fluorouracil)(57, 58). Targeted therapy against EGFR through administration of
cetuximab has since shown promising results with increased progression-free survival
compared to chemotherapy(59). EGFR inhibition, however, only shows benefit to
patients with wild-type KRAS(60, 61) and those patients with mutations downstream
of EGFR such as KRAS, BRAF(62, 63), PIK3CA(64) and NRAS(65) show poor
response or predicts resistance to targeted EGFR therapy such as cetuximab or
panitumumab. In fact it has been shown that monoclonal antibody inhibition of EGFR
in combination with FOLFOX may actually have detrimental effects on patients with
mutant KRAS CRC(66). KRAS and BRAF mutations are also informative concerning
prognosis and disease specific death(53, 67). Although there are multiple
heterogeneous subgroups of colorectal cancer(68) aside from KRAS mutation status,
there are relatively few prognostic and predictive biomarkers routinely used in the
clinic. Further research continues within this field to identify biomarkers for anti-
EGFR therapy resistance(69).
Although colorectal and has been used here as an example, most cancers can be sub-
grouped depending on histological and pathological criteria. This subsequent
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subgrouping can offer information on prognosis and optimal treatment options or
novel drug targets in, for example, breast(70, 71) prostate(72, 73), ovarian(74, 75) and
renal cell carcinoma(76, 77). A reason for recent successes over the past decade in the
targeted treatment of certain cancers is therefore due to accurately identifying
subgroups of patients which are susceptible or resistant to chemotherapy and targeted
treatments, thereby not only guiding the optimal combinatorial therapy, but avoiding
unpleasant or harmful side effects by withholding drugs from patients which will have
little to no advantageous effect for them.
1.1.5 Intra-patient heterogeneity
The ability to stratify patients into subgroups for more efficacious treatment and
prognosis, depending on the characteristics of their whole tumour, has seen recent
advancement and benefit to the patient in terms of progression-free survival. However,
systemic therapy frequently fails and, moreover, highly effective targeted therapies are
not resulting in long term benefits in terms of patient outcome in spite of initial
response(78). There is a danger in treating an individual’s cancer as an entity with
uniform molecular and phenotypic properties. Doing so could be the cause of
recurrence of disease and the reason why some members of a subgroup respond better
than others to their designated treatment(79). The fact that a cancer’s evolution plays
a major role in tumourigenesis is not novel (8, 10, 80), however, it is only more
recently that knowledge is being gathered on how this manifests as intra-tumoural
heterogeneity(12, 14, 15, 79). Quantifying the tumour’s inherent intra-heterogeneity
provides hierarchical data into the molecular, phenotypic and functional properties of
an individual’s cancer and as to whether they will respond positively in the long term
to targeted or personalised therapy.
Molecular pathology has the ability to subgroup patients not only on inter-patient
heterogeneity but also on intra-patient heterogeneity. Intra-patient heterogeneity may
be classed as either intra-tumour heterogeneity or heterogeneity between the primary
tumour and secondary distant metastasis. As the cells in the primary tumour evolve
toward malignancy and express the six major hallmarks of cancer (81), it becomes ever
more heterogeneous. Figure 3 shows the decrease in epithelial-associated markers at
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the invasive front of CRC compared to neoplastic glands closer to the centre of the
tumour. This intra-tumour heterogeneity may confer metastatic and invasive properties
to the cells at the invasive edge(82-84), while the cells nearer the core possess
differential expression patterns(85, 86) and can retain some properties to the
differentiated cells from which they originated.
Figure 3. Examples of subpopulations within the same tissue sample expressing differential protein
signatures. Serial sections of a TMA core taken from the invasive front of a CRC patient tumour block.
Neoplastic glands are visualized with antibody against panCK (green) and counterstained with DAPI
(blue). Membranous β-Catenin (red in section 1) and EpCAM (red in section 2) are not expressed in 
neoplastic glands at the edge of the cancer invasion (green box) but are expressed in the well
differentiated glands located closer to the tumour centre (red box). Image taken with a x10 objective.
The activating mutations in the EGFR pathway of KRAS, BRAF and PIK3CA in CRC
are shown to be differentially detected between the tumour core and invasive front
after macrodissection of primary tumour (87) . In a separate CRC study KRAS and
BRAF heterogeneity was shown when two tissue blocks were sampled per patient
EpCAMβ-Catenin
Intra-patient heterogeneity
Serial section 1 Serial section 2
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instead of just one(88). High grade expression of Laminin-5 gamma chain 2 (LN-
5γ2)(82) and nuclear beta-catenin(21) expression in CRC is predominantly expressed 
at the invasive front rather than at the centre of the primary tumour and the grades of
expression in these distinct areas hold prognostic value. Conversely VEGF and RKIP
expressing cells were found predominantly in the tumour core(86) and not the invasive
front. After discordant results of BRAFV600E mutation status using conventional
sequencing and mutant-specific PCR in melanoma tumours Yancovitz et al., laser-
capture microdissected primary tumours and found most to contain subpopulations of
BRAF mutant and wild type cells(89). These results may explain why some melanoma
patients do not respond well or show disease recurrence when treated with BRAF
inhibitors such as vemurafenib.
As with intra-tumour heterogeneity within the primary tumour there is also
discordance between the molecular profile of the primary tumour and distant
metastasis. In CRC mutant and wild-type KRAS, BRAF and PIK3CA heterogeneity
varies from primary tumour, lymph node metastasis and distant metastasis(87). EGFR
pathway related intra-tumoural heterogeneity could lead to the reporting of false
positive KRAS wild-type status, especially if only the primary tumour is tested, and
could explain why these patients may not respond well to cetuximab and panitumumab
and experience disease recurrence(60, 61). Patients with primary melanomas when
tested for mutational BRAF also carried metastasis with wild-type BRAF and in 5
cases separate metastasis from the same patient carried either wild-type or BRAF
mutations(89).
It is not only molecular differences which confer heterogeneity but morphology and
cell differentiation may vary from tumour core, invasive edge and metastatic sites. The
cells at the invading edge of CRC may be more mesenchymal and undifferentiated as
they undergo EMT and disseminate from the neoplastic glands (20, 27, 90). Although
there is an underlying molecular phenomenon associated with morphological change,
the pathologist need not know the exact mechanism driving this to recognise a
heterogeneous invasive pattern related to poor or good prognosis(91-93). Levels of
necrosis(94, 95), apoptosis(96, 97) and mitosis(98, 99) may also vary across the
primary tumour and be correlated to patient prognosis.
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The importance of the heterogeneous molecular and morphological tumour and its
interaction with the cancer microenvironment is apparent. It is also therefore important
to be able to capture this complex and hierarchical data in a meaningful way in order
to glean as much useful information on an individual’s tumour and thus inform clinical
decision making. The understanding of patient-wide heterogeneity may inform
oncologists on the optimal combination of therapies needed for the patient at a
personalised level rather than at a population based level.
1.2 Tissue Datafication
A wealth of prognostic and predictive information lies within the patient’s tissue
sample. Classical histopathology strives to infer dynamical prediction of disease
progression from the static artefact which is the tissue section. The pathologist directly
observes microscopically the complex diseased tissue and its interaction with the host
microenvironment in order to mentally compute these multiple signals into a
prognosis. This has long been the gold standard in clinical prognosis. Although
multiple novel prognostic methodologies for CRC have been developed to replace or
augment classical pathology, and while some show promise, for example the gene
expression signatures ColoPrint(100) and Oncotype DX® in colon cancer(101), none
have become established within routine CRC clinical prognosis. The classical Dukes
and TNM morphological and histological staging of the disease remains steadfast in
clinical pathology (102-104). One reason for this is standardisation and the
imperfection of tissue. The human eye can account for the variation and artefacts that
occur between surgical removal of the tissue through to mounting sections onto
microscope slides for analysis. Poor and small sample size, imperfection and damage
to tissue as well as poor tissue orientation can be easily disregarded by the pathologist
while they can glean the pertinent information from the final stained tissue section.
Automated quantification, spanning the CRC omics fields(105) of the tissue section
which is not able to be so selective, may return variable results and where
standardisation is a very real problem.
Advances in extracting data in a meaningful and robust manner could add value to
classical histopathology methodologies and provide greater impact and accuracy of
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patient stratification at a more personalised level than current population statistics.
This is increasingly relevant when the quantification techniques take into account the
heterogeneity of the disease and report on it. ‘Datafication’ of tissue is the extraction
of information in a fully quantifiable and standardised manner. This can take the form
of quantifying a single biomarker to capturing a complex and hierarchical multi-modal
omics signature. A single read-out may be extracted from a single tissue sample or
multiple readouts taken across distinct subpopulations identified through
morphometric or biomarker expression.
1.2.1 Quantifying inter-tumour heterogeneity
Understanding tumour heterogeneity is important in striving toward an intelligent and
individualised treatment strategy which translates to clinical impact. To truly fulfil a
personalised medicine approach and select the correct combination therapy for a
patient, it is essential to know which mutational or epigenetic aberrations their cancer
carries in both primary and distant disease and what the subsequent phenotypic and
functional effect on the cells and their microenvironment are.
Since the post omics era scientists have been armed with a suite of new tools to identify
biomarkers to subgroup a patient’s cancer at the molecular level. Using these tools a
raft of data and new biomarkers have been discovered over the last few decades and
allowed genome scale analysis and comparisons (105-108). The three main disciplines
to bear the wealth of the results are genomic, transcriptomic and proteomic studies
whereas work is also on going in epi-genetics. A recent epi-genetic example in CRC
showed hypermethylation of TWIST 1 and TWIST 2 in the stromal compartment of
the microenvironment in well differentiated tumours, whereas there was no
methylation of the gene promoters in tumours with an infiltrative invasive
pattern(109). Epigenetics is especially relevant to CRC where a patient’s cancer can
be subtyped by DNA methylation and correlated to genetic mutations(68, 107).
1.2.1.1 Genomics
The two main technologies at the disposal of investigators into genomic biomarkers
from patient tissue samples are: next-generation sequencing (NGS) and array
comparative genomic hybridization (aCGH). NGS allows cost-effective large scale
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genome wide DNA sequencing of the cancer genome and has led to the discovery of
at least one clinically relevant genetic alteration in 59 % of a group of colorectal and
non-small cell lung cancers revealing two gene fusions C2orf44-ALK and KIF5B-RET
respectively(110) and that the tumour suppressor gene ARID1A is mutated in more
than half of clear-cell ovarian cancer tumours tested(111). NGS’ integration into
clinical practice is comprehensively reviewed by Kohlmann et al(112). aCGH allows
the analysis of gene copy number loss or amplification across the genome. This can
directly translate to driver aberrations in cancers and the heterogeneity of copy number
in a patient population can give rise to patient subgrouping(113). Genetic intra-tumour
heterogeneity was found in cervical cancer after analysing core biopsies from 4
quadrants of the patient’s tumour with aCGH(114). In CRC copy number profiles were
related to stages and metastatic spread where Dukes D patients showed genomic losses
and Dukes C patients showed genomic gains(115). Detection and investigation of
subpopulations using aCGH can therefore identify resistant and sensitive cancer
signatures with prognostic and predictive outcomes. aCGH and its role in cancer
research is reviewed in detail by Micheuls et al (116).
1.2.1.2 Transcriptomics
Quantifying the mutation status at the genomic level alone does not portray the full
picture of how driver mutations affect cellular dysregulation and cancer progression.
Investigating how the genes are expressed through transcription allows insight into the
mutation’s effect on overall cellular control and protein production. Transcriptomics
follows the assumption that patterns of gene expression correlate to cellular function
at the proteomic level(105). Two technologies which allow gene expression profiling
are RNA microarray analysis and high throughput RNA sequencing (RNA-seq),
termed deep sequencing(117). RNA microarray analysis, allowing the genome-wide
analysis of gene-expression, was used to discover a 70 gene expression signature
which identified a poor prognosis signature in lymph node negative breast cancer
patients as well as identifying tumours from BRCA1 carriers(118) leading to
MammaPrint© the first commercial microarray assay used in the breast cancer
clinic(119). Oncotype DX® is also routinely used in the clinic for prognostic value
and looks at a 21 gene signature to predict which patients are at risk of disease
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recurrence(120). Similar approaches in the field of CRC have shown some prognostic
value, however little predictive value, and are currently without FDA approval(121).
A recent study applied gene expression microarrays to discover RNA biomarker
patterns in colorectal patients which can be detected in blood plasma for use in a point
of care companion diagnostic. KIAA1199 transcripts were found to be more abundant
in the plasma of patients with colorectal cancer than the control group(122). Deep
sequencing directly sequences the RNA transcripts from tissue samples, which are
mapped to a reference genome and quantified to assess level of gene expression.
Overexpression of CD151 in all stages of epithelial ovarian cancer was found by RNA-
seq and could become a new anti-invasive target for drug discovery(123). These
studies could result in a predictive test in which patients overexpressing CD151 are
chosen to receive treatment. Both transcriptomic technologies and how they can
complement each other are discussed in more detail by Malone et al(117).
1.2.1.3 Proteomics
Although transcriptomics report valuable information on the pattern of gene
expression, studying the proteome allows the understanding of functional proteomics.
Proteomics research quantifies the transcribed gene’s end product, the protein. The
way that proteins interact in complex signalling pathways, their cellular sub-
localisation and post-translational modification (such as conformation change and
on/off states controlling signal transduction pathways) has impact on cellular control.
In short, proteomics and not simply the gene expression provides insight into the
functional phenotypic effect of the genomic mutation or silencing and what this effect
has on cellular regulation or deregulation. The two technologies employed to analyse
multiple proteins and their interactions from a patient sample are Reverse Phase
Protein Arrays (RPPA) and mass spectrometry. RPPAs allow the quantification of
multiple signalling pathway responses and post-translational modifications where the
proteome can be spotted and analysed on a single chip(124). Each spot comprises the
entire lysed protein pool of the tissue sample in question and entire patient cohorts can
thus be quantified for heterogeneous total and phospho-state protein expression in a
highly comparable manner(125). RPPA was utilised to identify a prognostic proteomic
signature associated with the PI3k/AKT pathway for stage II CRC patients(126).
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Recently this technology has moved out of the research laboratory and into the clinical
setting and the technology is reviewed in more detail by Mueller et al(127). Mass
spectrometry has been utilised to profile the proteome from not only tissue but also
from blood and urine(105). Mass spectrometry was utilised to identify protein
signatures which correlated to the morphometry of the CRC glands and could identify
well, moderate and poorly differentiated tumours(128). This work provides some
insight into which proteins may be involved in tumour progression and malignancy.
The aim of all ‘omics’ research is to identify biomarkers which can lead to targeted
drug discovery programmes or companion diagnostics which will allow the clinician
and pathologist to make rapid informed decisions on the prognosis of the disease and
to predict which treatment will offer the greatest efficacy and best outcome possible
for the patient.
1.2.2 Quantifying intra-patient heterogeneity
Although the above methodologies to quantify the molecular mode of action driving
cancer subtypes have added significant value, they also hold disadvantages to assaying
such complex material. To extract DNA, RNA and protein molecules these assays
usually homogenise and destroy the tissue integrity. The tissue is literally “mashed and
measured” mixing together any subpopulations of cancer and host cells expressing
differential properties while losing spatial resolution. This results in one end-point
being reported for the whole tumour. Due to the nature of these applications, intra-
tumoural heterogeneity of the tissue may be under-detected where the dominant or
most abundant genotypes or phenotypes mask signal from smaller cell populations
within the tumour. Healthy tissue and host cells from the tumour microenvironment
are both also added to the molecular sample creating a further source of noise to the
signal and could increase the reporting of false positive or negative results. Under-
detection of tissue heterogeneity therefore leads to an urgent and difficult problem
when treating a patient with combination therapy, as resistant subgroups could go
unnoticed and untreated. There are, however, tools to overcome this problem which
attempt to better quantify, and thus comprehend, the complexity of heterogeneous
tumours.
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1.2.2.1 Laser capture microdissection
One such tool is laser capture microdissection (LCM) which isolates and analyses cells
and sections of the tissue of interest, usually those displaying morphological
differences(129). This technique allows the separate analysis of distinct
subpopulations as well as comparing the tumour’s core, invasive edge and the stromal
microenvironment. From these distinct sections DNA, RNA and protein can be
isolated and studied resulting in a cleaner profile of the difference between regions of
interest and their heterogeneity. Yancovitz et al performed LCM on distinct
subpopulations within primary melanomas and utilised SNaPshot® technology (which
allows the multiplexing of up to 10 single nucleotide polymorphisms in a single test)
to detect mutations from within them. They showed that subpopulations from within
the same tumour contained heterogeneity for BRAF mutations which were undetected
when sampling the whole tissue(89). LCM was further employed to segregate stroma
from epithelium in CRC and compare the differential expression signatures from each
using a microarray gene expression assay(52). LCM is also commonly used alongside
RPPA in proteomic studies for the molecular profiling of cancer specific signalling
networks and specific subpopulations or regions of interest(130). This technique was
utilised in a study where LCM and subsequent RPPA analysis of normal,
intraepithelial neoplasia and invasive prostate tissue showed an increase in
phosphorylated Akt, decrease in phosphorylated ERK and a decrease in apoptotic
signals, respectively, displaying increasing metastatic hallmarks through cancer
progression(131). There are drawbacks to LCM as the procedure can damage the
molecular material of interest and spatial integrity is still lost when performing
destructive homogenising assays. Recent technological advances such as Ion Torrent
sequencing(132) and RPPA using fully optimised platforms, for example Zeptozens’
ZeptoCHIP technology(133), allow molecular genomic and proteomic profiling
respectively with small sample sizes amenable to ever smaller tissue samples in the
study of heterogeneity. Background signals from complex tissue can still create noise
in these assays and robust and sensitive data depends on the LCM technique as well
as the specificity of probes, antibodies and detection technology used.
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1.2.2.2 In situ labelling
To avoid contamination of signals, from heterogeneous subpopulations within tissue,
in situ imaging of protein through Immunohistochemistry (IHC) and genomics through
fluorescence in situ hybridisation (FISH), may be applied. This has advantages over
destructive assays as the tissue structure, spatial orientation and sub-localisation of
molecules are retained and heterogeneity can be visualised, compartmentalised and
quantified while providing insight into cellular interactions within the tumour and its
microenvironment. IHC further allows the visualisation of morphological status of the
cells expressing the biomarker of interest and allows the observer to correlate
morphometric and proteomic signatures at the cellular resolution. IHC by has been the
gold standard for the detection of in situ protein expression and sub localisation for
many decades(134). Identifying and quantifying the heterogeneous patterns of the
invasive edge in CRC, for example, benefits greatly from cytokeratin
immunohistochemistry in order to identify the epithelial cells when compared to H&E
staining (135, 136). Semi-quantitative scoring of ER, PR and HER2 in breast cancer
samples by pathologists is the recommended clinical methodology practiced for
prognosis and prediction of effective drug combinations (137, 138). FISH, similarly to
IHC, allows the in situ visualisation and quantification of mutation status of genes of
interest and gene amplification analysis. This is performed by probing the chromosome
with fluorescent oligonucleotides which hybridise and bind to specific regions of
interest, such as a common mutation which could report on a prognostic or predictive
biomarker(139). Commonly IHC and FISH will be utilised together in a study to
understand the correlation of amplification and expression patterns of genes of interest.
HER2/neu gene amplification using FISH showed correlation with strongly positive
protein expression of the same gene using IHC in oesophageal squamous cell
carcinoma(140). Patients with gene amplification of HER2/neu showed poor
prognosis. Furthermore, heterogeneity was found within a CRC patient cohort when
analysing EGFR and Cyclin-D1 over expression and cellular localisation as well as
EGFR gene amplification using IHC and FISH respectively(141). The heterogeneity
could stratify patients into resistant or susceptible subgroups in response to anti-EGFR
therapy. Intratumoural heterogeneity was also found to be present in a high percentage
of Gastric cancer patients when assessed for HER2 gene expression and amplification
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using IHC and FISH respectively(142). This intratumoural heterogeneity could create
false positive or negative HER2 status and be the reason why subgroups of patients do
not respond well to HER2 targeted therapy. As with RPPA the specificity of the
antibody or probe and the use of correct controls are paramount to the success of these
assays.
Mass spectrometry has the ability to analyse the proteome of single cells and to assess
cell-to-cell heterogeneity(143) as well as in situ imaging mass spectrometry which can
analyse an area of tissue at the lateral resolution of ~150nm(144). The resolution of
formalin-fixed paraffin embedded (FFPE) tissue is usually in the order of 150-200µm
in diameter(145). These advances in mass spectrometry allow detailed interrogation of
the proteome of tumour subpopulations and the interface between the tumour and the
microenvironment.
There are currently certain drawbacks to analytical IHC, and international clinical
standardisation is still to be reached including standardisation of fixation, antigen
retrieval and staining. Reproducible semi-quantitative scoring by pathologists for
predictive testing is subjective and can lead to inter-observer variability while low
levels of staining may be hard to identify. These difficulties are further complicated
when analysing highly heterogeneous samples.
1.2.3 Image analysis
Although the field of high content analysis is not new(146, 147), where multiple
parameters and biomarkers are measured from fluorescently labelled cells(148), the
discipline has been slow to translate to histopathology and the clinic. This has been in
part due to the complexity of tissue and its imperfection compared to in vitro cell
studies and the need for extensive validation and standardisation for clinical use(149,
150). This is now changing and digital pathology as well as automated image analysis




Digital pathology is the high resolution, whole-slide imaging (WSI) of slide mounted
tissue sections. This can be undertaken with brightfield and immunofluorescence
illumination. The resultant virtual slide may be viewed and navigated on a computer
monitor and shared with remote parties for, amongst other things, secondary opinions
and research validation studies. Reporting for primary diagnosis has not passed UK or
US regulation where further validation is needed to ensure standardised quality
control(152, 153). The FDA has recently published a draft guidance for the technical
performance needed in WSI devices(154). Countries, where there may be large
distances between specialist pathologists have passed regulatory clearance for primary
diagnosis, for example, most recently approved in Canada and Sweden. The Canadian
Association of Pathologists has published its guidelines on establishing clinical
WSI(155).
There are multiple advantages of WSI in the reporting of histopathology. The most
obvious in clinical impact is rapid remote reporting on an urgent patient sample when
specialist pathologists may be geographically remote(156). Similarly if a second
opinion is needed or the hospital has no access to a subspecialist the virtual slide can
be shared between institutes almost instantaneously(157). This advantage also
facilitates international collaborative research into histopathology and drug
discovery(158). Further cost is saved in replacing and servicing of expensive
microscopes for each pathologist in an institute. The user interface of mouse and screen
is arguably more ergonomically friendly than traditional microscopy and multiple
persons may view the slide in one room without the need of multi-header microscopes.
Further advantages include ease of slide retrieval from the archive, teaching of medical
students and lack of slide breakage, loss and photobleaching of fluorescence
samples(159, 160). The assessment of FISH in WSI by image analysis was found to
be a robust alternative to traditional fluorescence microscopy which returns variable
results between observers(160). Although high concordance exists between glass and
digital reporting (unless there is an inconsistency of image quality) (161) there still
remain barriers to the technology. These barriers include reluctance of pathologists to
change, need for high speed IT infrastructures and storage for large file types(162).
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Widespread adoption will most likely occur once image quality can be robust and
standardised and the retrieval of sample from archive to screen is faster than mounting
glass slides onto a physical microscope.
1.2.3.2 Computer based image analysis
The integration of digital pathology with automated image analysis brings further
advantages to the field. These include the standardisation of quantification where
observer variability is excluded and the robust analysis of rare or complex features is
captured. Traditionally image analysis in histopathology concentrated on the
quantification of protein expression through IHC and IF(163). This was to overcome
the subjective manual and semi-quantitative scoring of a 1+, 2+, 3+ system. Upon
employing IF image analysis software can perform fully quantified continuous data-
export from which cut-offs can be calculated in order to stratify patient subgroups(150,
164).
Computer based quantification of nuclear morphometry, however, has been practiced
for over a decade(165-167). Continuous improvements to image analysis software now
allow the simultaneous export of morphometric parameters of cells and
histopathological features alongside biomarker quantification associated to this
feature. In this co-registering methodology it is possible to identify surrogate
morphological features which correlate with molecular phenotype.
The market leading tissue imaging platform manufacturers provide their own image




software/zen.html#features) and Leica (http://www.leicabiosystems.com/pathology-
imaging/aperio-epathology/analyze/). This allows segmentation of cells and
subcellular compartments and subsequent biomarker quantification within
heterogeneous tissue. These software packages are designed to work in connection
with the images captured from their own platforms and can sometimes be restrictive
to the quantification of set assays, biomarkers and parameters. Definiens
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(http://www.definiens.com/), Indica lab (http://indicalab.com/) and Visiopharm
(http://www.visiopharm.com/) offer image analysis packages which can import
images from most microscopes and allow a more flexible image analysis environment.
Definiens, for example, offers two main software packages for the automated image
analysis of tissue samples; Tissue Studio® and Developer XD™. Tissue Studio® is
an “out-of-the-box” software package which allows the quick application and tuning
of a set of sophisticated analysis algorithms to segment and quantify biomarker
expression profiles and morphometrics on an object by object basis. Their Developer
XD™ software involves additional programming but allows the user to build their own
customised image analysis solutions and provides greater flexibility to exploit
contextual information in heterogeneous tissue and to determine reliably the
quantitative readouts required.
1.2.3.2.1 Quantification of multiplexed biomarkers
While imaging a single biomarker can yield predictive or prognostic information the
ability to multiplex two or more markers on a single tissue section becomes a much
more powerful tool. An advantage of IF based image analysis is the ability to
multiplex, co-register and quantify biomarkers at the cellular resolution(168).
Multiplexing reports on protein interactions, pathway activation and multiple cellular
events. Accurate co-localisation and spatial resolution of multiple biomarkers or
histological features on the same section of tissue reports a richer high content and
functional data than serial sections of one biomarker while saving the precious
resource which is the tissue sample. Researchers can quantify multiple proteins on a
per cell basis or accurately quantify multiple cell types within a heterogeneous
population. Traditional multiplexing is limited by bleed through of fluorophores and
chromogens as well as antibody cross-reactivity of secondary host-species. Multi-
spectral imaging and un-mixing of chromogens and fluorophores allows an accurate
spectral readout for each biomarker of interest, increases the multiplexing capacity and
negates any autofluorescence(150, 169, 170).The additional use of Quantum Dots with
multi-spectral imaging increases the amount of multiplexing available to the
researcher(171), however limits must still be reached. The Toponome Imaging System
(TIS)(172) allows the ability to spatially map over 100 proteins with subcellular
resolution. This is done by sequential rounds of incubating, imaging and bleaching of
22
fluorescently tagged antibodies building up a spatial map of hundreds of protein
interactions and whole protein networks on a single tissue section. Not only does this
technology give rise to in situ protein network signatures of different subpopulations
of heterogeneous healthy and diseased tissue, it also paves the way for next-generation
biomarkers for combinatorial drug discovery strategies(173).
1.2.3.2.2 Image analysis of Tissue Microarrays
Tissue microarray (TMA) cores can be punched out of a region of interest from the
original tumour block and spotted onto microscope slides for digital image analysis
post biomarker labelling(174, 175). Whole slide image analysis may also be employed
in order to identify regions of interest (ROI) to select for TMA construction(176). This
creates the ability to select samples from areas of distinct morphological and
histopathological interest from multiple patients onto a single slide for standardised
comparative analysis. The major advantage of using TMAs is the ability to image and
quantify protein and genetic heterogeneity in situ for entire cancer cohorts under
identical, and so fully comparable, IHC and IF. The majority of automated image
analysis packages can import TMA images for quantification. Utilising IHC or IF with
image analysis makes it possible to quantify the protein expression levels from full
cohorts as well as report spatial information relating to the heterogeneity within the
TMAs and also between TMAs sampled across the primary tissue and distant
metastasis. Image analysis has been performed on TMAs from breast(177), mantle cell
lymphoma(178) and ovarian cancer(75) as well as a proposed novel score for
predicting metastasis in adrenocortical carcnimoas(179). In situ genomics can also be
studied using TMAs and FISH technology making it possible to quantify the
heterogeneity of mutations or amplification of genes(180, 181).
1.2.3.2.3 Image analysis of whole slide images
While TMAs allow a large number of samples to be analysed in a time and cost
efficient manner, imaging entire tissue sections to quantify biomarkers and
histopathological features across them yields objective and standardised assessment of
intra-tumour heterogeneity(182, 183). Imaging the whole tissue section coupled with
automated image analysis allows the investigator to quantify differential protein
expression and sublocalisation for biomarker identification across the entire
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sample(184). Classical pathology reporting of histopathological events in H&E stained
tissue can yield high inter-observer variability and is subjective. Whole slide image
analysis may be applied to quantify such events in a more reproducible manner, for
example, reporting mitotic index in breast cancer(185). The tumour microenvironment
and its interaction with the tumour may also be quantified where spatial heterogeneity
and density parameters are reported such as for lymphocytic infiltration and(186) the
vasculature(187). Although image analysis of whole slide imaging features
predominantly within cancer research other fields of histopathology, such as transplant
pathology, are beginning to utilise the same technology(188). Quantitative whole slide
imaging of omics based biomarkers has distinct advantages over the more traditional
quantification through ‘mash and measure’ homogenisation of the tissue. The
homogenisation of tissue for e.g. NGS, mass spectrometry and RPPAs destroys
information on spatial heterogeneity and does not report on heterogeneous
subpopulations within the tissue sample. The image analysis of WSI can capture these
heterogeneities across the sample and extract information regarding even small
subpopulations while the traditional methods will only report the most abundant
signal.
1.2.3.3 Tissue phenomics
Although big-data is now associated with the post-omics era of clinical medicine(189,
190), advances in image analysis allow the approach to be adopted in the field of
morphometrics and tissue histopathology. Tissue phenomics is the term which
describes the big-data capture from image analysis based segmented tissue sections to
quantify the data-rich histopathology and the interactions and spatial heterogeneity of
the cancer microenvironment’s phenotypic features. This involves the extraction of
complex and hierarchical data pertaining to a single segmented feature or set of
features across the segmented tissue section. This data may be captured through co-
registering of biomarkers as proteomic or genomic signals, as multiple morphometric
and texture parameters or a combination of both; essentially extracting as much data
as possible from each single segmented object within the image(191). A multi-
parametric signature is therefore built up for each tissue sample which may be
compiled of multi-omic image based features. Sophisticated data mining is required to
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identify the significant single or combination of parameters within the signature in
order to stratify patients for prognostic or predictive purposes. Data mining techniques
previously applied to identify significant parameters have been logistic regression
analysis and ensemble decision tree models(192-194).
Advances in imaging technology, such as next-generation IHC, which combines mass
spectrometry with IHC, provide an ideal methodology to be incorporated into tissue
phenomics. Next-generation IHC enables the exportation of highly multiplexed
proteomic data at sub-cellular resolution(195). This data can also be combined with
spatial information(196). Image analysis software such as from Visiopharm and
Definiens allow hundreds of morphometric and texture parameters to be exported on
every single segmented object and spatial statistics calculated between them. These
can be co-registered to multi-plexed biomarker data for the same object; which can be
a nucleus, a cell or a histopathological feature. By applying a multi-parametric
morphometric data capture approach Beck et al were able to identify a novel
prognostic stromal signature in breast cancer(192). This signature was distilled from
over 6000 features relating to intensity, shape, texture and neighbouring objects. More
recently a study in glioblastoma correlated a nuclear morphometric signature with
clinical and genomic data, which would allow a simplistic morphometric measurement
to act as a surrogate for expensive genomic testing(193).
Tissue phenomics may identify novel phenotypic features which may be too subtle to
observe by the naked eye. Image analysis can also reproducibly quantify these features
in a continuous data manner. Mapping multiple spatial and morphometric
heterogeneous parameters in whole tissue sections brings a new dimension to
histopathology and can map its intrinsic architecture(197). These features can be used
for prognostic purposes, understanding the role of the microenvironment and acting as
surrogates for underlying molecular pathways.
1.3 Integrative pathology
Traditional omics research attempts to identify single molecular or histopathological
features which could be utilized for prognosis or prediction of response to drug
therapy. Cancer is, however, a very complex disease with multiple molecular
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interactions within the cell and multiple cellular interactions within the
microenvironment(105). Many single biomarkers never translate to the clinic, as they
do not take into account the complexity and heterogeneity of the disease. Integrating
large scale data from multiple omics fields may help to address this problem as it will
create a better understanding of the multiple molecular interactions occurring within
the cell and how these translate to disease progression. The diagnosis and prognosis of
CRC has been recently re-assessed by subgrouping patients on their epigenetic and
genetic profiles(198). A further study in CRC integrated histopathological subtypes
with molecular features to assess their correlation and impact on prognosis(56).
Integrative large scale pathology has been implemented in breast cancer where cellular
resolution of in situ and co-registered genotype and phenotype was utilised to study
intra-tumoural heterogeneity between primary and distant metastasis for prognostic
and potential drug target studies(199). A further breast cancer study integrated a multi-
omics signature and discovered JAK-STAT and TNF signalling pathways to be
significant in triple negative disease which could lead to novel and personalised drug
treatments(200).There is a wealth of data collected during classical histopathology
which largely remains unused in clinical decision making. This clinical data is
beginning to be integrated with the modern datafication modalities as a further
hierarchical level of understanding of the disease from the tissue. In mucoepidermoid
carcinoma, histopathology, immunophenotypic and cytogenetic parameters were
integrated to identify a signature which was able to identify the pulmonary disease
from other subtypes of lung cancer(201). Clinical and molecular data is now also being
integrated with the complex and data-rich image-based phenotypic signatures to
investigate cancer heterogeneity and its interaction with the microenvironment. The
morphometric signatures can also be correlated to the genomic profile and clinical
outcome(191). Computational IT solutions are becoming available which allow the
incorporation of multiscale omics data(202, 203) as well as to integrate it with clinical
information(204).
1.3.1 Systems pathology
Modern pathology is no longer hampered by a lack of large-scale hierarchical data
encompassing multi-omics and morphometrics. This data, however, must be integrated
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in a meaningful way which makes best use of its complexity and is robust enough to
be clinically relevant. Systems medicine, and more recently systems pathology, takes
a holistic view of tissue, the cell and its multitude of interactions(205). Systems
pathology requires a large amount of high-quality multi-scale data to be extracted from
tissue and which acts as input for predictive mathematical models(206). Although
systems pathology has predominantly concentrated on molecular profiling of the
genome, transcriptome or proteome, tissue phenomics and morphometry is perfectly
matched to add to the hierarchical data within a systems model.
Essentially, a modern integrative pathology would adopt the principles of 4P medicine
in a systems pathology approach. 4P medicine consists of Prediction, Personalisation,
Prevention and Patient participation(207). Although many definitions of systems
medicine exist CASyM (https://www.casym.eu/what-is-systems-medicine/), a
European consortium tasked to develop an implementation strategy for clinical
systems medicine, defined it as the following:
Systems Medicine is the implementation of Systems Biology
approaches in medical concepts, research and practice. This
involves iterative and reciprocal feedback between clinical
investigations and practice with computational, statistical and
mathematical multiscale analysis and modelling of
pathogenetic mechanisms, disease progression and remission,
disease spread and cure, treatment responses and adverse
events as well as disease prevention both at the
epidemiological and individual patient level. As an outcome
Systems Medicine aims at a measureable improvement of
patient health through systems-based approaches and
practice.
The principle of systems pathology is to predict a dynamic pathological response from
static data sets. Systems pathology is complex with the implementation of multiple
differential equations into a multiscsale dynamic model to predict a drug effect on a
patient or inform how that patient will respond over time(206, 208, 209). Systems
pathology, under this definition, was utilised to confirm the role of PTEN in
trastuzumab drug resistance(210). Systems pathology can also be implemented to track
tumour evolution post chemotherapy through intra-tumour heterogeneity and spatial
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distribution of phenotype and genotype at the cellular level(211). In CRC a systems
pathology approach was employed to identify a disease recurrence signature in early
stage patients from a multi-omics data set where parameters associated with immune
response were found to be the most significant predictors(212).
The ultimate goal of integrative and systems pathology is to make use of hierarchical
data captured across multiple modalities from an imperfect and static tissue sample, in




Colorectal cancer (CRC) is the third most common cancer in the world(213) and in
Scotland, with 3849 new cases being diagnosed and 1578 deaths recorded in 2013 in
Scotland alone(214). Incidence and mortality rates are lower amongst women than
men. Although incidence rate has decreased only slightly in the last decade, the change
in mortality has decreased significantly by 20.7% in males alone, between 2000 and
2010, with 55% of all patients surviving after 5 years post diagnosis (215). Reasons
for the decrease in mortality include early detection of disease(216), targeted therapy
borne through omics research (217), novel prognostic factors coupled with more
accurate pathological and clinical staging of disease (104) and advances in surgical
technique. These factors culminate in more effective treatment of patients at an early
stage and at a personalised level. Survival rates in early stage cancer, where the tumour
is localised, are good with ~90% of patients experiencing 5 year disease free survival.
Upon spread to localised lymph nodes survival decreases to 50-70% and if distant
metastasis has occurred survival is only 12%(216, 218).
CRC may develop through either hereditary or sporadic origins. The two most
common types of hereditary CRC are Familial Adenomatous Polyposis (FAP) and
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) which is also referred to as
Lynch syndrome; the hereditary cancers account for 1% and 2-3% of all CRC
respectively. It is thought that up to 35% of all CRCs have associated hereditary factors
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although these are poorly understood(219). The majority of cancers are termed as
sporadic CRC cancer and result in mutation or epigenetic aberration. Lifestyle affects
CRC and a higher incidence is associated with a sedentary lifestyle, diet, alcohol,
obesity, diabetes and smoking(219).
1.4.2 Adenoma to carcinoma sequence
Sporadic colorectal tumours are generally thought to evolve from an adenomatous
polyp through a multi-step process where mutations or epigenetic silencing in critical
genes accumulate toward malignant neoplasia. This somatic evolutionary process was
termed the adenoma to carcinoma sequence by Fearon and Vogelstein in 1990(220)
who describe a set of genetic aberrations which are needed for a precursor lesion to
mature toward malignancy (Figure 4). These are thought to generally occur in a
specific order; however it is their temporal accumulation which is essential for
metastasis. The most simplistic model proposed begins with a mutation in the APC
gene, involves constitutive activation of KRAS (a signal transducer in the EGFR
pathway), aberrant TGFβ signaling through loss of 18q and finally TP53 mutation. 
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Figure 4. Fearon and Vogelstein’s adenoma carcinoma sequence, expanded to illustrate current knowledge of chromosomal (CIN)
and microsatellite instability (MSI).
The earliest detectable abnormality is the aberrant crypt focus (ACF), characterised by hyperproliferation and resistance to apoptosis. In the CIN pathway,
these are seen to derive following bi-allelic inactivation of the APC tumour-suppressor gene (a pivotal regulator of the wnt/β-catenin proliferation pathway), 
which initiates chromosomal instability. Constitutive activation of the EGFR-signal transducer KRAS (more often than BRAF) accompanies adenoma
formation.  Further progression is associated with altered TGFβ signalling, most frequently due to or SMAD2/4 inactivation through loss of heterozygosity
(LOH) at 18q, and final malignant transformation with inactivation of TP53, a critical cell cycle caretaker.
The MSI pathway by contrast originates from defective DNA mismatch repair. The resulting genomic instability affects several critical genes with effects
analagous to those of the classical pathway; interruption of wnt signalling, BRAF (more than KRAS), CDC4, TGFβRII, BAX and IGF2R have all been
described, bringing about adenocarcinoma by a TP53-independent mechanism.
Figure compiled by Richard Matthews and reproduced with full permission; adapted from Knudson (2001); additional data from Walther et al (2009).
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1.4.3 Colorectal cancer subtypes
CRC is a very heterogeneous disease as well as consisting of multiple molecular and
histopathological subtypes. These subtypes can correlate to prognosis and prediction
of response to therapy although few are taken into account within clinical diagnosis.
1.4.3.1 Molecular subtypes
Apart from familial and hereditary CRC subtypes there are multiple pathways to
malignancy within sporadic disease. Sporadic disease stems from genetic instability
which can take multiple forms(68). Although Fearnon and Vogelstein’s model is still
sound, it is too simplistic to explain all of CRC and in fact plots the somatic evolution
of CRC within the predominant genetic instable CRC subtype of the chromosomal
instability (CIN) pathway. CRC can also occur through other forms of genetic
instability namely: microsatellite instability (MSI) and the CpG-island methylator
phenotype (CIMP)(53).
1.4.3.1.1 Chromosomal instability
The CIN pathway is found to be responsible for between 70 and 85% of all CRC(55,
219). The presence of CIN usually confers a worse prognosis than other subtypes and
has a higher probability of distant metastasis(53, 55). CIN, as mentioned previously,
has the molecular hallmarks of loss of the tumour suppressor genes APC, SMAD4,
DCC and TP53 and activation of the oncogene KRAS. Tumours with CIN phenotype
also tend to be highly differentiated and rarely mucinous with little lymphocytic
infiltration and located in the distal colon (221).
1.4.3.1.2 Microsatellite instability
The MSI pathway is characterised by multiple mutations at microsatellites (short
tandem repeats in the DNA) and is correlated to a loss of DNA mismatch repair
(MMR) enzymes through mutation of their genes or hypermethylation of their
promoters(219, 222). The most common MMR genes lost in the MSI pathway are
MLH1, MSH2 and MSH6 (223). MSI CRCs make up approximately 15% of CRC,
arise in the proximal colon, are typically mucinous with moderate to poor
differentiation and have a high immune infiltrate(222, 224). These cancers also have a
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better prognosis than CIN as the patient rarely experiences distant metastasis(53, 219).
MSI high patients are typical of the hereditary Lynch syndrome but can also be found
in sporadic cancer, in which they tend to have a mutation in BRAF(225).
1.4.3.1.3 CpG Island Methylator Phenotype
CIMP positive pathway overlaps molecularly with the MSI one. The CIMP pathway
induces epigenetic silencing through hypermethylation of promoters of MMR genes
in particular MLH1, MSH2 and MGMT(226). The hypermethylation of CpG promoter
sites of tumour suppressor genes also occurs and CIMP is associated with BRAFV600E
mutations (227). CIMP is present in 20-30% of all tumours and is associated with poor
differentiation, mucinous CRC, high immune infiltrate, located in the proximal colon
and poor prognosis(55, 228), although it has also been shown to confer better
prognosis than CIMP negative tumours(229).
The three molecular pathways involved in CRC are not mutually exclusive and CRC
tumours may be classified at the molecular level by a combination made up of the three
definitions(68). These molecular subtypes have been shown to confer prognostic and
predictive information for the personalised clinical treatment of a patient’s tumour.
1.4.3.2 Histolopathological subtypes
Although 90% of CRC tumours are adenocarcinomas there are multiple
histolopathological and morphological subtypes which may also confer information
on the prognosis of the patient. Prognosis is, however, not correlated to
histopathological subtype in clinical practice(230). These histopathological subtypes
may also be correlated to a certain molecular profile. Aside from classical
adenocarcinoma the most prevalent of these subtypes is mucinous carcinoma; which
makes up around 10% of CRC adenocarcinomas. Mucinous carcinoma is diagnosed
by the presence of secretory mucin in at least 50% of the tumour and is loosely
associated with a poor prognosis(231), although it has not been shown to be
independently associated with disease specific death(232). Mucinous carcinomas are
associated with MSI and CIMP however a more aggressive subtype is associated with
microsatellite stability (MSS) CRC(103, 233). Signet cell carcinomas are so called as
they have at least 50% of the cells in the tumour where intra-cellular mucin pushes the
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nucleus to one side; these CRCs make up around 2-4% of the adenocarcinomas(230).
Signet cell carcinomas have a more established link to poor prognosis and feature poor
differentiation(234). Other more rare CRC histological subtypes include medullary
carcinoma, squamous cell carcinoma and small cell carcinoma(235).
Other heterogenous histopathological features which have correlation to prognosis
with CRC adenocarcinomas are: Grade (Differentiation), perineural invasion,
vasculature invasion, vasculature density, immune cell infiltrate and the pattern of the
invasive margin(102, 236, 237).
1.4.4 Tumour staging of CRC
Although multiple subtypes of CRC exist and while some are correlated with
prognosis, routine clinical pathological prognosis and recommendation for adjuvant
therapy is still mainly determined by stage and grade of the tumour. Tumours are
graded as ‘well differentiated’ with an epithelial and gland forming phenotype which
suggest a more non-invasive tumour and ‘poorly differentiated’ where greater than
50% of the tumour is gland forming but has non-epithelial, and a more mesenchymal,
cell phenotype and can be highly proliferative and invasive(230, 238). However, due
to the assessment of grade being very subjective and thus reports high observer
variability(233) the decision to administer adjuvant therapy is less focused on tumour
grade and more on tumour stage.
1.4.4.1 Tumour Node Metastasis
The Tumour Node Metastasis (TNM) system is universally implemented for the
staging of CRC patients and directly impacts on prognosis and adjuvant therapy
decision making(239). TNM staging is summarised in Appendix B of this thesis
(AJCC Colon and rectum staging, 7th edition). TNM staging for CRC is continuously
revised and updated by the International Union against Cancer (UICC) who have
published the 7th edition(240), however within the UK, pathologists still report from a
standardised pro forma which includes the 5th edition of TNM(102, 241). This is due
to a lack of evidence base to support the alterations in the newer editions and no
significant improvement on prognosis(239, 241).
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The TNM staging is based on gross observation and analysis of histopathological
tissue sections under the microscope and revolves around the depth of local invasion
(T), presence of cancer within the lymph nodes (N) and if the cancer has metastasised




































0  x x x x x x
1   x x x x x
2A    x x x x
2B     x x x
3A   x x  x x
3B     x  x x
3C    x  x   x
4    x  x  x  x 
 Cancer is present x Cancer is not present
 x Cancer may or may not be present
Table 1. Summary of TNM staging criteria.
TNM staging is excellent at returning prognostic information on a population of
patients; however, it is less specialised at predicting prognosis at the personalised
level(219). A patient’s prognosis is worse the higher the stage they are classified
within, however the TNM system does not differentiate between good and poor
outcome of patients within the same stage(237). There are defined adjuvant treatment
guidelines associated with the various stages of CRC(242). Stage 0 and I cancers will
not routinely receive adjuvant chemotherapy and surgical resection is considered
curative. Adjuvant therapy is recommended for Stage III and IV patients however
there remains ambiguity about whether to treat all, a subset or no stage II patients with
adjuvant chemotherapy(243, 244).
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1.4.4.1.1 Stage II sub-stratification
Although the majority of stage II patients will receive no adjuvant therapy an average
of ~30% will experience disease recurrence and poor outcome(243, 245, 246). The
QUASAR clinical trial reported only a 3.6% increase in absolute survival in a stage II
patient population which were treated with adjuvant chemotherapy(247). Due to
quality of life factors, including increased morbidity and mortality associated with
treatment related toxicity and cost-effectiveness, it is recommended that in general
stage II patients do not receive chemotherapy(243, 246). Accurate identification and
stratification of high-risk stage II patients, some of whom have comparable or worse
outcome than stage III patients(248), who could benefit from adjuvant therapy is
therefore imperative to increase disease free survival rates.
Lymph node involvement is a key prognostic indicator which correlates with poor
outcome and distant disease. Lymph node involvement upgrades a patient from a stage
II classification to a stage III one which in turn triggers the decision to administer
adjuvant therapy(249). A possible reason for the poor outcome of a subgroup of stage
II patients could be due to their understaging(250). Although patients in stage I and II
CRC have been classified as pN0 occult lymphatic and nodal involvement may be
present, suggesting the cancer has taken on invasive and metastatic capabilities. Occult
nodal involvement, whether it is isolated tumour cells or micrometastasis, is also
significantly associated with poor prognosis(251, 252). It is essential that at least 12
lymph nodes are harvested and examined for cancer cell involvement(238, 241) while
number of nodes examined is a prognostic marker in itself(253).
There are additional histopathological factors which have been correlated with poor
prognosis and lymph node metastasis and are listed within the core data sets for the
reporting of CRC as dictated by the Royal College of Pathologists (RCPath)(102)
(Appendix A). Although some are disregarded in clinical decision making for the
management of stage II CRC patients some features, if present, may invoke the
decision to treat the patient with thymidine synthase inhibitors in combination with
oxaliplatin. These “high-risk” factors include pT4 local spread (where the tumour has
directly invaded neighbouring organs or structures (pT4a) and/or perforates the
visceral peritoneum (pT4b)), extramural lymphovascular invasion and poor
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differentiation(238, 244, 254). However, there are no clinical trials to date which have
examined the advantage of adjuvant therapy on stage II patients with additional high
risk factors.
Furthermore there exist promising histopathological features listed in the literature
which have been significantly correlated with poor prognosis and lymph node
metastasis but which are only listed in the non-core data set and rarely feature in final
clinical reports(102) (Appendix A). There is growing evidence that immune cell
infiltrate(50, 255) and perineural invasion(256, 257) are strongly correlated with poor
patient outcome while lymphatic vessel invasion and the invasive growth pattern,
including tumour budding, are two of the most promising histopathological features
which have been significantly associated with lymph node metastasis and disease
specific survival(20, 90, 236, 252, 258-260).
1.4.4.1.1.1 LVI
Cancer cells must invade the lymphatic vasculature locally prior to metastasising to
the lymph nodes(4). Lymph node metastasis is highly correlated to poor prognosis and
is an essential feature of stage III CRC(238, 241, 261). The robust quantification of
lymphatic vessel invasion (LVI) within the primary tumour could therefore be an early
and sensitive feature to predict both lymph node metastasis and disease specific
survival; in fact several studies have proven this theory and shown a significant
correlation(252, 260, 262-264). Although there is mounting evidence of the prognostic
value of LVI it is still listed as a non-core data item and the evidence is not thought to
be sufficient to be included as a core data item(102). A reason for this could be the
difficulty in the accurate observation of lymphatic vessels in H&E stained CRC tissue
sections, which in turn is a reason for variable results(265, 266). The use of
immunohistochemical labelling with antibodies such as D2-40, which specifically
bind to the endothelial cells of the lymphatic vasculature, may aid in the reporting of
LVI and decrease observer variability(252, 265).
1.4.4.1.1.2 Invasive growth pattern
The pattern of the cancer’s invasive front has been significantly correlated to lymph
node metastasis and disease specific death(236, 267, 268). Poor prognostic factors
associated with the morhphology and histology of the cancer’s invasive edge include
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an infiltrating invasive pattern, tumour budding and poorly differentiated clusters(20,
259, 267, 269). Tumour budding is commonly defined as clusters of tumour cells
within the stroma at the leading edge of cancer invasion and which are up to 5 cells in
size(270). Poorly differentiated clusters are similarly located within the cancer
microenvironment but are larger than 5 cells in size but are not gland forming(269,
271). Although there is a strong body of evidence for the prognostic significance of
these features, only tumour budding is listed within the RCPath guidelines and then
only in the non-core items section(102). This is due to non-standardised quantification
methodology and variability in reporting. Variability in observer rates of tumour
budding is in part due to inherent patient heterogeneity as well as the feature’s
obscurity when reporting on H&E stained tissue sections(272); although this may be
overcome in part by the use of cytokeratin-based immunohistochemistry(92, 265).
Reproducible and reliable studies with large patient cohorts which take into account
standardised prognostic factors may allow for tumour budding to be included in the
core date set of the UK guidelines.
1.4.4.1.1.3 The role of image analysis in stage II patient stratification
The standardisation and robust quantification of both lymphatic vessel invasion and
tumour budding could result in both features being reported routinely within clinical
practice. Automated computer-based quantification of these histopathological features
would not only allow the standardisation of reporting criteria but also negate observer
variability. The proof of a robust quantification method, which reports consistently
high significance associated with prognosis in stage II patients, could allow for these
features to be included in clinical decision making.
It is important to not only standardise the reporting of promising histopathological
features, or identify novel ones through image analysis, but to assess which features
are most significant. Meat-analysis reviews attempt to identify the most significant
parameters which predict poor outcome(258), however, this is optimally carried out
when comparing quantification methodology on the same tissue section. As TNM
staging is the internationally recommended system to make a prognosis on CRC(239,
241) it would be prudent to evaluate how novel image based significant
histopathological features can augment the classical system instead of replace it. An
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integrative pathological signature could prove to be more significant and robust at
predicting poor outcome in stage II CRC patients than any one individual method.
1.5 Hypotheses
Image analysis can be utilised to quantify set histopathological features in order to
stratify stage II CRC patients into low and high risk of disease specific death.
Image analysis may be employed to capture unbiased multi-parametric signatures from
the invasive front of CRC in order to identify novel histopathological features to
stratify stage II CRC patients into low and high risk of disease specific death.
1.6 Aims and objectives
1.6.1 Aims
1. To develop an image analysis algorithm to allow standardised quantification
of set histopathological features from the invasive front of CRC.
2. To develop an image analysis based pipeline to identify significant parameters
from the unbiased multi-parametric data capture of automatically segmented
objects within a tissue sample.
3. To integrate image based histopathological features with parameters from the




1. Create image analysis algorithms for histopathological feature segmentation
and quantification. Employ the image analysis algorithm to quantify tumour
budding, vasculature invasion and density across a training and validation set
of CRC patients in order to stratify stage II patients into high and low risk of
disease
2. Employ an image analysis algorithm to segment and extract multi-parametric
data from each object within an immunofluorescence digital image. Employ
decision tree models to identify the parameter within the imaging data which
are most significant at prediction of disease specific death. Apply the novel
parameter to a validation set of stage II CRC patients
3. Identify significant parameters from the clinical pathology report associated to
the patient cohorts. Assess statistical methodology to compute the integration
of optimal clinical and image-based parameters to be included into novel
prognostic signature.
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Chapter 2: Materials and Methods
2.1 Patients and specimens
2.1.1 Colorectal cancer training cohort
The training cohort (n = 118). The training cohort contained all the patient tissue and
follow up data made available to this study and was taken from part of a larger cohort
which was prospectively collected and compiled as previously described (273). CRC
patients in the training cohort were under the age of 55 diagnosed between February
1996 and July 2003. Patient follow up comprised date of death, CRC specific death
and disease specific survival (months). All patients were initially interviewed soon
after diagnosis and gave written consent for their tissue to be used for research
purposes. Half the patients were male and half were female. Nineteen percent of whom
died of disease.
2.1.2 Colorectal cancer validation cohort
Validation cohort (n=134): The validation cohort was comprised of all sequential cases
of stage II CRC treated in NHS Lothian hospitals over 2 concurrent years (years 2002
and 2003), resulting in a cohort of 147 patients. Clinical follow up was up to 11.5
years. Due to insufficient available material 13 patients were excluded leaving a
remaining 134 patients within the validation set; 20 of whom died of disease during
follow up.
Corresponding clinical pathology data sets for each patient were retrieved from the
original pathology report through NHS Lothian’s APEX laboratory information
system (Table 8). Patient follow up was sourced from the Information Services
Division (ISD) which is within NHS Scotland. Patient follow up comprised date of
death, CRC specific death and disease specific survival (months). Census was taken
on the 31st of March 2014. The resultant validation cohort comprised 56 (42%) patients
who survived follow up, 58 (43%) patients who died of other causes and 20 (15%)
who died of CRC disease during follow up.
40
2.1.3 Tissue Microarray (TMA)
H&E stained whole tissue sections for each patient to be included in a TMA were
sourced from their archives. Histopathological microscopic evaluation was carried out
by a consultant pathologist, alongside either a trained technician or myself. During
histopathological examination, regions of interest (ROI) within the whole tissue
sections were marked. Tissue cores were extracted from corresponding areas within
the paraffin embedded tissue blocks and TMAs were subsequently constructed by a
qualified technician (Y. Zhou or In hwa Um) as described in detail by Kononen et al.
(274). 3µm thick sections were cut from the completed TMA block and mounted on
glass microscope slides for histochemistry or immunohistochemistry analysis.
2.1.3.1 Optimising TMA
Residual diagnostic CRC material was requested for 10 patients from the NHS Lothian
NRS BioResource. A tumour rich ROI was selected from each tissue section and a
0.6mm core extracted. This TMA was utilised for optimising histochemical stains and
antibodies for immunohistochemistry.
2.1.3.2 Training cohort TMA
The training cohort TMA comprised of cores from all 118 patients within the training
cohort. The ROIs in this TMA were from tumour rich areas at the invasive front from
where a 0.6mm core was extracted. This TMA was utilised to evaluate if TMAs were
a suitable material to report prognostic significance from the quantification of
histopathological features.
2.1.3.3 Tumour Bud TMA
50 patients from within the validation cohort were selected who had high tumour
budding. Histopathological examination of the corresponding H&E stained tissue
sections confirmed the budding status of the sections. High budding ROIs from the
invasive front and well differentiated tumour gland ROIs from the tumour centre were
marked on the tissue section from where a 1mm core was extracted. Two cores from
each ROI for each patient were included in the TMA.
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2.1.4 Whole tissue sections
3µm thick whole tissue sections were cut from paraffin embedded tumour blocks and
mounted on glass slides for histochemistry or immunohistochemistry based analysis.
2.1.4.1 Control whole tissue sections
Tissue blocks containing lymph nodes associated with patients in the training cohort
were utilised as positive controls for lymphatic vessel visualisation.
A positive and negative control patient sample was selected from the training cohort.
Histopathological analysis of H&E stained tissue sections was undertaken by a
consultant pathologist and myself. A tissue section which contained a high level of
lymphovascular invasion was termed as the positive control and a tissue section which
contained no lymphovascular invasion was termed as the negative control. The
positive and negative controls were utilised in assay and image analysis development.
2.1.4.2 Training set whole tissue section
A 50 patient subset was taken from the patient training cohort on which to perform
whole tissue section image analysis. This patient number corresponded to all whole
tissue blocks which were available for this study. The patients had CRC diagnoses
from Stage I through to Stage III. The Stage II patients (n=29) comprised of good
prognosis Stage II CRC patients (n=16; survived follow up) and poor prognosis
patients (n=13; died of CRC during follow up). Stage I patients (n= 13) and Stage III
patients (n=8) were also included to assess if the good or poor prognosis Stage II
patients respectively responded similarly.
Patient follow up comprised date of death, CRC specific death and disease specific
survival (months). Of the 50 patients selected for whole slide imaging, 40% died
specifically of CRC and one patient died of other causes during the follow up period.
Census was taken on the 1st of July 2012. Patient data is listed in Table 7.
2.1.4.3 ECCS Whole tissue section
All 134 Stage II patients selected for the validation cohort were analysed by whole
tissue section. In this manner the validation cohort was handled as a prospectively
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collected retrospective trial and there were no exclusion criteria, making it a clinically
relevant cohort.
2.1.5 Ethical approval
The provision of this material and the subsequent research was conducted under the
approval held by the NHS Lothian NRS BioResource, which is a REC-approved
Research Tissue Bank (REC approval ref: 13/ES/0126). This approval was granted by
East of Scotland Research Ethics Service, which is part of the National Research Ethics
service and NHS Health Research Authority. This provides the necessary ethical
approval for the BioResource, and associated researchers to collect, store and use
patient samples and associated clinical data for research. In accordance with the
approval held, all samples were anonymised when released by the BioResource to the
research group.
2.2 Histochemistry and Immunohistochemistry
2.2.1 Tissue section preparation
Formalin fixed paraffin embedded tissue blocks, containing either full tissue or TMAs
were cut in 3µm sections and mounted on positively charged microscope slides prior
to incubation at 37°C overnight. The sections were then dewaxed in three 5 minute
washes of xylene and rehydrated in decreasing grades of ethanol (100% x2, 80% and
50%) and finally running water for 2 minute washes each. Post staining (apart from
immunofluorescence staining) tissue is dehydrated through increasing graded alcohol
washes (50% and 80% for 30 seconds and 100% two x 2 minutes), next the slides are
washed for three 5 minute washes in xylene before mounting using pyrex and a
coverslip.
2.2.2 Haematoxylin and Eosin (H&E) staining
The following staining protocol was applied to all H&E stained sections after a reagent
optimisation experiment.
Post tissue preparation slides are incubated in Haematoxylin solution for 5 minutes,
washed in water, dipped in 1% acid alcohol for 3 seconds, washed in water, dipped in
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Scott’s tap water solution for 15 seconds, incubated in Eosin aqueous solution for 5
minutes before a final wash in water. The tissue is next air dried, dehydrated, mounted,
as described in section 2.2.1, prior to microscopic analysis.
2.2.3 Elastic Verhoeff-Van Geison (EVG) staining
The following staining protocol was applied to all EVG stained sections after a reagent
optimisation experiment.
Post tissue section preparation slides were stained in Verhoeff solution (alcoholic
haematoxylin, ferric chloride and Lugol’s iodine solution; 20ml, 8ml, 8ml
respectively) for 30 minutes, rinsed in water and differentiated in Ferric chloride
solution (20ml ferric chloride and 80ml water) for 3 minutes before transfer into 95%
alcohol for 1 minute, rinsed in water and counterstained in Van Gieson solution for 1
minute before a final rinse in water. Tissue is dehydrated and mounted as described in
section 2.2.1, prior to microscopic analysis.
2.2.4 Immunohistochemistry
Post tissue section preparation heat induced antigen retrieval is performed in a pressure
cooker containing either Tris EDTA, pH9 buffer or 0.15mM Sodium Citrate, pH6
buffer. The solution is pre-boiled for 10 minutes in a microwave prior to the addition
of tissue slides whereupon the solution is further heated for 5 minutes. Slides are left
to cool for 20 minutes in the heated buffer after cold water is added. Slides are next
washed in 0.1% PBST (Phosphate saline solution with 0.1%Tween) two times for 5
minutes each. Endogenous hydrogen peroxidase is blocked with incubation of the
slides in 3% hydrogen peroxide solution for 10 minutes. Two further 5 minute washes
in 0.1% PBST are performed prior to 10 minute incubation in Dako serum-free block
(Dako, #X0909) in order to prevent the binding of primary antibody to non-specific
antigens. Sections are next incubated in a primary antibody solution diluted in Dako
antibody diluent (Dako, #S0809) at either room temperature for 1 hour or overnight at
4ºC. If dual staining is performed a further three 5 minute PBST wash steps are carried
out between primary antibody incubations and once again prior to visualisation. A list
of all primary antibodies utilised and their conditions is located in Table A.
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Antibody Supplier Species Dilution QC
PanCK Dako, Z0622 Rabbit 1:150 Specific
PanCK Dako, M3515 Mouse 1:300 Specific
CD31 Dako, M0823 mouse 1:1000 Specific
D2-40 Dako, M3619 Mouse 1:2000 Specific
Beta catenin BD Biociences, 610153 Mouse 1:500 Specific
E-Cadherin BD Biociences, 610181 Mouse 1:1000 Specific
CK7 Dako, M7018 Mouse 1:250 Specific
CK20 Sigma, SAB4502249 Rabbit 1:250 Specific
CK5/6/8/18 Leica, CK5/6/8/18 Mouse 1:100 Specific
CD44 CST, 3570S Mouse 1:100 Specific
EpCAM CST, 2929S Mouse 1:200 Specific
Vimentin Sigma, V6630 Mouse 1:400 Specific
Snail Abcam, ab180714 Rabbit 1:800 Specific
MMP9 Dako, A0150 Rabbit 1:250 Specific
CD133 Mitlenyi biotech, 130090422 Mouse 1:500 Specific
Ki67 Dako, M7240 Mouse 1:50 Specific
EGFR Invitrogen, 28005 Mouse 1:50 No stain
Src CST, 2110S Mouse various No Stain
Lgr5 Abgent, AP2745d Rabbit various No stain
MMP7 CST, 38015 Rabbit various No stain
UPAR Dako, M7294 Mouse 1:25 No stain
TGFB1 R&D Systems, MAB240 Mouse 1:25 No stain
PARD3 Sigma, HPA030443 Rabbit Various Non specific
Scrib Thermo, PA5-2862 Rabbit various Non specific
MET CST, 4560S Rabbit various No stain
MEK1/2 CST, 4694S Mouse 1:50 No stain
YAP CST, 4912 Rabbit 1:200 No stain
p-YAP Abcam, ab76252 Rabbit 1:100 No stain
Nanog CST, 4903 Rabbit 1:400 No stain
Oct4 CST, 2840 Rabbit 1:100 No stain
Sox2 CST, 3579 Rabbit 1:100 No stain
Table A. Primary antibodies utilised throughout the study and their experimental conditions.
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2.2.4.1 Chromogenic visualisation
Single antibody visualisation was carried out by incubating slides in DAKO Envision
antibody labelled with horse radish peroxidase (HRP) (Dako, anti-mouse: #K4001 or
anti-rabbit: #K4003) for 30 minutes. Slides were next washed three times for 5 minutes
in PBST whereupon the tissue is incubated in 3, 3 -diaminobenzidine (DAB)
visualisation solution.
The initial step in dual antibody staining was as above; however, with the addition of
goat anti-mouse bound Alkaline Phosphatase (Sigma, #A3562, 1:50) to the anti-rabbit
HRP. Visualisation was performed using the Vector Black Alkaline Phosphatase
Substrate Kit (Vector laboratories, #SK-5200) and Vector NovaRed Peroxidase
Substrate Kit (Vector laboratories, #SK-4800) as per manufacturer’s protocol.
The slides were washed in water for 2 minutes after visualisation steps and incubated
in Haematoxylin for 1 minute prior to tissue dehydration and mounting, as described
in section 2.2.1, before microscopic visualisation.
2.2.4.2 Immunofluorescence visualisation
Dual antibody visualisation was performed by incubating slides in a secondary
antibody solution of 1:25 dilution of goat anti-rabbit or goat anti-mouse Alexa555 Ab
(Invitrogen, anti-rabbit; #A21428, anti-mouse; #A21422) in Dako Envision goat-
mouse HRP antibody for 1.5 hours in the dark at room temperature. Slides were
washed for three x 5 minutes in PBST. Cy5 Tyramide was diluted 1:50 in target signal
amplification diluent (Perkin Elmer, #SAT705A001EA, 1:100) and used to incubate
the tissue for 10 minutes at room temperature in the dark. A final wash of PBST was
performed prior to tissue dehydration using 80% alcohol for 1 minute and air drying
for 2 hours in the dark. Once the tissue was dry slides were mounted by adding Prolong
Gold anti-fade reagent containing DAPI (Invitrogen, P36931) to a coverslip which was




Brightfield microscopic images of tissue sections or TMA cores were captured and
digitised on an Olympus DotSlide (Olympus, Southend- on-Sea) microscope or a
Leica SCN400 whole slide scanner (Leica Microsystems UK Ltd, Milton Keynes,
UK).
2.3.2 Fluorescence
Whole slide and TMA immunofluorescence images were captured and digitised on an
Olympus AX-51 epifluorescence microscope (Olympus, Southend-on-Sea, UK) or a
Carl Zeiss AxioScan.Z1whole slide scanner (Carl Zeiss, Göttingen, Germany). Both
microscopes were fitted with filter blocks for DAPI, Cy3 and Cy5 visualisation. The
set exposure times on the Olympus AX-51 epifluorescence microscope were as
follows: DAPI (200ms exposure for nuclei), Cy3 (35ms exposure for panCK) and Cy5
(200ms exposure for D2-40). The set exposure times on the AxioScan.Z1whole slide
scanner were as follows: DAPI (50ms exposure for nuclei), Cy3 (10ms exposure for
panCK) and Cy 5 (50ms exposure for the various biomarkers)
The Olympus AX-51 epifluorescence microscope was linked to HistoRX’s
AQUAsition image capture software. This allowed an overview scan of the whole slide
at 4x objective to be captured. ROIs within the whole slide image were then selected
through the AQUAsition software and were captured with a 20x prior to exporting for
image analysis as .TIFF files.
2.4 Image Analysis
All image analysis algorithms were developed and executed using Definiens image
analysis solutions (Definiens AG, Munich, Germany). The two software packages
from Definiens which were used were Definiens Tissue Studio® and Definiens
Developer XD. Tissue Studio® utilises pre-installed algorithms to build image
analysis solutions for the detection, segmentation and quantification of tissue
morphometrics and associated biomarkers. Developer XD, although more user
47
intensive and complex to programme, allows the creation of bespoke image analysis
solutions which results in a higher flexibility of image manipulation. Both software
packages are capable of brightfield and fluorescence image analysis. Initial image
analysis solutions from Tissue Studio® may be imported into Developer XD for
further algorithm development and optimisation.
Images were imported into the Definiens software as 8bit .TIFF files when captured
on the Olympus AX-51 epifluorescence microscope coupled to the HistoRX’s AQUA
image capture software. A customised import algorithm was created in order to
perform this action. Images captured by the other three whole slide scanners were
imported directly into Definiens in their native file formats; the 10bit Olympus dot-
slide (.vsi), the 12bit Leica SCN400 (.scn) and the 16bit Carl Zeiss AxioScan.Z1 (.czi),
through Definiens pre-installed image importers.
Multiple iterative image analysis algorithms and solutions were created in Definiens
Tissue Studio® brightfield and immunofluorescence software environments to
optimise the segmentation of tumour from stroma and tumour gland lumen/necrosis
and to quantify set histopathological features. Initial tissue detection and the
segmentation of images was consistently performed within Tissue Studio®, however
due to constraints within the software package, tissue artefact and tissue heterogeneity
the Tissue Studio® segmented images were imported into Developer XD for further
processing. An iterative process of algorithm programming within Developer XD
allowed for more sophisticated image analysis development. Further details of the
image analysis algorithms are provided in the Results chapters and specific settings
for each algorithm are detailed in the appendices.
2.5 Installation of a Digital Pathology Pipeline
The digital pathology pipeline consists of components which allow the capture of high
resolution digital pathology images from microscope slides, their storage, the remote
viewing of stored digital pathology slides and their analysis by computer-based image
analysis algorithms (Figure A).
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Figure A. Fully integrated digital pathology pipeline. Glass tissue sections were digitised by either the
Leica SCN400 or the Zeiss AxioScan.z1 whole slide imagers. Whole slide images (WSI) were saved
and backed-up to a remote storage location. Remote viewing software (SlidePath or Zen Browser) can
access the remote storage and allow access to WSI through the internet. Definiens image analysis
software accessed images within the remote image repository for automated image analysis. Image
analysis processing and software licences were stored centrally and accessed remotely by users.
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2.5.1 Leica SCN400
A Leica SCN400 brightfield whole slide scanner was installed in the Royal Infirmary
of Edinburgh’s pathology department laboratories. The scanner has the capability of
capturing high resolution brightfield images of whole tissue sections and TMAs at 20x
or 40x magnification using a single 20x objective. The scanner can automatically scan
4 slides in each run. This scanner was introduced to the pipeline to digitise small
batches of routine clinical and research chromogen stained slides.
2.5.2 Carl Zeiss Axio Scan.Z1
The Carl Zeiss Axio Scan.Z1was also installed in the Royal Infirmary of Edinburgh’s
pathology department laboratories. The scanner has the capability to digitise either
brightfield and fluorescence whole tissue sections or TMAs mounted on microscope
slides with 5x, 20x and 40x objectives. The scanner contains 2 separate cameras for
brightfield or fluorescence and has two separate illumination sources: an HXP bulb
illumination and LED illumination alongside 9 separate fluorescence filter blocks for
multiplexing. The scanner can hold a magazine of 100 slides in each run. This scanner
was introduced to the pipeline for complex multiplexed immunofluorescence based
pathology and for large batches of chromogen stained slides.
2.5.3 Image Storage
Images captured with the whole slide scanners are uploaded to and stored on a remote
file storage system within the University of Edinburgh’s IT infrastructure (ECDF
NAS, University of Edinburgh). The file storage system is NTFS formatted with
SAMBA file sharing capabilities. The storage system also has an associated UNC path
to make the files accessible for the remote viewing software. The data storage contains
a 1TB hard drive and is managed and fully backed up by the University of Edinburgh.
2.5.4 Remote viewing
Two virtual machines with associated MS SQL server databases (Microsoft
Corporation, Redmond, USA) were installed within the digital pathology pipeline to
facilitate the remote viewing of digital slides. Each machine requires a quad core CPU,
4GB of RAM a 1GB NIC card and 64-bit windows server 2008 to be installed. One
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machine hosts Leica’s Slidepath remote viewing and file indexing system while the
other hosts a similar system from Zeiss called Zen Browser.
Both SlidePath and Zen Browser allow users to store and view their images remotely
with no client software needed on the end user’s computer or device. Images can be
accessed, annotated and shared or saved locally from any compatible device with an
internet connection and access to the World Wide Web (www). Both systems are
password protected and users only have access to images they are authorised to view.
2.5.5 Image Analysis
The digitized images which are stored on the remote storage file system can be directly
imported from this location into Definiens image analysis software. A central
workstation computer holds both the Definiens software licences and the engine
licensce. The central image analysis workstation has the recommended system
requirements of: Windows 7 64-bit operating system installed, an Intel Quad Core
CPU, a NVIDIA graphics card, 8GB RAM and a 1TB hard disk. The Definiens
software is downloaded onto an end-user’s computer and the end-user utilises the
remote software license, which sits on the central workstation, in order to activate the
software. The images are imported directly into the software in their native format
(Leica; .scn files and Carl Zeiss; .czi files) using Definiens pre-installed image
importers. The end user configures the image analysis solution locally. Once the image
analysis solution is ready to be run across all images within a project workspace the
end user sends the workspace for batch processing to the analysis engine located on
the remote central workstation server. Once the image analysis is complete the end
user can view the results on their local machine. Multiple image analysis workspaces
can be queued for analysis on the analysis engine and from multiple users.
2.6 Statistics
Where multiple images were captured across a patient tissue sample the resultant
export parameters were either summed or averaged to create a single row of data per
sample. Optimal cut-offs, based on disease specific survival, were calculated for each
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histopathological parameter reported in the thesis. Parameter values were loaded into
X-Tile (University of Yale) (275) software along with patient outcome information
and significant cut-offs for each parameter were calculated from Kaplan-Meier
analysis. To avoid over-fitting and multiple cut-point selection, corrected P-values for
the cut-offs were calculated using cross-validation within Monte Carlo simulations
(n=1000). Monte Carlo simulations are a problem solving technique used to
approximate the probability of certain outcomes by running multiple trial runs, called
simulations, using random variables.
Patient survival data and binary parameter data, according to cut-offs, were uploaded
into SPSS software (IBM, New York, USA) for univariate and multivariable Cox-
regression analysis. Pearson’s Correlation between set histopathological features was
calculated using the SPSS software and P-values for the correlation were adjusted by
Bonferoni correction for multiple testing. Principle Component Analysis was also
executed within the SPSS software. TMA navigator
(http://www.tmanavigator.org/)(276) was used to calculate and plot Kaplan-Meier
survival curves and the significance of the separation was calculated via the log-rank
(Mantel-Cox) test while the P-values are false discovery rate (FDR) corrected using
the Benjamini-Hochberg procedure to account for multiple hypothesis testing.
From the 123 parameter phenotypic fingerprint the most significant features which
differentiate between good and poor outcome were identified using Random Forest
and associated Gini score while a decision tree mathematical model to identify novel
histopathological features was constructed using a classification and regression tree
approach (CART) (Salford Predictive Miner, Salford Systems, San Diego, USA).
Random Forest results were validated by 2/3rds out-of-the bag validation. To avoid
over-fitting in the CART model, 10-fold cross-validation was carried out as part of
the binary recursive partitioning.
PCA was utilised in this study to reduce the dimensions of the large multi-parametric
phenotypic fingerprint and enable its visualisation and clustering of patients in a 2D
scatter plot. PCA was therefore output as 2 dimensions. PCA identifies the principal
components within the data which differentiate the patient samples ie which
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parameters contain the most variance. PCA converts the data into linearly uncorrelated
principal components where the 1st component accounts for the most amount of
variability and the second the most variance after the 1st. 72% of the variance was
captured within the 2 components in this study.
Random forest was utilised to identify the significant parameters within the phenotypic
fingerprint. The random forest model created 5000 decision trees to model 2/3rds of
the original data. The remaining 1/3rd of the data was used for out of the bag validation
of the model. Random forest examined every branch of every tree in deciding the
overall model and the importance of each parameter via majority ensemble voting and
outputs the parameters which are the most statistically relevant in making the binary
decision of risk of disease specific death. Random forest assigns a Gini score to each
parameter which directly correlates to the variable importance and the extent to which
each variable contributes to optimal separation of the outcome patients (disease
specific death during follow up). This model was used to reduce the phenotypic
fingerprint to only its significant parameters and to delete redundant ones.
Unlike random forest, CART produces a single decision tree which acts as a flow chart,
where each node or branch point is a test on a parameter. CART identifies the optimal
combination of parameters and calculates their cut-off from these tests. CART is
therefore applicable to a clinical test as it identifies the single optimal combinations of
parameters within a multi-parametric data set and informs on a patient’s cut-off for
that test from their continuous data set of that parameter.
53
Chapter 3: Quantifying the lymphatic
vasculature through image analysis
1.1 Introduction
The lymphatic and blood vasculatures are vital components of the tumour’s
microenvironment. They are not only responsible for delivering the host’s immune
reaction to the neoplastic growth but also for providing the oxygen and nutrients
needed for the tumour’s expansion, while ultimately providing routes of invasion from
the primary tumour allowing systemic and metastatic spread of the disease (277).
A wealth of original studies, systematic and meta-analysis reviews have been
published on the subject of lymphatic vessel invasion (LVI) (252, 256, 260, 264, 278),
blood vessel invasion (BVI) (256, 278-280) and vessel density (281-283). A number
of these have concentrated on early stage disease and the ability to utilise
histopathological features to predict lymph node metastasis, distant metastasis or to
stratify patients at high risk of disease recurrence and poor outcome (47, 252, 262-264,
283, 284). Although LVI and BVI have been shown to be significantly prognostic in
the majority of these studies, only extramural lymphovascular invasion (EMLVI), not
intra-tumoural, is stated historically as being a parameter to be recorded routinely as
part of the core data set compiled by the RCPath (261). In reality the parameter which
is predominantly reported is extramural venous invasion, because LVI itself is difficult
to recognise confidently in H&E stained CRC tissue sections. The parameter of
EMLVI has been replaced, by RCPath in 2014, with venous invasion to acknowledge
this fact and due to the possibility that intra-tumoural invasion may also be
prognostic(102). The pathologist is encouraged to distinguish between the two
classifications of vasculature invasion, although only venous invasion and not
lymphatic invasion is recorded within the core data set (102). LVI can be difficult to
observe within H&E stained tissue sections. LVI’s obscurity is due to the lack of a
surrounding rim of muscle and the absence of blood cells in lymphatic vessels, such
as is found with blood vessels(285), and confusion of lymphatic vessels with retraction
artefact(286, 287). Retraction artefact is a product of the fixation process and the result
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is that of retraction of the stromal tissue from a neoplastic gland or nest of tumour
cells, leaving white space surrounding the tumour cells, which can be misrepresented
as an invaded lymphatic vessel (Figure 5).
Figure 5. Examples of retraction artefact in H&E stained CRC tissue. Black arrows show retraction
artefact around cancer cells or neoplastic glands. Green arrow shows cancer cells within white
space which may be a lymphatic vessel or may be retraction artefact. Images captured with a x 20
objective.
The phenomenon of ‘occult LVI’ or unobserved isolated tumour cells is even more
pronounced when involving microvessels within an H&E stained tissue section; in this
case a single or small number of tumour cells have invaded such a microvessel, which
easily goes unreported due to its obscurity.
Although blood vessels are simpler to identify in H&E stained tissue sections both
BVI and LVI are routinely under-recognised under observation (266, 279), affecting
the variability of reporting within these studies. There are a number of reasons for
this: inter and intra-observer variability (92, 93, 278, 283), multiple quantification and
sampling methodologies resulting in no agreed or standardised reporting system (20,
55
272, 288, 289) and the difficulty in observing occult and rare phenomena in routine
H&E stained tissue sections (265, 266, 279). Thus the manual, semi-quantitative
scoring employed in these studies is subjective, open to variability and is time
consuming.
Specific stains are more frequently being employed (136, 252, 260, 265, 279, 283) in
order to increase reporting rate and decrease observer variability but there is no
consensus yet on what is best. The use of specific histochemical markers, such as
Elastin staining, CD31and CD34, have been employed to highlight blood vessels and
increase reporting rates of invasion events (279, 286, 290). Roxburgh(279) and Kirsch
R et al(291) have both recently and independently shown a 3-fold and a 2-fold increase
respectively in events of BVI in CRC when employing Elastin staining compared to
H&E staining. Studies also showed a decrease in observer variability when an elastin
based stain is employed(291). To overcome the problem of identifying LVI and
differentiating blood vessels from lymphatic vessels, studies have employed
immunohistochemical staining with a D2-40 antibody which specifically binds to
lymphatic vessel endothelial cells (252, 265). The Royal College of Pathologists now
recommends the use of D2-40 to verify LVI when it is suspected, although they do not
insist on the routine application of the stain(102). Although there are rarely blood cells
within the lymphatic vessels, multiple immune cell types may be present. Invading
CRC epithelial cells can take on a more mesenchymal or rounded phenotype which
may be confused with such immune cell types. These morphological transitions may
be another source of LVI reporter variability adding to the reasons it has not provided
enough proof to be included in the core data set. Dual staining of epithelium and
vessels allows easier recognition and reporting of LVI events (265) within the complex
tumour microenvironment which should decrease observer variability.
Whether BVD and LVD are predictors of poor outcome and disease recurrence is
somewhat more controversial. Studies published in the literature have shown both
significance and non-significance in a correlation of LVD and prognosis(43, 283, 284,
292). Due to this reason vessel density is not mentioned in the UKs institutional
guidelines(102). There is even greater scope for observer variability when manually
reporting vessel densities in a semi-quantitate manner in H&E stained slides and
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vasculature stains are routinely adopted to allow such quantification(43, 284).
Vasculature density assessment is, however, not standardised and most researchers
employ various magnifications and numbers of vessel “hot-spots” utilised to create a
mean vessel density. Observer variability has been shown to be strong in reporting
vessel density (283).
Although specific histochemical and immunological stains may increase the observer
rate of rare and obscure histopathological events there is still scope for variability and
human error. The utilisation of computer aided quantification of digital images brings
additional robustness with the ability to standardise the quantification of
histopathological features while minimising observer variability(293, 294). Modern
and sophisticated image analysis solutions allow the robust quantification of such
features across TMAs as well as whole slide images while simultaneously correcting
erroneous object segmentation of tissue artefacts such as non-specific staining and
autofluorescence. Accurate and standardised reporting of histopathological features,
such as vasculature invasion, through image analysis could allow the more robust
analysis of their prognostic value, as the same algorithm may be tested on multiple
validation cohorts from international institutes.
This chapter lays out the optimisation of specific histochemical stains to visualise the
vasculature within the CRC microenvironment and details the development of novel
associated computer based algorithms created for the quantification of lymphatic
vessel invasion and lymphatic vessel density. Occult LVI, isolated tumour cells or
small tumour clusters within microvessels, are especially difficult to observe in H&E
stained tissue sections, and therefore remain unquantified in the clinical setting. The
hypothesis for this study is that occult LVI is a poor prognostic factor and the
quantification of this event could sub-stratify stage II CRC patients. The finalised
quantification algorithm is therefore designed to quantify occult LVI, larger invasion
events and LVD across a CRC training set and from where optimal prognostic cut-offs
are calculated. These cut-offs are then applied to larger and clinically relevant
validation set to assess their prognostic relevance. The standardised quantification of
the histopathological features, if proven prognostically significant after further large
validation studies, is amenable to being applied to clinical practice.
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1.2 Optimisation of vasculature histochemical stains
Specific histochemical stains were employed to evaluate the visualisation of the blood
and lymphatic vasculature and its quantification in a reproducible manner. These stains
were first assessed for specificity, before being optimised, in colorectal tissue sections.
Two methodologies were tested for specificity of staining blood vessels and one for
the staining of lymphatic vessels.
1.2.1 Elastic Verhoeff-Van Geison (EVG) histochemical stain
Elastic Verhoeff-Van Geison (EVG) stain specifically binds to and stains the elastin
fibres present in tissue, such as in the adventitia of veins and associated arteries, a
black colour while lymphatic vessels remain unstained. The stain can therefore be used
to visualise and differentiate blood vessels from lymphatic vessels and aids in the
reporting of venous invasion. Serial sections were cut from the control CRC whole
tissue sections and stained with H&E or EVG (at 2 minutes and 3 minutes
differentiation with Ferric Chloride) for comparison. The slides were scanned using
the Olympus Dot-slide. The EVG methodology successfully stained the elastin within
the walls of arteries and larger blood vessels black, although not always encompassing
the entire vessel. This was the case when the tissue was differentiated for both 2 and 3
minutes in Ferric Chloride, although the black elastin fibres were more pronounced
after only 2 minutes of differentiation (Figure 6 A, B, D & E). EVG allowed blood
vessels to be visualised with greater ease than in H&E stained serial sections (Figure
6 C & F). Although EVG was specific for staining larger blood vessels, the majority
of microvessels and capillaries remained unstained (Figure 6 G, H & I). As
microvessel invasion is more difficult to observe and report than larger arterial
invasion in classical H&E stained tissue sections, and as they remained unstained by
the EVG, this stain was not taken forward for the final vasculature quantification assay.
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Figure 6. Optimisation of EVG labelling of blood vessels. Yellow arrows show positively labelled blood
vessels by EVG. Red arrows show non labelling of blood vessels after EVG. Black arrows show elastin
fibres in H&E stained tissue. A) EVG stain with 2 minutes differentiation in Ferric Chloride, B) EVG
stain with 3 minutes differentiation in Ferric Chloride and C) H&E stain show serial sections of a CRC
tumour block captured with a 4x objective; arrows show elastin fibres surrounding blood vessels. D, E
and F show the serial sections captured with a 10x objective which correspond to A, B and C
respectively. G, H and I show small blood vessels which remain unstained after EVG labelling. Image
captured with a x 10 objective.
1.2.2 CD31 immunohistochemistry
In an attempt to obtain a more complete contrasting stain for blood vessels, IHC, using
the antibody CD31 (Platelet endothelial cell adhesion molecule; PECAM-1), was
performed. CD31 is an endothelial cell marker which is specific to blood vessels and
does not bind to the endothelial cells of the lymphatic channels. Antibody dilution was
optimised on the CRC optimising TMA (Figure 7) and visualised through DAB
staining while nuclei are counterstained with haematoxylin. The slides were digitised








using the Olympus Dot-slide. At a dilution of 1:1000 the antibody was found to be
specific to blood vessels within the CRC tissue samples. More concentrated dilutions
of antibody resulted in non-specific binding within the tumour microenvironment.
1.2.3 D2-40 immunohistochemistry
In order to visualise the lymphatic vessels, and differentiate them from retraction
artefact and from smaller blood vessels, IHC using the antibody D2-40 (Podoplanin)
was tested. D2-40 binds specifically to the antigen Podoplanin which is present in
lymphatic vessel endothelial cells but absent from blood vasculature. The dilution of
antibody was optimised using the CRC optimising TMA (Figure 7) and visualised
through DAB staining, while nuclei were counterstained with haematoxylin. The
slides were digitised using the Olympus Dot-slide. A dilution of D2-40 antibody at
1:1000 was found to specifically bind to lymphatic vessels and not stromal components
of the tumour microenvironment as was the case at more concentrated dilutions.
1.2.4 Immunohistochemistry specificity and robustness
To further investigate the specificity of the antibodies to solely stain the intended
vessel type, either blood or lymphatic, further IHC was performed for each antibody
on serial sections of the control whole CRC tissue block and in parallel with H&E
stained sections. On the serial sections the same area containing blood and lymphatic
vessels was identified and the specificity assessed visually. The slides were digitised
using the Olympus Dot-slide. In Figure 8, two areas where D2-40 and CD31 have
accurately labelled lymphatic or blood vessels respectively can be seen. In the H&E
stained section, the larger blood vessels are easy to identify, however some lymphatic
channels are difficult to differentiate from white space and retraction artefact.
This adds strength to the argument that specific stains are needed to observe lymphatic
channels and quantify occult lymphatic vessel invasion within smaller vessels. The
D2-40 label’s contrast to background is strong and complete lymphatic vessels are
stained compared to partial or weak labelling of blood vessels by CD31.
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Figure 7. CD31 and D2-40 antibody optimisation. At 1:500 dilution both CD31 and D2-40 antibodies
showed non-specific stromal labelling (black arrows). CD31 (blood vessels; red arrows) and D2-40







Figure 8. Accuracy of CD31 and D2-40 vasculature labelling. A and B show 2 areas containing blood
and lymphatic vessels. Serial sections were cut and labelled with either H&E, D2-40 or CD31. Black
arrows indicate lymphatic vessels and red arrows indicate blood vessels. Left panel was captured with










This inconsistency in labelling of blood vessels by the antibody CD31 is further
demonstrated in Figure 9. Not all blood vessels are completely labelled by CD31 and
weak DAB visualisation may be further masked by the haematoxylin counterstain,
whereas some remain completely unlabelled.
Figure 9. Incomplete labelling of blood vessels by CD31. A and B show two areas of a tissue section
labelled with CD31 immunohistochemistry. These areas contain large and small blood vessels. Red
arrows show blood vessels which remain unlabelled. Black arrows show blood vessels with partial or
weak labelling. Left panel was captured with a x 5 objective and the right panel was captured with a x
10 objective.
For this reason, and due to CD31 also reacting to certain T-Cells, leukocytes and
neutrophils, its use was not continued to label blood vessels. In contrast the D2-40
antibody robustly labelled the lymphatic vasculature and therefore the study
progressed to computer based analysis of only the lymphatics within the CRC tumour
microenvironment and assessed their prognostic significance in CRC. To add further
proof of specificity and to act as a positive control for the D2-40 antibody to label
lymphatic vessels, IHC with D2-40 was performed on lymph nodes from CRC
patients. Lymphatic vessels within the lymph node and surrounding fatty tissue are
labelled strongly and completely with D2-40 while lymphocytes and blood vessels




Figure 10. Positive control lymph nodes labelled with D2-40 Immunohistochemistry. Red arrows show
lymphatic vessels in the lymph nodes labelled with D2-40. Black arrows demonstrate blood vessels
which remain unlabelled by the D2-40 antibody. Images captured with a x 10 objective
Histochem icallabel optim isation vasculaturestained specificity utilisedinfinalassay
EVG 2 min differentation venous only incomplete staining No
CD31 1:1000 dilution venous only incomplete staining No
D2-40 1:1000 diltuon lymphatic only complete staining Yes
Table 2. Summary of the optimisation of histochemical vasculature labelling.
1.3 Brightfield image analysis
To quantify the D2-40 labelled lymphatic vessels through image analysis the tissue
section must first be digitised. Sections were taken from the control CRC blocks and
D2-40 based IHC performed with DAB visualisation and haematoxylin counterstain.
The tissue sections were digitised on the Leica SCN400 and imported into Definiens
Tissue Studio®, using the Definiens pre-installed Leica image import algorithm.
1.3.1 Automated quantification of lymphatic vessels
Post image import the chromogen optimised Vessel Detect algorithm was selected
from the list of pre-installed Tissue Studio® algorithms and used to detect lymphatic
A B
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vessels within the digitised tissue section. DAB stain thresholds and vessel area
metrics were selected to allow the segmentation and quantification of lymphatic
vessels (Figure 11, Vessel Detection). Once segmented the vessels are classified by
size and if they contain a lumen (Figure 11, Vessel classification). The cut-offs for
small, medium and large vessels were performed manually and under the supervision
of a consultant pathologist. Full algorithm settings are listed in Appendix 1.
Figure 11. Tissue Studio’s Vessel Detect algorithm. Algorithm detects vessels through chromogen and
area thresholds before classifying them by size. Vessel detection section allows the adjustment of the
DAB chromogen threshold which relates to quantifying the positive labelling of vessels. The Vessel
classification section allows the thresholding of vessels dependent on size. Arbitrary figures may be
selected to identify small, medium or large vessels.
The algorithm successfully segmented and quantified vessels accurately (Figure 12).
Algorithm export parameters are listed in appendix 2 and include; number of vessels,
area of vessels and vessel density.
Adjust chromogen threshold and
minimum stained area
Adjust vessel size for classification
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Figure 12. Segmentation of D2-40 DAB labelled lymphatic vessels through image analysis. A) Original
digitised image of lymphatic vessels labelled with DAB after IHC with D2-40. B) Definiens image
analysis mask classifying vessel by size. C) Definiens image analysis mask segmenting vessel walls and
lumen. Images captured with a x 5 objective.
1.3.2 Automated quantification of lymphatic vessel invasion
After manual assessment of digitised whole tissue sections stained with D2-40, some
lymphatic vessels containing cells within the lumen were observed (Figure 13).
Although the majority of the cells within the lymphatic vessel lumen seemed non-
epithelial containing small and round nuclei akin to lymphocytes, it proved difficult to
be certain of distinguishing host from epithelial cancer cells. A reason for this is the
heterogeneous morphology of host immune cell nuclei. Invading CRC epithelial cells





Figure 13. Cells observed within lymphatic vessel lumen. Immunohistochemsitry with D2-40 visualised
with DAB shows lymphatic vessels containing haematoxylin stained nuclei within their lumen. Images
captured with a x 20 objective.
To be able to quantify LVI accurately through image analysis, the software must be
able to detect if the cells within the vessel are epithelial cancer cells and not host
immune cells. An initial attempt was made to utilise Tissue Studio®’s nuclear
detection and morphometry algorithm, in concert with the previously optimised vessel
detect algorithm, to train the software to recognise only epithelial cancer cells using
nuclear morphology and exclusion parameters (Figure 14). The algorithm detects all
nuclei based on haematoxylin and size thresholds. Nuclei are excluded depending on
length/width, haematoxylin stain and area parameters. Using these parameters an
attempt was made to exclude host immune cell nuclei which were round, small and
dark haematoxylin stained. The non-round, large and lighter haematoxylin stained
nuclei which were more typical of epithelial cancer cells remain quantified. Nuclei
which pass the parameter exclusion criteria were then classified as small, medium or
large. Full algorithm settings are listed in Appendix 3.
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Figure 14.Tissue Studio Vessel Detect algorithm utilising exclusion parameters to differentiate host
immune cells from cancer epithelial cells. All Nuclei are segemented by haematoxylin but the nuclear
morphology and filter settings are utilised to attempt to exclude small and round host cells. Post vessel
detection nuclei are classified dependent on their size.
Limitations within the Tissue Studio® software only allow a maximum of 3 exclusion
nuclei parameters and are unable to perform logic gating on the parameters. This
coupled with the heterogeneity of epithelial, mesenchymal and immune cell
populations resulted in this algorithm not being robust enough to ensure only epithelial
cells were quantified. This resulted in host cells being retained for quantification and
epithelial cells being excluded from the algorithm. (Figure 15).
Detects all nuclei in tissue section
Excludes nuclei from algorithm
dependent on parameters
Classifies segmented nuclei into size
classification
Features applied to exclude host
Immune and stromal cells from
algorithm
Detects all vessels in tissue section
Classifies segmented vessels into size
classification
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Figure 15. Vessel Detect algorithm’s incorrect classification of host and cancer cells. Image A) shows
cells within neoplastic glands as well as host stromal cells counterstained with haematoxylin. Image B)
displays Tissue Studio’s nuclear classification image analysis mask. Epithelial cells should be classified
as small (yellow), medium (orange) or large (red) while stromal host cells should be excuded (grey).
Green arrow shows correctly identified cancer cells, red arrow shows cancer cells excluded as host cells
and yellow arrow shows stromal cells included and classified as tumour cells. Images captured with a x




Cancer epithelial cells were not able to be detected and differentiated from host cells
through nuclear morphometry and haematoxylin alone. In order to quantify epithelial
cancer cells robustly though digital pathology and automated image analysis a specific
epithelial stain was utilised. Cytokeratins are exclusively expressed in epithelial cells
and an antibody recognising a broad number of cytokeratins, named as a pan-
cytokeratin antibody (panCK), can be used to visualize adenocarcinoma cells. A
panCK antibody ensures the visualization of all epithelial cells which may be
expressing heterogeneous cytokeratins due to mutations in the cancer cell’s genome.
Dual IHC would allow the visualisation of both lymphatic vessels and epithelial cells
within the same tissue section and therefore allow a more robust analysis of lymphatic
invading cancer cells.
1.4.1 Pan-cytokeratin immunohistochemistry
The ability of the panCK antibody to specifically label epithelial cells was first
assessed in a single antibody assay with DAB chromogen visualisation. Control whole
tissue sections were utilised for this experiment. All epithelial cells within neoplastic
glands or existing as smaller invasive subpopulations were contrasted against tissue
stroma and identified with greater confidence than with H&E alone (Figure 16).
Figure 16. Immunohistochemistry with panCK DAB (brown stain) visualisation of colorectal cancer
epithelial cells. Tissue section was counter stained with haematoxylin. Image captured with a x10
objective.
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1.4.2 Multi-colour chromogen visualisation
In order to differentiate and visualise antibodies against panCK and D2-40, on a single
tissue section, contrasting coloured chromogens must be used. The antibodies against
panCK and D2-40 were combined in a multiplexed IHC which implemented NovaRed
and Vector Black respectively for antibody visualisation and haematoxylin as
counterstain. The resultant combination of colours on the single tissue section would
be red (D2-40), black (panCK) and blue (nuclei). Prior to multi-plexing, the two
chromogenic visualisation reagents were tested individually using the D2-40 antibody
and were compared to DAB labelling of lymphatic vessels. Serial sections of the
optimising TMA were cut and D2-40 IHC performed with DAB, NovaRed or Vector
Black visualisation reagents. Both NovaRed and Vector Black reagents caused non-
specific stromal staining and the contrast of vessel from stromal and tumour
background, for both new reagents, was worse than that of using DAB (Figure 17).
Figure17. Immunohistochemistry of serial tissue sections with D2-40. D2-40 visualised with A) Vector
Black, B) NovaRed and C) DAB. Red arrows show lymphatic vessels positive for D2-40. Images
captured with x5 objective.
A) Vector Black C) DABB) NovaRed
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Upon performing the triple multiplex IHC on single tissue sections taken from the
Optimising TMA, it proved difficult to differentiate the red from black chromogen and
the NovaRed reagent additionally created artefacts within the epithelium (Figure 18).
Vessels were also poorly contrasted when compared to the original DAB experiment.
Due to their poor labelling, the introduction of artefacts and the inability to
differentiate the two stains, without spectral unmixing, these images were not imported
into Definiens for image analysis and the methodology was abandoned.
Figure 18. Brightfield based IHC dual labelling of epithelial cells (panCK) and lymphatic vessels (D2-
40). Both Vector black and NovaRed visualisation reagents created non-specific staining of the stromal
tissue (A & B). C) DAB visualised D2-40 highlights lymphatic vessels (black arrows). D) Dual labelling
of panCK and D2-40 created similar chromogenic colours and Vector Black created staining artefact in
the epithelium (red arrows).
A) Vector Black B) NovaRed
D) NovaRed D2-40 & Vector Black CKC) DAB D2-40
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1.5 Immunofluorescence
Immunofluorescence allows the clear visualisation and separation of the three
histopathological features of interest within the multiplexed antibody IHC described
above. Each antibody as well as nuclear DNA is labelled with a distinct fluorophore
and fluorescence is captured on a fluorescence microscope at distinct wavelengths
ensuring no bleed through of emission spectra. This results in three separate and
individual grey-scale images containing the visualisation of either panCK
(epithelium), D2-40 (lymphatic vessels) or DAPI (all nuclei). These three images are
combined into a composite image where all three histopathological features can be
visualised distinctly in a single image (Figure 19). The multiplexed
immunofluorescence assay allows the clear identification of tumour cells within the
lymphatic vessels with no confusion with host cells. Immunofluorescence images were
captured on the Olympus AX-51 microscope as monochromatic high definition image
layers for the panCK (epithelium), D2-40 (lymphatic vessel) and DAPI (nuclei)
wavelengths prior to being imported into Definiens Tissue Studio® image analysis
software to create composite images and for image analysis.
1.5.1 Immunofluorescence Image analysis
1.5.1.1 Tissue Studio algorithm Development
Tissue Studio®’s immunofluorescence analysis builder creates algorithms based
around pre-installed image analysis solutions and which are made up of three stages
of analysis. The 1st stage is “ROI detection” where the tissue is initially segmented
dependent on histologically relevant regions of interest (ROI). The 2nd stage is
“Cellular analysis” where objects such as nuclei and cells are segmented and classified
within the previously segmented ROIs. The 3rd stage is “Data Export” from both ROIs
and segmented objects.
Fluorescence image analysis algorithm development was performed on the control
whole tissue sections. These positive and negative control tissue sections were utilised
to test the algorithms accuracy in quantifying LVI events and to identify LVI positive
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patients. 35 images were randomly captured at x20 magnification across the two tissue
sections for image analysis. Two separate image analysis algorithm approaches were
created around the backbone of two pre-installed Tissue Studio algorithms and
executed to quantify LVI and LVD. The two pre-installed algorithms were Tissue
Studio®’s immunofluorescence ‘Vessel Detect and ‘Marker Area’ algorithms. The
results from both image analysis approaches were compared against manual scoring,
and sensitivity and specificity to detect LVI was assessed.
Figure 19. Immunofluorescence visualisation of panCK, D2-40 and nuclei multi-plexed on a single
tissue section. Grey scale image layers captured at each wavelength; A) DAPI (nuclei), B) D2-40
(lymphatic vessels) and C) panCK (epithelial cells). D) Composite image showing all three image
layers. Composite images showing: well differentiated neoplastic glands (E), high lymphatic vessel
density and large neoplastic gland within a vessel (F) and high tumour budding with occult lymphatic
vessel invasion (G). H) & I) show micro vessel invasion of occult LVI at higher magnification. Images
captured with a x 20 objective.




Blue – DAPI, Red – D2-40, Green – PanCK
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1.5.1.2 Tissue segmentation
Both initial ‘Vessel Detect’ and ‘Marker Area’ algorithms executed the same ROI
tissue segmentation method which initially segmented the image into three distinct
ROIs: ‘tumour’, ‘stroma’ or ‘lumen/necrosis’. This initial segmentation was performed
using Definiens machine learning Composer technology™ which trains the computer
algorithms to segment and quantify the regions of interest (ROI) in the tissue section.
This is performed by manually selecting or “painting” representative areas of tumour,
stroma or tumour gland lumen/necrosis. The algorithm ‘learns’ the intensity and
morphometric parameters associated with these areas and automatically segments the
rest of the tissue section accordingly. (Figure 20). Figure 21 displays the image
analysis algorithm settings.
Figure 20. Composer Technology™ machine learning for automated tissue segmentation. A) Composite
image of panCK (green), D2-40 (Red) and DAPI (blue). B) Tissue studio auto-image segmentation. C)
Sections of stroma (turquoise), tumour (purple) and lumen/necrosis (yellow) are labelled by the user.
D) Composer Technology™ learns the spectral properties of each ROI and segments images




Figure 21. Tissue ROI Segmentation algorithm. The algorithm automatically separates tissue from
background dependent on user specified settings. Next it automatically segments the image into regions
of similar homogeneity prior to the user training the algorithm to recognise ROIs (Composer training).
The algorithm next grows all tumour ROI out by 2µm in each direction as specified by the user. Finally
any ROI classified as tumour which is below 5000µm
2
is automatically reclassified as Stroma. Once the
algorithm is taught it automatically segments and classifies all subsequent images within the Definiens
workspace. Within each section of the algorithm shown above are further settings which the user can
apply to uniquely programme the software to perform the listed tasks.
Lymphatic vessels are located within the stroma area only and the algorithm is
programmed only to quantify D2-40 positive objects exclusively within the stroma
ROI, however panCk invasive subpopulations may be classified as tumour by the
Composer technology™. The panCk subpopulations and the vessels which they invade
may therefore be classified within the tumour ROI and remain unquantified. Therefore
the next step of the tissue segmentation is to reclassify any region of segmented tumour
ROI which is below 5000µm2 into stroma ROI. This allows any invading panCK
positive cancer cells to be quantified within the stromal area (Figure 22). Full





Train algorithm to segment tissue
dependent on panCK and DAPI
Grows tumour areas outward
by 2µm





Figure 22. Automatic reclassification of small Tumour ROI into Stroma. A) Composite raw image. B)
Epithelial cells are classified as Tumour. C) Algorithm automatically reclassifies any Tumour below
5000µm
2
as stroma in order to quantify occult LVI. Images captured with a x 20 objective.
1.5.1.3 Vessel detect algorithm.
The initial image IF analysis algorithm to be tested was based around Tissue Studio®’s
pre-installed ‘Vessel Detect’ module.
Post ROI segmentation, iterative steps of intensity and size thresholding were
performed to ascertain the optimal settings for nuclei segmentation and vessel
detection. Nuclei are segmented from DAPI positive objects based on intensity and
size thresholding. Post nuclei segmentation all nuclei are discarded apart from those
which are above a 50au threshold of panCK intensity and are above 5µm2 in area. The
nuclei which are kept are deemed to be epithelial and the panCK threshold is set high
due to the observation that invasive tumour cells had increased panCK intensity over
the cells within the neoplastic glands. Smaller DAPI positive objects are discarded as
stromal, debris or artefact and not quantified. Vessels are next segmented based on
D2-40 threshold intensity. As vessel staining is occasionally incomplete, any gap of
4µms between D2-40 positive objects is automatically linked and segmented as one
vessel. The remaining nuclei are then classified as LVI ‘nucleus high’ if they contain
a D2-40 intensity of above 18au; essentially quantifying nuclei which have an area of
D2-40 and panCK colocalised above set thresholds equating to an epithelial cell within
a vessel. Vessels are then classified as small, medium or large and if they contain a
A B C
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lumen or not (Figure 23). Full algorithm threshold settings listed in appendix 5. An
overview of the algorithm set-up is displayed in Figure 24.
Figure 23A. Immunofluorescence vessel detect algorithm. A) & B) display 2 separate tissue sections
which were analysed by the algorithm. 1) The raw composite image (panCK: green D2-40: red, DAPI:
blue) is segmented into ROIs (tumour: orange, stroma: green, lumen: grey). 2) All nuclei (greyscale
DAPI) are segmented automatically (blue image analysis outline). 3) D2-40 positive lymphatic vessels
(greyscale D2-40 labelling) are segmented and classified dependent on size (orange mask shown equates
to a medium sized vessel. Images were captured with a x 20 objective. 4) panCK positive nucleus
(greyscale PanCK) within a D2-40 positive vessel (Composite; green: panCK, red: D2-40, blue: DAPI)
are classified as “Nucleus High” (dark red nuclear mask) within a positive vessel (purple vessel mask)
and quantified as an occult LVI event.
A BComposite ROI segmentation Composite ROI segmentation
DAPI Nuclei segmentation DAPI Nuclei segmentation










Figure 23 B. Digital zoom of: A) segmented vessel with vessel wall (purple) and vessel lumen (green)
classified. B) Epithelial nuclei not within a vessel (blue; Nucleus Negative). C)lymphatic vessels
classified as small (yellow), medium (orange) and large (red). D) automatic segmentation of nuclei.
Vessel with lumen Negative nuclei




Figure 24. Immunofluorescence vessel detect algorithm settings. Post Tissue segmentation the vessel
detect algorithm segments all nuclei through user specified DAPI thresholding. Discards small and low
intensity panCK nuclei through user specified panCK and object area thresholding. Segments vessels,
classifies nuclei as positive or negative dependent on user specified D2-40 intensity thresholding and
finally classifies vessels dependent on area.
Post analysis it was discovered that false positives were created when quantifying
positive nuclei in the stromal ROI due to areas of high background intensity of
fluorophores. Positive LVI hits were therefore re-classified as “Nucleus high” which
bordered a vessel wall. False positive nuclei were also located within the Tumour ROI
due to artefact staining of D2-40 antibody. A final positive LVI nucleus count was
classified as positive cells bordering a vessel within the stromal ROI only. Tissue
Studio® allows customisable data exports. The algorithm was set to export the number
of “Nucleus high” within the stroma and which bordered a vessel. The number of these
positive events were quantified for each tissue section and classified as the number of
LVI events per sample.
The results compare the LVI positive and negative control tissue sections from both
the image analysis results and from manual visual quantification of the fluorescence
images (Figure 25). Eight images within the positive LVI control were manually
identified as containing LVI events and of those five were correctly quantified by the
algorithm as positive for LVI. The algorithm correctly quantified zero LVI events in
the negative control section. Manually identified positives, in the positive control
section, in image 18 and 24 are excluded by image analysis due to being falsely
classified within the tumour ROI and thus not quantified.
Microvessel density is reported for each image and this parameter is automatically
exported from the algorithm. The negative control section contained LVD hotspots
(large areas of dense vasculature) while the positive control did not. Initial results
Segments all nuclei. DAPI thresholding
Discards low panCK and small nuclei
Segments all vessel. D2-40 thresholding
Classifies nuclei. D2-40 thresholding
Classifies vessels. Size thresholding
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suggest that increased LVD does not correlate with LVI, albeit after analysing only
two cases (Figure 26). The full results are summarised in Table 3.
Figure 25. Immunofluorescence Vessel Detect image analysis results. Quantifying only positive nuclei
which were bordered to a vessel (red) gave false positive LVI events due to tumour gland cells being
quantified as positive nuclei. Final automated LVI count was therefore reported as positive nuclei which
were bordered to a vessel within the Stroma (green). This was compared to LVI quantified by manually
assessing the IF images (purple).
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Figure 26. Quantification of microvessel density across the separate A) negative control and B) positive
control whole tissue sections through the immunofluorescence Vessel Detect algorithm. Vessel density
is reported across each image captured across each section
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Positive control Negative control
No. Manual assessed LVI 8 0
No. Image analysis LVI 5 0
specificity 100%
sensitivity 62.50%
Table 3. Summary of the exported Vessel Detect algorithm LVI results.
1.5.1.4 Marker Area algorithm
Post ROI segmentation the algorithm is programmed only to quantify objects of
interest within the stromal region. Nuclei are not segmented or quantified in this
algorithm. The algorithm segments objects within the stromal region which are above
a set intensity threshold for panCK and D2-40 which were established per tissue
section due to inter-section heterogeneity (Figure 27). Positive objects must also be
above a minimum stained area of 11µm2 as below this an object was not considered
big enough to be a cell or vessel. The algorithm classifies panCK positive objects as
“marker 1”, positive D2-40 objects as “marker 2” and colocalised panCK and D2-40
objects as “marker 1 & 2” (Figure 28). A full list of algorithm settings can be found in
appendix 6. Co-localised markers classified as “marker 1 & 2” are deemed to represent
LVI. To calculate LVD the area (µm2) of marker 2 (D2-40) objects per image within
the stroma is divided by the total stromal area (µm2). An advantage of this algorithm
over the ‘Vessel Detect’ algorithm is that it does not rely on the panCK intensities
measured within the nucleus, which will naturally be lower than within the cytoplasm.
The ‘Marker Area’ algorithm simply quantifies the area of co-localisation and so picks
up cytoplasmic expression of panCK as well as nuclear intensity. This results in the
algorithm accurately identifying more true positives.
Figure 27. Cellular analysis section for Marker Area Algorithm. Algorithm segments positive panCK
and D2-40 fluorescence objects above a set threshold. Algorithm next classifies any colocalised objects.
Segments D2-40 & PanCK objects
As well as their colocalisation
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Figure 28. Immunofluorescence Marker Area algorithm. A) & B) display two tissue sections which
were quantified by the Marker Area algorithm. 1) composite raw image of panCK (green), D2-40 (red)
and DAPI (blue). 2) Tissue Studio automatically segmented Tumour (orange) from Stroma (green). 3)
Algorithm segmented positive D2-40 (green mask) or panCK (red mask) objects within the Stromal
ROI only. 4) Occult LVI is quantified as colocalisation of D2-40 and panCK (yellow mask).
In the positive LVI control 6 out of 8 images were correctly quantified as containing
LVI events whereas the negative control reported no LVI events quantified (Figure
29). As with the Vessel Detect algorithm, two images were visually identified as
containing LVI but were not quantified within the algorithm, due to a mis-
classification of stromal ROI and tumour ROI.
A
B
1 2 3 4
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Figure 29. Immunofluorescence Marker Area image analysis results. Positive control reports 6 images
within the section which contain positive D2-40 and panCk co-localisation. The negative control reports
no LVI events within any images taken across this section
Similar to the vessel detect algorithm, it was observed that the positive control tissue














































Figure 30. Immunofluorescence Marker Area algorithm microvessel density export across images
captured within the positive control or negative control. The parameter is calculated by dividing the






















































The results for LVI quantification reported by the ‘Marker Area’ algorithm are
summarised in Table 4.
Positive control Negative control
No. visual LVI 8 0
No. quantified LVI 6 0
specificity 100%
sensitivity 75.00%
Table 4. Summary of Marker Area results.
1.5.2 Tissue Microarray LVI & LVD quantification
Both ‘Vessel Detect’ and ‘Marker Area’ algorithms reported no LVI events in the
negative control and successfully identified the majority of LVI events within the
positive control. The 35 images which were randomly captured across each whole
tissue section required analysis resulting in a processor heavy assay. An advantage of
using TMAs is that patient numbers can be scaled up with only one image to analyse
per patient sample and hundreds of patients may be analysed on a single microscope
slide. The training cohort TMA was employed in this experiment to evaluate the
accuracy and robustness of the image analysis algorithms to automatically quantify
LVI and LVD across a large heterogeneous TMA mounted patient cohort in a batch
process manner with no manual intervention.
After immunofluorescence and image capture on the Olympus Ax-51 microscope
system the images were imported into Definiens immunofluorescence Tissue Studio®
for analysis with both the ‘Vessel Detect’ and ‘Marker Area’ algorithms. Seven tissue
cores were manually identified as containing LVI events and classified as ‘visual
positives’. Extensive iterative optimisation was required to convert the algorithms to
be TMA amenable. The main source of error within the algorithms when run across a
TMA was due to tissue, biomarker and nuclear inter-patient heterogeneity, both in
intensity and morphology, as well as artefacts introduced by the TMA creation such
as tissue folding and edge effect.
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1.5.2.1 Tissue Segmentation
Due to inter-core heterogeneity the algorithm could no longer robustly quantify
necrosis. The tissue was segmented into tumour, stroma and ‘no tissue’. The ‘no tissue’
trained ROI was introduced to overcome edge effect, where non-specific staining is
prevalent (Figure 31). Classifying background as ‘no tissue’ allows the exportation of
the distance of a biomarker to ‘no tissue’. If the biomarker is within 30µm of ‘no tissue’
it is discarded as a false positive in post processing. Post processing consisted of
manually analysing of output data and removing objects within the 30µm distance to
‘no tissue’ exclusion zone. An area of high panCK intensity may overlap the
segmented border of a neoplastic gland and be segmented within the stroma which
result in a false positive LVI event occurring if a vessel is close to this border. To
overcome this, the algorithm automatically grows out all tumour areas into stromal
space by 2µm in all directions. The algorithm only quantifies biomarker intensity
within stromal areas. TMA ROI segmentation algorithm settings are listed in
Appendix 7.
Figure 31. TMA tissue ROI segmentation algorithm. A) Composite image of TMA core (green:
panCK, blue: DAPI). B) Tissue Studio automatically segmented Tumour (purple), Stroma (turquoise)
and no tissue (green) after composer training. C) Example of edge effect non-specific antibody




1.5.2.2 Vessel Detect algorithm results
The ‘Cellular analysis’ section of the algorithm, which quantifies ‘Nuclei high’ as LVI,
is identical to the whole tissue algorithm detailed in section 3.5.1.3. Table 5
summarises the results from the TMA analysis with the ‘Vessel Detect’ algorithm.
Five cores of the seven manually identified LVI positive cores were identified by the
algorithm as containing LVI events; however the nuclei within TMA core 51 and 104
which were identified as LVI were false positives while the true positives within these
images were missed. Due to false positive nuclei being detected in core 51 and 104
only three of the seven LVI positive cores were identified correctly. Only TMA core
30 and 66 identified all LVI nuclei within each image correctly. Image 65 was not
quantified as LVI positive due to stroma being incorrectly classified as ‘no tissue’.
Other reasons for positive LVI nuclei not being quantified were due to a below-
threshold nuclear panCK intensity or poor nuclear segmentation due to inter-core
DAPI intensity heterogeneity. Twenty nince false LVI positive cores were identified
across the TMA. Manual post-processing and quality control of the images and the
data discarded the majority of false positives, which were due to TMA effect (folded,
torn and overlapping tissue) and edge effect, leaving 8 images containing false positive
nuclei. Post processing is a manual and labour intensive step which involves the
deletion of cores from the quantification which contain TMA artefact or the exclusion
of objects due to edge-effect. The export of parameters ‘distance to no tissue’ and
‘Stromal intensity’ allows such post processing to occur. The remainder of the false
positives were due to incorrect tissue or nuclear segmentation and non-specific panCK
staining (Table 5). Microvessel density was also quantified and automatically reported
by the algorithm (Figure 32).
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Visualpositives Algorithm quantified positives
Algorithm reported
falsepositives
R em ainingfalsepositivesafterm anualpost-
processing
10 (5) 10 (1) 8 (6) 16 (3)
30 (3) 30 (3) 12 (1) 26 (2)
51 (1) 51 (1) 16 (4) 48(1)
66 (1) 66 (1) 23 (4) 55 (1)
65 (>10) 65 (0) 25 (3) 73 (2)
82 (1) 82 (0) 26 (2) 84 (1)
104 (9) 104 (2) 43 (2) 106 (1)





















Table 5. Summary of Vessel Detect TMA algorithm results. Positive LVI cores are entered under each
heading and the number of LVI events within each core is reported within brackets. Visual positives
were identified manually from the IF images. Quantified positives were reported by the analysis
algorithm. False positives were also reported by the algorithm. LVI events in bold type were within LVI
positive cores, however the algorithm reported on false positive events within these. Positive LVI Cores
in red type were not quantified by the algorithm.
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Figure 32. Microvessel density results reported by the Vessel Detect TMA. Vessel density is reported
per TMA core.
1.5.2.3 Marker Area algorithm results
Post ROI tissue segmentation the ‘cellular analysis’ section of the algorithm, which
quantifies colocalisation of “Marker 1” (panCK) and “Marker 2” (D2-40) as LVI, is
identical to the whole tissue algorithm in section 3.5.1.4. All 7 cores visually identified
as LVI were correctly quantified by the algorithm while 23 false positives were
reported. After manual post-processing of the false positives, there remained 5 cores
reporting false positive LVI (Table 6). Manual post-processing steps were similar to
the vessel detect algorithm with a few additional exclusion parameters added. If a
panCK positive object was deemed to be too small to be a cell (under 22µm) or if there
was a high background D2-40 staining in the stroma (mean stromal intensity threshold
of 17au across the TMA core) the positive object was removed. These results reported
a specificity of 91.82% and sensitivity of 100% for the number of correctly identified
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Table 6. Summary of Marker Area TMA algorithm results. The TMA core number quantified by the
algorithm is entered under each heading. Algorithm reports total area of LVI and so individual events
are not listed.
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Figure 33. Microvessel density results reported by the Marker Area TMA algorithm.
1.5.3 Tissue Studio® algorithm constraints
Although manual post processing decreases the number of false positives reported in
both TMA optimised algorithms there still remains multiple sources of false positives
and negatives. Manual post processing is not amenable to automatic image analysis.
Nuclei are not used for LVI quantification in the ‘Marker Area’ algorithm due to
Definiens’ hierarchical image analysis layers. Definiens image analysis algorithms
produce multiple layers of tissue segmentation which allow objects to belong to other
objects located on above or below layers. Therefore objects in a layer below other
objects, such as marker 1 and marker 2 objects within but below the Stroma ROI layer,
will always be connected to and belong to the Stroma ROI (Figure 34). This object
relationship means that objects in a layer below retain the segmentation from the object






























































TMA core image number
93
Figure 34. Definiens hierarchical image object relationships. Objects within image levels are connected
in a hierarchical fashion. An object in an image level below another object will belong to that object
and retain its’ segmentation. E.g. LV = lymphatic vessel & TB = tumour bud both belong exclusively
to the stroma ROI.
Object layer hierarchy cannot be altered in Tissue Studio®. In the Marker Area
algorithm nuclei must always be in the hierarchical layer above ‘markers’ (panCK or
D2-40). Therefore the nuclei segmentation dissects the objects in the layer below
(Figure 35). This results in nuclei segmenting the objects below into multiple smaller
objects and creating a false increase in numbers of positive tumour cell, vessel and
LVI objects. This also results in the algorithm not being able to quantify nuclei within
a marker object, making it impossible to report on the number of nuclei or cells which







Figure 35. Marker 1 and marker 2 objects segmented by hierarchical objects within the layer above. A)
composite raw image displaying occult LVI (green: panCK, red: D2-40, blue: nuclei). B) D2-40 image
layer displaying panCK (red outline) and D2-40 (green outline) objects segmented by the image analysis
algorithm. C) & D) Digital zoom of examples where the D2-40 positive lymphatic vessels have been
segmented into multiple objects due to hierarchical image segmentation. E) panCK image layer
displaying panCK and D2-40 objects segmented by the image analysis algorithm. F) & G) Digital zoom
of examples where the panCK positive cancer cells have been segmented into multiple objects due to
hierarchical image segmentation. Image captured with a x20 objective.
In the ‘Marker Area’ algorithm only basic intensities are measured and not complete
cells or nuclei, therefore the algorithm can be prone to creating false positive objects
due to staining artefacts. Quantification of LVI relies on the colocalisation of panCK
and D2-40 markers. Only a small area, or sometimes none, of an invading cell’s
cytoplasm and membrane may colocalise with the D2-40 positive vessel wall, creating
further challenges to accurately quantify the positive result.
Within the ‘Vessel Detect’ algorithm many true positives remain unquantified while
false positives are detected. The main reason for this is stain intensity heterogeneity.
Low DAPI intensity can result in nuclei being undetected while a high DAPI
background can result in false nuclei being segmented. Similarly high and low
background intensities for panCK and D2-40 may cause erroneous results. PanCK is
primarily a membrane marker, however the algorithm relies on quantification of
panCK intensity within the nuclei which may be low even in positive epithelial cancer
cells. D2-40 is also measured within the nuclei and if a LVI positive cell is within the
A B C D
E F G
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lumen of a large vessel there may be very low D2-40 staining present in the segmented
nuclear compartment resulting in an invading cell remaining unquantified.
There was too much scope for erroneous results to take the ‘Vessel Detect’ algorithm
forward for a prognostic assay and so this algorithm was discarded. Although the
‘Marker Area’ algorithm quantified all correct LVI cores, it was felt that due to the
constraints mentioned above true LVI and LVD could not be accurately quantified in
a large heterogeneous patient cohort without further algorithm optimisation.
1.6 Image analysis development in Developer XD
Due to the constraints of the Tissue Studio® software the ‘Marker Area’ algorithm was
imported into Definiens’ Developer XD image analysis software for further
development. Developer XD is a much more flexible and powerful image analysis
software, however it does not include pre-installed analysis algorithms and so image
analysis solutions must be created through programming by the user. Pre-segmented
images from Tissue Studio® can be imported into Developer XD and further
developed. The images which had been segmented by the ‘Marker Area’ Tissue
Studio® algorithm were imported into Developer XD in order to programme solutions
to the constraints listed above. One addition in Tissue Studio® to the ‘Marker Area’
algorithm is the quantification of all nuclei through the DAPI channel. This was done
in the same manner as detailed in section 3.5.1.3 for the ‘Vessel Detect’ IF algorithm.
Post import of the ‘Marker Area’ segmented images, the initial step within the
Developer XD software is to split the analysis into two separate unconnected scenes.
One scene contains only segmented marker 1 objects (panCK) and the other contains
only marker 2 objects (D2-40). The nucleus level and all associated nuclear
segmentation is deleted from both scenes at the marker 1 or 2 level. The algorithm next
merges all neighbouring markers in each scene, and fills in any gaps enclosed by the
newly formed object. Marker 2 objects are also expanded into any neighbouring area
above 40au D2-40 intensity to capture more complete vessels and their lumen. This
creates a more accurately segmented area of epithelial cell invasive bodies as well as
vessels and their lumen (Figure 36).
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Figure 36. Developer XD optimisation of Marker object areas. A) Invasive tumour cells (green) with
Tissue Studio and Developer XD image analysis mask (red). B) & C) Lymphatic vessels (red) with
Tissue Studio and Developer XD mask (green). Images captured with a x 20 objective.
The DAPI channel along with its segmented nuclei is then reinstated as an image layer
below the marker layer. This results in no false segmentation of markers by the nuclear
segmentation while simultaneously allowing the number of nuclei within an invading
cancer cluster to be quantified. A distance calculation of all marker 1 or 2 objects to
‘no tissue’ is programmed and a marker object within 50µm is automatically
reclassified as ‘edge effect’ (Figure 37).
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Figure 37. Automatic classification of edge-effect artefact by image analysis algorithm. A) non-specific
labelling of D2-40 antibody at the edge of tissue. Algorithm classifies this as edge effect (blue mask).
Images captured with a x 20 objective.
Any marker 1 (panCK) object below 55µm2 was deemed to be too small to be a cell
and therefore reclassified as ‘debris’.
Due to heterogeneous levels of DAPI staining across cores, as well as varying levels
of background DAPI intensities, some false nuclei are segmented. These are
automatically ‘cleaned up’ and reclassified as ‘false nucleus’ within Developer XD
programming (Figure 38). Similarly autofluorescence of muscle in the cy3 (panCK)
channel as well as non-specific staining of panCK is reclassified as ‘Non-specific CK’
(Figure 39). Both ‘false nuclei’ and ‘Non-specific CK’ are excluded through area,
intensity and texture parameters.
A B
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Figure 38. Automatic image analysis false nuclei re-classification. A) Composite image with nuclear
segmentation overlay; DAPI channel only displaying high background intensity within cancer cells with
classified nuclear segmentation; Developer XD mask classifying the false nucleus (pink) and the
genuine nucleus (khaki). B) High stromal DAPI intensity results in multiple false nuclei which the
image analysis algorithm corrects. C) High autofluorescence in DAPI channel within colonic glands;
















Figure 39. Automatic image analysis autofluorescence re-classification. A) Composite image (blue:
DAPI, red: D2-40) where considerable autofluorescence (green) is captured within the panCK channel.
B) Image analysis algorithm is programmed to identify autofluorescence and re-classify as Non-specific
CK (orange). Images captured with a x 20 objective.
Once vessels (marker 2) and epithelial invasive clusters (marker 1) are accurately
classified within their own image analysis scenes the two scenes are merged together
and colocalisation of the optimised marker 1 and 2 is classified as ‘marker 1&2’
(Figure 40). Figure 40 also shows that the area of colocalisation captured in Tissue
Studio® between a vessel’s wall and invading cancer cells can be small and incomplete.
Tissue Studio® analysis also does not always capture the entire vessel wall. Developer
XD optimisation, as detailed above, allows not only the complete vessel wall to be
segmented as one object, but also the vessel’s lumen. Upon colocalisation, in
Developer XD, whole invading cells with an accurate area of colocalisation are
quantified. Marker 1&2 positive areas are further classified depending on the number
of nuclei within the marker 1 object. The algorithm quantifies and exports cancer cell
clusters with ≤5 associated nuclei within a vessel as ‘occult LVI’ and larger invading 
clusters (>5 associated nuclei) as LVI. LVD is also exported as a calculation of the
marker 2 (vessels) area percentage of stroma (µm2).
A) B)
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Figure 40. Developer XD algorithm’s quantification of LVI. Composite image (red: D2-40, green:
panCK, blue: DAPI). A) & B). Single cancer cell invasion of microvessels with Tissue Studio mask and
Developer XD mask of colocalisation of marker 1 and 2 (yellow mask). Developer XD captures an
accurate representation of the invading cancer cell. C) Only a very small area of colocalisation of four
cancer cells within a vessel wall is quantified by the Tissue Studio algorithm (yellow mask). The
Developer XD algorithm quantifies the entire vessel and thereby captures an accurate representation of
all four invading cancer cells (yellow mask). Images captured with a x 20 objective.
A)
B)
Com positeim age DeveloperX D m askT issueS tudio® m ask
C) Com positeim age
DeveloperX D vesselm ask
T issueS tudiom ask
DeveloperX D L VIm ask
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The final Developer XD algorithm outlined above and optimised from the Tissue
Studio® ‘Marker Area’ algorithm was used for all future results to quantify LVI and
LVD. This algorithm was subsequently named the Lymphatic Vasculature Analyser
(LVA).
1.7 Prognostic evaluation of Lymphatic Vasculature
Analyser (LVA) quantified Occult LVI & LVD
1.7.1 Quantification of CRC training cohort TMA
The LVA allows a higher accuracy of quantifying lymphatic vessels and lymphatic
vessel invasion. The training set TMA of 118 patient cores was labelled with the triple
multiplexed immunofluorescence for panCK, D2-40 and DAPI. The algorithm was
executed across the training set TMA images and the exported results of the number
of occult LVI events and the LVD per patient were assessed for prognostic
significance. The image analysis algorithm was completely automated with no manual
interference. Results along with survival data were loaded into TMA Navigator for
prognostic survival analysis. TMA navigator automatically splits the patients into up
to three evenly sized groups according to each reported parameter from the analysis
algorithms. Survival for each parameter is plotted as a Kaplan-Meier curve. Neither of
the two parameters (occult LVI and LVD) was able to predict significantly poor
prognosis or stratify patients into high or low risk groups (Figure 41).
Occult LVI events can be rare and often located at the invasive front of the CRC
tumour. A single TMA core may be too low a sampling area to capture occult LVI
events if they do occur within a patient’s tumour. Similarly, manual quantification
methodology for LVD usually requires the observer to locate LVD hotspots. These
hotspots may not be captured by a single TMA core.
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Figure 41. Kaplan-Meier curves for patients within the training set TMA (n=118) post quantification by
LVA. Patients were not significantly stratified into high and low risk groups from quantification of
occult LVI or LVD.
FDR corrected P= 0.9051
































1.7.2 Quantification of CRC whole slide imaging
1.7.2.1 Training Cohort
To assess if a single TMA core was too low a sampling area to accurately report if a
patient’s tumour had invaded the lymphatic vasculature, a whole slide imaging
approach was performed. The whole tissue section training set was utilized to assess
the algorithm’s export parameters’ ability to stratify high and low risk patients of CRC
specific death. All tissue sections were labelled with the triple immunofluorescence
multi-plex assay of panCK, D2-40 and DAPI.
A low resolution 4x objective was emplyed to image the whole tissue section in the
panCK channel on the HistoRX imaging platform. From this image the invasive front
is manually located and highlighted for automatic imaging at high definition using the
20x objective (Figure 42).
Figure 42. Locating the invasive front of CRC from whole slide imaging. Whole tissue section was
digitised with a 4 x objective in the panCK channel. Invasive front is manually located and labelled for
capture (blue squares) at high resolution through a 20x objective.
x20 images taken from the invasive
front.
Low res pan-CK channel
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All 20x images are imported into Definiens Developer XD and LVA was executed
across them. Due to inter-patient heterogeneity in labelled fluorophore intensities the
initial algorithm thresholds in Tissue Studio® are set for each tissue section. Automated
tissue segmentation is taught through the Composer Technology™ for each set of
images from each tissue section. An ROI correction step was added to the Tissue
Studio® tissue segmentation. This allows the end user to manually correct any
erroneously automatically segmented tissue. After the initial intensity thresholds were
set for each tissue section the algorithm is run automatically. Occult LVI and LVD
results were exported from the LVA. The invasive front of the smallest tissue section
was captured in its entirety by 15 images. Therefore only 15 images from the invasive
front of subsequent tissue sections were used to quantify the histopathological features.
The 15 images containing the highest number of occult LVI events were selected from
each patient. The sum of all occult LVI events and the mean of LVD are calculated
across the 15 images per patient for the final exported prognostic parameters.
1.7.2.1.1 Clinicopathological and Cox-regression analysis
Significant cut-offs for each parameter were calculated from the full Stage I-III
training cohort for high and low sub-groups and their significance established by
Monte Carlo simulations for occult LVI (cut-off = 16 LVI events across 15 images, p
<0.0001), LVD (cut-off = 0.7 vessel percentage of stroma averaged across 15 images,
p = 0.002). The cut-offs established in this manner were then applied to stratify the
Stage II subpopulation. Clinicopathological data, from the corresponding pathology
report, the quantified occult LVI and LVD parameters and regression analysis are
summarised in Table 7. Univariate analysis showed occult LVI (HR =9.9; 95% CI,
3.57-27.98) and LVD (HR =5.1; 95% CI, 2.04-12.99) to be significant predictors of
survival within the cohort. In multivariable cox-regression analysis the predictive
model was adjusted for T stage, N stage, Dukes stage, occult LVI and LVD, these
being the four parameters which reported significance in univariate analysis, and the
results showed that only depth of local invasion (T stage, HR = 5.22; 95% CI,1.77-
15.44) and occult LVI (HR =6.08; 95% CI, 1.17-31.41) were independent predictors
of survival. To assess if LVD and occult LVI were associated Pearson’s correlation
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was performed and found them to be significantly correlated (r=0.71, p <0.0003)
(Figure 43).
Clinicopathological patient U nivariate M ultivariable
param eters num ber(n) HR 95% CI P value HR 95% CI P value
low erupper low erupper




Gender 1.77 0.73 4.31 0.26 N/A
M 24
F 26


















Histology 0.49 0.11 2.11 0.34 N/A
Standard 42
Mucinous 8




O ccultL VI 9.99 3.57 27.98 0.0001 6.08 1.17 31.41 0.03
High 17
Low 33
L VD 5.15 2.04 12.99 0.0001 1.3 0.3 5.59 0.72
High 19
Low 31
Table 7. Clinicopathological data with associated univariate and multivariable analysis for disease
specific survival within the CRC training cohort.
106
Figure 43. Pearsons’ correlation of LVD and Occult LVI within the training cohort.
1.7.2.1.2 Kaplan-Meier survival curves
Kaplan-Meier plots were computed to assess the ability and significance of LVD and
occult LVI in stratifying high and low risk CRC patients and particularly the
stratification of Stage II patients.
1.7.2.1.2.1 Lymphatic vessel density
High LVD was significantly associated with poor outcome and shorter disease specific
survival in the full training cohort (p = 0.0001) and the Stage II subpopulation (p =
0.0001). Only 26% of patients within the full training cohort and 11% within the Stage
II subpopulation, who were within the above-cut-off LVD (> 0.7% vessel density)





















Figure 44. Kaplan-Meier curves for LVD; training cohort whole slide imaging. Patients within the full
cohort (n=50) and the stage II subpopulations (n=29) were significantly stratified into high and low risk
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stroma
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1.7.2.1.2.2 Occult lymphatic vessel invasion
KM analysis was performed and occult LVI was shown to be the most significantly
prognostic parameter associated with shorter survival times in both the full training
cohort (p <0.0001) and the Stage II subpopulation (p <0.0001) (Figure 45). No
patients survived full follow up within the above cut-off occult LVI group (>16
occult LVI events) in the Stage II patient subpopulation and only 11% survived
follow up within the full cohort.
Figure 45. Kaplan-Meier curves for Occult LVI; training cohort whole slide imaging. Patients within
the full cohort and the stage II subpopulations were significantly stratified into high and low risk of
disease specific death through the quantification of Occult LVI.









































Both LVD and occult LVI are predictors of disease specific death within the 50 patient
training cohort and the stage II subpopulation (n=29). The main objective of this
chapter was to determine if the quantification of LVD and occult LVI allowed the
stratification of high risk Stage II patients. To validate the results from the training set
a clinically relevant and larger validation cohort, consisting of 134 Stage II patients,
was analysed by the LVA algorithm across WSI captured images.
The immunofluorescence and image acquisition methodology as well as image
analysis was identical to section 3.7.2.1.
1.7.2.2.1 Clinicopathological and Cox-regression analysis
Training set LVD and occult LVI parameter cut-offs were applied to the validation set
results and the corresponding data assessed for significance in survival prediction by
cox-regression analysis.
Clinicopathological data and regression analysis is summarised in Table 8. Univariate
analysis showed high occult LVI (HR =2.46; 95% CI, 1 - 6.05) but not high LVD (HR
=1.39; 95% CI, 0.46 - 4.16) to be significant predictors of survival within the validation
cohort. The hazard ratio and significance of the occult LVI parameter was however
greatly reduced within the validation set, compared to the training set.
From the clinicopathological core data set parameters only T-stage and differentiation
were also significant predictors of disease specific death. Pearson’s Correlation
showed that Occult LVI and LVD were correlated within the validation cohort (R =
0.64, P<0.0001) (Figure 46).
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Clinicopathological patient U nivariate




Gender 0.933 0.601 1.45 0.759
M 69
F 65




T stage 4.26 1.76 10.33 0.001
pT3 102
pT4 32












T um ourDiam eter* 1.7 0.66 4.42 0.27
<5cm 68
≥5cm 48
T otalN odeexam ined 0.6 0.24 1.5 0.27
<12 35
≥12 99
EM L VI 0.359 0.14 0.94 0.04
Yes 20
No 114
O ccultL VI 2.46 1 6.05 0.05
High 35
Low 99
L VD 1.39 0.46 4.16 0.56
High 25
Low 109
Table 8. Clinicopathological data with univariate cox-regression analysis for disease specific survival
within the validation cohort.
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Figure 46. Pearsons’ correlation of LVD and Occult LVI within the validation cohort.
1.7.2.2.2 Kaplan-Meier survival curves
Survival over time was calculated and plotted on KM curves for both LVD and occult
LVI
1.7.2.2.2.1 Lymphatic vessel density
LVD was not associated with poor outcome and shorter disease specific survival in the
Stage II validation cohort (p = 0.56). High and low LVD cut off groups could not be


















Figure 47. Kaplan-Meier curves for LVD within the validation cohort (n=134). Patients within the
validation cohort were not significantly stratified into high and low risk of disease specific death through
the quantification of LVD.
1.7.2.2.2.2 Occult lymphatic vessel invasion
KM analysis was performed for occult LVI on the Stage II validation cohort. Occult
LVI was shown to be a significantly prognostic parameter associated with shorter
overall survival times (p = 0.05). The results reflect the Cox-regression analysis and
occult LVI is much less significant at high risk patient stratification than in the training
cohort results (Figure 48).
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Figure 48. Kaplan-Meier curves for occult LVI within the validation cohort (n=134). Patients within the
validation cohort were significantly stratified into high and low risk of disease specific death through
the quantification of occult LVI.
1.7.2.3 Total Lymphatic vessel invasion
In the previous studies within this chapter occult LVI was quantified and reported by
the image analysis algorithm. Occult LVI was defined as small islands of tumour cells,
of 1-5cells in size, which had invaded a lymphatic vessel. Although a highly significant
prognostic parameter within the training set, occult LVI was only marginally
significant in the validation set. In order to attempt to stratify high risk stage II patients
more effectively and significantly a parameter named ‘Total LVI’ was exported from
the analysis algorithm. The LVA already quantifies LVI involving tumour clusters
which are larger than 5 cells, although this parameter was not yet used in this study.
The number of ‘LVI’ was subsequently added to ‘occult LVI’ to create a new
parameter of ‘Total LVI’. An optimal cut-off of 43 ‘Total LVI’ events (p <0.0001)
was calculated for the training set by Monte Carlo simulations within X-tile software.
This cut-off was then applied to the Stage II patient validation set and KM curves were




















across 15 images at
the invasive front
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plotted for both the stage II populations of the training cohort and validation cohort
(Figure 49).
Figure 49. Kaplan-Meier curves for Total LVI within the training (n=50) and validation cohort (n=134).
Total LVI was highly significant in stratifying patients within the training cohort into high and low risk
of disease specific death; however this parameter was not significant within the validation cohort.
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Compared to occult LVI, ‘Total LVI’ increased patient stratification for the training
cohort where no patients in the high cut-off group survived for over 4 years (p
<0.00001), however it decreased the significance of patient stratification within the
validation cohort to below a significant threshold (p = 0.15).
1.7.2.4 Optimal Validation set cut-offs
Optimal training cohort cut-offs were calculated by performing 1000 iterations of
Monte Carlo simulations and identifying the optimal p value from KM curves. Upon
plotting p values for each possible cut-off of the training cohort it was observed that
large ranges of cut-offs were highly significant for Occult LVI and Total LVI (Figure
50A, 51A). The computationally selected training cohort cut-off, which was one of
many possibilities, may therefore not be the optimal cut-off for the validation cohort.
Other significant cut-offs from the training cohort may be more significant for the
validation cohort. In order to identify a cut-off which is significant for both the training
cohort and the validation cohort all possible p values for both cohorts were plotted on
the same graph. This was performed for Occult LVI, Total LVI and LVD (Figure 50A,
51A, 52). A cut-off was then selected which was highly significant, in relation to KM
curve p values, for both the training cohort and the validation cohort.
1.7.2.4.1 Kaplan-Meier survival curves
This new optimal cut-off was utilised to sub-stratify the Stage II patients within the
validation cohort into high and low risk of disease specific death by plotting the
survival times as a KM curve. The new optimal cut-off for Occult LVI was 19 events
and this reported a p value of <0.0001 for the training cohort and 0.018 for the
validation cohort. The significance in the training cohort was not altered, however the
significance increased from a p value of 0.05 to 0.018 in the validation cohort upon
plotting when utilising the new cut-off (Figure 50 B).
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Figure 50. Assessment of optimal cut-offs within the training and validation cohorts for occult LVI. A)
P values for all possible cut-offs within the training cohort and validation cohort were plotted on the
same graph. An optimal cut-off of 19 occult LVI events was selected which reported significant values
for both cohorts (red line). The green lines mark the area containing 80% of the training cohort. B) The
optimal cut-off of 19 occult LVI was utilised to plot Kaplan-Meier curves which significantly stratified
the validation cohort (n=134) into high and low risk of disease specific death.
The new optimal cut-off for Total LVI was 37 events and this reported a p value of
<0.0001 for the training cohort and 0.01 for the validation cohort. The significance in
the training cohort was not altered, however the significance increased from a p value
of 0.15 to 0.018 in the validation cohort (Figure 51B).
Occult LVI and Total LVI yielded identical significance and stratification of high- risk
stage II patients within the validation cohort.
There was no significant LVD cut-off for the validation cohort at any data-point and
therefore LVD was deemed to be non-significant in a larger clinically relevant stage II
patient cohort (Figure 52).
O ccultL VI(L og2)
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Figure 51. Assessment of optimal cut-offs within the training and validation cohorts for Total LVI. A)
P values for all possible cut-offs within the training cohort and validation cohort were plotted on the
same graph. An optimal cut-off of 37 Total LVI events was selected which reported significant values
for both cohorts (red line). The green lines mark the area containing 80% of the training cohort. B) The
optimal cut-off of 37 Total LVI was utilised to plot Kaplan-Meier curves which significantly stratified
the validation cohort (n=134) into high and low risk of disease specific death.
Figure 52. Assessment of optimal cut-offs within the training and validation cohorts for LVD. A) P
values for all possible cut-offs within the training cohort and validation cohort were plotted on the same
graph. There was no significant cut-off associated with the validation cohort which was optimal for the
training cohort.
T otalL VI(L og2)
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Univariate cox-regression analysis was performed on the categorical sub-grouped
Stage II validation cohort, after applying the new optimal cut-off, for both occult LVI
and total LVI. Both of the LVI parameters were significant predictors of disease
specific death with identical hazard ratios (HR= 2.9) and p value significance (p =0.02)
(Table 9), which reflected the KM curve results.
Clinicopathological patient U nivariate
param eters num ber(n) HR 95% CI P value
low er upper
O ccultL VI 2.9 1.2 7 0.02
High 30
Low 104
T otalL VI 2.9 1.2 7.1 0.02
High 29
Low 105
Table 9. Univariate Cox regression of occult LVI and Total LVI utilising optimal cut-offs on the
Validation cohort.
1.8 Discussion
Venous invasion is widely under-reported in the clinic with large observer variability
when observing under H&E stained tissue sections alone(266, 291, 295). To overcome
this problem pathologists are employing the use of specific stains such as CD31(286)
and, more commonly in the clinic, elastic based labelling(279, 291, 295). These studies
show an increase in observer concordance as well as an increase in the number of
events reported. The increase in the reporting of blood vessel invasion was shown to
have a prognostic impact correlated to poor outcome or prediction of metastasis(47,
279, 296).
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In this study it was found that Elastica staining and CD31 did not label all blood vessels
and it displayed incomplete staining of the venous vasculature, which could allow for
some venous invasion to go unreported. Although it clearly has the potential to be
utilised to aid the reporting of venous invasion by manual quantification(279), it would
be unsuitable for computer-based quantification. The disadvantage of computer-based
quantification is the lack of extra histological knowledge which can be gleaned from
manual observation even with feint and incomplete venous labelling. Due to this fact
image analysis contrasts must have a high signal to noise ratio and allow robust
staining of vessels in order to quantify them accurately under computer-based analysis.
Blood vessel invasion was therefore not included in the automated vasculature
quantification within this study.
Unlike CD31 and Elastica based staining, D2-40 immunohistochemistry demonstrated
strong staining of lymphatic vessels. The study therefore concentrated efforts on
quantifying LVI and LVD through automated image analysis. LVI is not included in
the clinical core data set as described by RcPath(102) due to insufficient evidence of
significance in prognosis. A reason for lack of evidence is that pathologists do not
routinely quantify LVI due to its obscurity in H&E stained sections. This, alongside
no standardised reporting methodology, are contributing factors for the absence of
lymphatic vascular based prognostic features from the clinical core data set and so
standard practice is not to routinely report LVI or LVD in the clinic. Automated
quantification, however, adds robustness and standardisation to histopathological
feature reporting while minimising observer variability. LVI alone has been associated
with lymph node metastasis (LNM) and poor outcome (252, 260). The under-
recognition of LVI may therefore be a contributing factor for the under-staging of CRC
patients (252, 266) and disease recurrence in ~30% of the Stage II population (245,
297).
Definiens Tissue Studio is an “out of the box” image analysis solution which comes
with multiple pre-installed image analysis algorithms. Although the software is user-
friendly and powerful it is not flexible. The study attempted to quantify LVI and LVD
through two of the pre-installed algortihms. Although LVD could be quantified
accurately through the ‘Vessel Detect’, algorithm LVI could not. Due to patient
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heterogeneity and tissue artefact many false positives were associated with LVI
quantification. Manual post processing of the data can correct most false positives but
this negates the advantage of automated image analysis. Although studies do perform
image analysis to quantify histopathological features through pre-installed
manufacturer software algorithms, they do not address how they overcome image-
based problems such as biomarker intensity heterogeneity and tissue artefacts without
manual intervention(298, 299). To overcome the complexity of accurately quantifying
tumour cells within vessels, Tissue Studio® was purely utilised to segment the tissue.
Developer XD is a much more programmer-intensive software package but allows for
much greater flexibility. By importing the Tissue Studio® segmentation into Developer
XD the constraints of the algorithm can be overcome allowing the accurate
quantification of entire vessels and invasive tumour, as well as quantifying the number
of cells within the cancer clusters. Developer XD also allowed the automated exclusion
of false positives due to heterogeneity and tissue artefacts.
Our methodology quantifies tumour cell clusters of either under or over 5 cells in size
which have invaded lymphatic vessels; which were termed as ‘occult LVI’ or ‘LVI’
respectively. The sum of the two parameters was termed ‘total LVI’. The results show
that occult LVI and total LVI are significantly prognostic in the training cohort. Occult
LVI is also significantly associated with disease specific death in the validation cohort
when the training set cut-off is applied; however Total LVI is not. KM analysis shows
that no stage II patients with above cut-off LVI survived follow up within the training
cohort. Occult LVI was also the only image based quantified parameter to be
associated independently with an adverse effect on disease specific survival in the
training cohort and it was also significant at predicting poor outcome in univariate
analysis in the validation cohort when the training cohort cut-off was applied.
Some studies have shown LVD to be prognostic and associated with poor outcome or
LNM (292, 300), however others show that no correlation exists (283, 301). LVD
assessment is, however, not standardised and most researchers employ various
magnifications and numbers of LVD “hot-spots” utilised to create a mean LVD while
observer variability has been shown to be poor (283). Bias is therefore introduced in
these studies which can be negated by WSI and automated image analysis of the
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invasive front or entire tissue sections. In the methodology, which was demonstrated
here, the stroma is automatically segmented from the tumour and by doing so it was
possible to calculate the LVD only within the stromal compartment. The methodology
does not rely on the manual locating of LVD hot-spots, rather it quantifies LVD across
15 images taken from the invasive front and which contained the highest occult LVI
events. By adopting this LVD calculation and minimising sampling bias, it was shown
that LVD is significantly associated with poor outcome (p = 0.0001) in a small training
cohort, however it is not significant when quantified across a large and clinically
relevant validation cohort (p= 0.56). All stage III patients within the training set were
within the high category of LVD which suggests that lymphangiogenesis may occur
as the disease progresses. It is unknown whether lymphangiogenesis occurs due to a
host reaction attacking the tumour or by tumour cell signalling; however the results
show that LVI is correlated to LVD (r=0.71, p<0.0003) which is in accord with
separate studies (281, 302).
The training cohort in this study was specifically selected for similar numbers of stage
II patients who survived or died specifically of CRC during follow up. Although this
is a relevant cohort to test if image analysis quantification of occult LVI and LVD can
stratify the two groups, it is not a clinically representative cohort and therefore the cut-
offs calculated within the training cohort may not be optimal when applied to a larger
validation set. The training cohort had multiple highly significant cut-offs and the X-
tile software, used to identify significant cut-offs in data sets, selected one of these
automatically. Upon applying the LVI based training cohort cut-offs to the validation
cohort occult LVI was just significant prognostically, but Total LVI was not.
Identifying an optimal cut-off for the validation cohort alone would defeat the purpose
of including a training cohort and therefore an “optimal” cut-off was identified which
was highly significant for both CRC cohorts and utilised to stratify the validation
cohort. Upon applying the optimised cut-off to the training cohort no decrease in
significance was observed in occult LVI (p < 0.0001). When applying the optimised
cut-off to the validation cohort the prognostic significance of both occult LVI and
Total LVI increased to p =0.018 for KM patient stratification and a hazard ratio of 2.9
with associated significance of p = 0.02 in cox regression prediction of disease specific
death. Interestingly occult LVI and Total LVI yielded identical prognostic results. This
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suggests that small clusters of cancer cells invading into microvessels are an indicator
of poor prognosis and a risk of disease specific death, presumably via distant
metastasis through the lymphatic vasculature. Isolated tumour cells within lymph
nodes have shown to be predictors of disease relapse(251) however an automated
image analysis algorithm requiring only a single tissue section per patient would save
considerable time over the manual quantification of multiple tissue sections from
multiple lymph nodes per patient.
In summary this study reports a novel computer based methodology to identify and
quantify the prognostic histopathological features of LVI and LVD across the invasive
front of colorectal carcinoma. The features are captured and exported from a single
tissue section using one continuous image analysis algorithm: LVA. This saves
considerable resource, compared to serial sectioning and staining across multiple
tissue blocks per patient, prior to manual semi-quantification of each histopathological
feature. The LVA negates observer variability or bias and allows the standardised
quantification of LVI thus making the approach amenable to a time-dependent clinical
setting.
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Chapter 4: Quantifying Tumour Budding
through Image Analysis
1.1 Introduction
Although TNM classification is the gold standard in CRC prognosis(239, 241), there
have been multiple attempts to improve on its ability to stratify high risk CRC patients.
Tumour morphology(68) and differentiation(303, 304) are two histological features
which have been investigated in an attempt to identify a more invasive or aggressive
cancer. Jass et al proposed a novel way to grade CRC which was based on
differentiation, lymphocytic infiltration and the morphology of the invasive margin
(an expanding and pushing border or an infiltrative one) (Figure 54)(236).
Initial results proved promising, however, they were unable to be reproduced
independently(305) and, although observer variability was good for infiltrative border,
it was poor for lymphocytic infiltration(267). The concept of prognostic value being
attached to tumour morphology at the invasive front of CRC was re-investigated
predominantly by a group of Japanese researchers who investigated clusters of tumour
cells unattached to tumour glands at the invasive front. Morodomi(306) in 1989 was
the first to term this phenomenon “Tumour Budding” (TB). Hase, in 1993, further
defined TB as ‘Microscopic clusters of undifferentiated cells just ahead of the invasive
front’ (307). In order to overcome observer variability this definition was further
refined by Ueno in 2002 who stated that tumour buds were individual cancer cells or
clusters of cancer cells consisting of up to five cells in size located in the stroma at the
invasive margin(270). Although Ueno’s definition of a tumour bud has become widely
accepted, the research community has not come to a consensus on a standardised
quantification methodology and there exists high inter-observer variability and
associated reproducibility issues(93, 308). Two reported quantification methods have
shown a decrease in observer variability, but these have not been widely adopted(92,
309). Further reason for observer variability in TB is its obscurity in H&E stained
tissue sections, especially when isolated cancer cells are concerned and where there is
a high immune cell infiltrate(272). Recent reports state that poorly differentiated
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clusters of cancer cells which are larger than 5 cells, but have no glandular
morphology, are more significantly associated with lymph node metastasis and poor
patient outcome than TB(269, 271). Inter-observer variability when counting poorly
differentiated clusters was also shown to be less than with TB which the researchers
attributed to easier visualisation of the larger tumour clusters(90, 269).
Immunohistochemistry with Cytokeratins has also been employed in order to increase
the accuracy of TB counts and decrease observer variability by differentiating them
from stromal cells(136, 288).
Figure 54. Invasive pattern of stage II CRC. A) H&E stained CRC tissue section demonstrating a
pushing invasive border (arrow). B) H&E stained CRC tissue section demonstrating an infiltrative
pattern invasive border (arrow). C) Digital zoom of section B) demonstrating tumour budding (arrows)
at the tip of the invasive infiltrate. Image captured at x 10 objective.
125
Although there exist multiple scoring methods, cut-offs and sampling areas in the TB
literature, a large body of evidence shows that TB is a significant predictor of poor
prognosis and is correlated to lymph node metastasis(20, 91, 135, 136, 265, 272, 307),
however a recent paper showed no association of TB and lymph node metastasis(271).
TB is not, however, included as a core data item in RcPath guidelines and is still only
listed as a non-core data item due to insufficient evidence and a lack of a standardised
quantification methodology(102). Although tumour bud count has been shown to hold
prognostic power, there is still a debate over whether these buds have disseminated
from the invasive front or if they are in fact a 2D mechanical artefact which has been
cut from a larger tumour gland (272). When serial sections are cut and examined it was
shown that almost all tumour buds were in fact attached to spindle-like outgrowths
from tumour glands(205, 310).
TB may be a significant parameter to stratify Stage I and II CRC patients into high and
low risk of disease recurrence(136, 311-313). In fact, it has been reported that Stage II
patients with a high degree of TB show similar or worse outcome to Stage III
patients(307).
It is widely accepted in the literature that tumour buds, no matter their 3D structure,
have undergone a certain level of EMT. EMT is the loss of a polarised cell’s epithelial
phenotype, which involves attachment to the basement membrane and neighbouring
epithelial cells, and the gain of a more invasive and mesenchymal one(17). The loss of
E-cadherin is one of the first steps of EMT which is closely related to the loss of
membranous β-catenin, both of which play a major role in cell-cell junction 
complexes(18). A loss of cell membrane connections allow the cells to disseminate
and migrate away from an epithelial sheet of cells. Tumour buds have been shown to
have a decrease in E-Cadherin, an increase in the mesenchymal marker Snail as well
as an increase in nuclear β-Catenin whereupon it acts as an oncogenic transcription 
factor and is involved in aberrant WNT signalling(314-316). Tumour buds have also
shown a loss in other epithelial markers such as CD44 and EpCam and a decreased
proliferation rate marked by a decrease in Ki67 expression(317-319). Mesenchymal-
like cells may also display a loss of polarity through aberrant expression of Pard3 or
126
Scrib3(320, 321) which allows their dissemination from the polarised epithelial layers
from which they originated. The mesenchymal phenotype also involves the
upregulation of proteins involved in ECM remodelling such as MMP and uPA/R in
order to invade through the stroma and muscle(26). Tumour buds have been reported
to show an increase in ECM remodelling protein expression(322, 323). Cancer stem
cell-like phenotypes are advantageous for a metastasising cell to display. This
phenotype may allow the cell to survive outwith homeostatic control but also undergo
MET and the colonisation of a metastatic site in order to form a secondary tumour
mass. Tumour buds have been associated with higher expression levels of Colonic
stem cell markers such as CD133 and ABCG5(314, 324).
All previous TB scoring methodology and associated proteomic evaluation has relied
on manual semi-quantitative reporting where, no matter which cut-off and scoring
method is utilised, it will be open to observer variability. The era of quantitative digital
pathology allows the reporting of biomarker expression and histopathological features
in a fully quantifiable and robust manner (187, 298, 299). Computer-based
quantification is also amenable to the standardisation of bud scoring where an identical
image analysis algorithm can be executed across remote institutes with the
minimisation of observer variability. The study reported here will detail the
development of a computer based analysis algorithm to automatically quantify TB
across the invasive front of digitised CRC tissue sections. The algorithm is executed
across a training and validation cohort in order to assess the prognostic power of
quantifying tumour buds. A further algorithm, detailed within this study, will allow
the segmentation of the tumour into distinct subpopulations and investigate their
proteomic expression profile across the invasive front and the tumour centre.
1.2 Brightfield image analysis
Brightfield image analysis solutions were performed on either H&E stained or panCK
immunohistochemistry labelled CRC tissue sections to assess their ability and
accuracy in segmenting and quantifying tumour buds within the tumour to stroma
invasive margin. The mainstream methodology for visualising tissue within medical
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laboratories is through brightfield microscopy. Therefore the quantification of tumour
buds by image analysis through brightfield microscopy was attempted in the first
instance.
1.2.1 Automated quantification of tumour bud nuclei in H&E
stained tissue sections
Tissue sections were cut from optimizing CRC tissue blocks, stained with H&E and
digitized on the Leica SCN400. Images were imported directly from remote storage
utilizing the Digital Pathology Pipeline into Definiens Tissue Studio®. Tissue
Studio®’s “Nuclei” algorithm was employed to segment tumour bud nuclei within the
stroma for a TB count. This was undertaken in an attempt to classify tumour cells,
through their nuclear morphology, as either belonging to tumour buds or tumour
glands and to differentiate them from stromal cells. Initial nuclear segmentation in
H&E stained sections was inaccurate and could not be used to differentiate cells within
tumour buds from those within tumour glands or stromal host cells through nuclear
morphometry alone (Figure 55). Image based automatic quantification of H&E stained
sections was therefore abandoned.
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Figure 55. Nuclear segmentation of H&E stained digital tissue sections. CRC tissue sections were
stained with H&E and digitized prior to image analysis to segment nuclei. Nuclei were incorrectly
segmented and therefore H&E was not able to be used for accurate differentiation of tumour buds and
stromal cells. Image A highlights an area where there are no nuclei although the algorithm has
segmented two false nuclei (blue outline). Image B highlights an area containing 5 nuclei (correct
segmentation in green) although the algorithm has segmented them incorrectly (blue outline).
1.2.2 Automated quantification of tumour bud nuclei in
panCK immunohistochemistry labelled tissue sections
Cytokeratins are expressed in epithelial cells but not in stromal cells. PanCK
immunohistochemistry was performed on CRC tissue sections in order to visualise
epithelial cells within tumour buds, tumour glands and to differentiate them from the
stroma. Whole tissue sections from control CRC tissue blocks were cut and panCK
immunohistochemistry performed. The panCK antibody was visualised with DAB and
the nuclei were counterstained with haematoxylin. Tissue sections were digitised on
the Leica SCN400 and images imported into Definiens Tissue Studio® for image
analysis. The image analysis algorithm, which was built around the brightfield “Nuclei
& Marker Area” pre-installed algorithm, was developed to segment tumour from
stroma ROIs and to attempt to quantify tumour buds automatically within the stroma
(Figure 56).
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Figure 56. Algorithm for quantification of tumour buds through DAB immunohistochemistry and
automated image analysis. A) ROIs are automatically segmented across tissue sections by training the
Tissue Studio Composer technology and reclassifies areas of Tumour into stroma which are below
5000µm2. B) Cellular Analysis module of the algorithm detects nuclei based on haematoxylin thresholds
prior to segmenting DAB positive areas above a set size threshold and classifying them dependent on
intensity.
Tissue is initially segmented into ROIs using Tissue Studio’s Composer™ as
previously described in chapter 3. Briefly areas of panCK, lumen/necrosis and stroma
are used to teach the technology to automatically segment the tissue into ROIs. (Figure
56 A) Figure 57A-C). The algorithm’s ‘Cellular Analysis’ section (Figure 56 B) first
segments nuclei dependent on haematoxylin settings on size and stain threshold
(Figure 57 D). PanCK positive DAB areas above a set threshold and a minimum
stained area are segmented and classified as marker 1. Marker 1 objects are classified
as low, medium or high for marker intensity (Figure 57 F, I & L). Marker 1 objects
within the stroma were assessed for their ability to report TB. Full algorithm settings
are listed in Appendix 9.
The algorithm was not further developed nor taken forward for tumour bud
quantification as the software could not accurately segment nuclei or tumour buds.
Dark areas of DAB were falsely segmented and classified as nuclei thereby obscuring









Figure 57. Quantification of tumour buds through DAB immunohistochemistry and automated image
analysis. A) Invasive front of a CRC tissue section labelled for panCK. B) Composer technology
automatically segments tumour (purple), stroma (turquoise) and Lumen/Necrosis (yellow). C) Tumour
areas under 5000µm2 are reclassified as stroma. D) All nuclei are segmented. E) Digital zoom of DAB
positive neoplastic gland with Tissue Studio mask overlay (F) displaying nuclei and medium (orange)
or high (red) DAB intensity areas of tumour. G) & J) DAB positive tumour buds, H) & K) Tissue Studio
segmentation of DAB and nuclei. I) & L) Erroneous nuclear segmentation in tumour buds (blue). Images
taken with a 10x objective.
1.3 Immunofluorescence image analysis
To quantify nuclei and panCK positive tumour cells more accurately an
immunofluorescence approach was implemented with an antibody against panCK and






(epithelial cells) were captured at different wavelengths and in different channels so
that there was no bleed through of fluorescence. Nuclei could then be segmented
purely on DAPI with no interference from the panCK. For algorithm development
whole tissue sections were cut from the optimising CRC TMA block and labelled with
panCK and DAPI. Tissue sections were imaged on the AQUA HistoRX imaging
platform and imported into the Definiens software suite through a customised image
importer.
1.3.1 Tissue Studio quantification of tumour buds
“Marker Area” was selected from the pre-installed Tissue Studio®
immunofluorescence algorithms. The immunofluorescence algorithm ROI
segmentation was constructed in the same manner as in Chapter 3.5.1.2. Post ROI
segmentation only the “marker area detection” algorithm was utilised for panCK
(Marker 1) object segmentation (Figure 58). Algorithm set up and thresholds were
identical to those stated for panCK segmentation and Marker 1 classification in
Chapter 3.5.1.4. Only quantification of Marker 1 areas within the stroma are utilised
and exported from the algorithm.
Figure 58. Immunofluorescence panCK object segmentation in Tissue Studio. A), B) and C) display
examples of tumour budding visualised through IF with panCK (green) and the Tissue Studio image
analysis mask (red). Image taken with x 20 objective.
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C
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Manual post processing of the data from Marker 1 (panCK) objects allows the
estimated quantification of tumour buds. After extensive manual evaluation of
multiple tissue sections the majority of tumour buds fell between an area of 22 and
270µm2. If the exported area data of Marker 1 objects fall within these area margins
they are manually classified as tumour buds. If a Marker 1 object falls above 270µm2
or below 22µm2 they were deleted from the dataset as debris or tumour clusters larger
than 5 cells.
1.3.1.1 Whole slide image analysis
The IF algorithm was initially tested for tumour bud quantification on whole tissue
sections cut from the positive and negative control tissue blocks as detailed in Chapter
3.5.1.1
Images were randomly taken from across each control tissue section on the HistoRX
imaging platform, imported and analysed with the Tissue Studio® ‘Marker Area’
algorithm as detailed above. The number of tumour buds was quantified for each image
across the tissue sections. It was noted that the LVI positive control contained a larger
total number of TB than the LVI negative control. TB heterogeneity was also observed
across the tissue section with some areas containing high TB and some low for both
sections (Figure 59).
Figure 59. Results of immunofluorescence whole slide image quantification of tumour buds in Tissue
Studio®. Tumour buds are quantified within each image taken across the whole tissue sections. Negative
control tissue section contains fewer TB than the positive control.
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Tissue Studio® ‘Marker Area’ algorithm’s capability to automatically quantify tumour
buds across a heterogeneous patient cohort, mounted as a TMA, was assessed. The
TMA, immunofluorescence and image import was the same as detailed in Chapter
3.5.2, apart from no D2-40 being incorporated. The number of tumour buds was
automatically quantified as panCK objects within the stroma and manual post
processing excluded objects below 22µm2 and above 270µm2 (Figure 60).
Figure 60. Results of immunofluorescence TMA image quantification of tumour budding in Tissue
Studio®. Cores (n=118) across the TMA show inter-patient heterogeneity in the number of buds/core.
Due to heterogeneity of panCK fluorescence, resulting in poor segmentation, whole
buds were on occasion incorrectly segmented into several, resulting in an over- scoring
of buds per image.
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1.3.1.3 Tissue Studio® algorithm constraints
The cells which make up tumour buds are heterogeneous in size, both within a TMA
core and between patient cores. This in turn makes tumour bud size heterogeneous
across a section and between patient samples. The average tumour bud fell between
22µm2 and above 270µm2 however some were indeed outwith this range leading to a
false tumour bud count. Epithelial cell debris may also be picked up as a tumour bud
and false positives can be reported. To quantify a tumour bud as it is defined in the
literature, the cluster of cells must be 1-5 cells in size. Therefore a panCK object must
contain 1-5 nuclei for it to be classified as a tumour bud regardless of its area. As stated
in Chapter 3.5.3, if nuclei are segmented within the Tissue Studio® algorithm they will
create false segmentation of the panCK object in the image layer below, which will in
turn create a false number of buds within each image (Figure 61).
Due to the constraints presented within Tissue Studio® the algorithm was deemed not
to be suitable for tumour bud quantification without further development.
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Figure 61. A) & B) The false segmentation of two tumour buds by image analysis of nuclei. 1. show
examples of two tumour buds (green: panCK, blue: DAPI). 2. Tissue studio nuclei segmentation (red
line) in the image layer above is retained in the marker 1 layer and falsely segments the tumour buds
into multiple smaller areas creating a false TB count. Image was taken with a x 20 objective.
1.3.2 Quantification of tumour buds using Definiens
Developer XD™.
The Tissue Studio® segmented image, as detailed above, was imported into Definiens
Developer XD software for further optimization.
Identical marker 1 (panCK) object optimisation was carried out as described in Chapter
3.6; neighbouring objects were merged, holes within panCK objects are filled and the
segmented nuclei were relocated in an image layer below the marker 1 object layer.
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This allows for accurate epithelial panCK object area segmentation within the stroma
ROI and the quantification of nuclei per object (Figure 62). Non-specific panCK and
false nuclei are similarly excluded as in Chapter 3.6.
Figure 62. Accurate segmentation of tumour buds through Developer XD algorithm development. A)
& B) 1 show examples of two tumour buds. 2. Tissue studio nuclei segmentation in the image layer
above is retained in the marker 1 layer and falsely segments the tumour buds into multiple smaller areas
creating a false TB count. 3. Developer XD tumour bud segementation creates an accurate otline of the
tumour buds. Image taken with a x 20 objective.
After optimising the segmentation of epithelial objects within the stroma they were
further classified depending on their associated nuclei: ‘irrelevant marker’ (no
associated nuclei), ‘bud with debris marker’ (only debris nuclei associated with
marker), ‘tumour bud’ (1‐5 associated nuclei) and ‘Large tumour bud’ (over 5 nuclei
associated and below 5000µm2) (Figure 63).
The final algorithm as set out was utilised for all subsequent tumour bud
quantification in this study and was named the Tumour Bud Analyser (TBA).
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Figure 63. Classification of panCK objects into tumour bud categories. A), B) & C) 1. Raw composite
images of tumour bud examples. 2. Tissue Studio classifies all panCK positive objects as ‘marker 1’. 3.
Developer XD image analysis algorithm classifies panCK objects dependent on the associated nuclei.
Image taken with a x 20 objective.
1.4 Prognostic evaluation of Tumour Bud Analyser
quantified Tumour Budding
1.4.1 Quantification of TMA – training set
A higher accuracy of TB quantification and a classification in line with the TB
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The algorithm was applied to the training cohort TMA and the number of tumour buds
was exported by the TBA for each core. The TBA was fully automated and no manual
intervention took place thereby excluding any observer variability. Patient
stratification was assessed by KM curves which were plotted in TMA Navigator
software. The quantification of tumour buds across a single core from a TMA was
unable to stratify a cohort of early stage CRC patients into high and low risk of disease
specific death (Figure 64).
Figure 64. Kaplan-Meier curves for patients within the training set TMA (n=118) post quantification by
TBA. Patients were not significantly stratified into high and low risk groups from quantification of
tumour budding.
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1.4.2 Quantification of CRC whole slide imaging
1.4.2.1 Training cohort
Reports in the literature quantify TB from the invasive front and usually over multiple
fields of view, although some researchers employ only a single field of view(20). In
order to assess if a single core was too low a sampling area for prognostic
quantification of TB, whole slide analysis was performed on the whole tissue section
training cohort involving 50 patients, as in Chapter 3.7.1. Whole tissue sections
underwent immunofluorescence with panCK and DAPI. Image capture and import into
Definiens Developer XD was similar to that set out in Chapter 3.7.1. The number of
tumour buds per image was exported from the TBA. The 15 images from each patient
containing the highest number of tumour buds were retained for analysis and the
number of buds totalled across these 15 images. The total number of tumour buds
across the 15 images was the final parameter assessed for prognostic significance.
1.4.2.1.1 Cox-regression survival analysis
Monte Carlo simulations, within X-tile software, were again utilised to establish
significant high and low tumour bud patient sub-group cut-offs from the training
cohort (cut-off = 287 tumour buds across 15 images, p= 0.0001). The cut-off of 287
tumour buds was then applied to the stage II subpopulation for the assessment of
stratification of high risk patients. Cox-regression analysis is summarised in Table 10.
TB was a significant predictor of disease specific death in univariate analysis (HR
=5.7; 95% CI, 2.38-13.8), but was insignificant when a multivariable model was
adjusted for T, N and Dukes staging as well as the image analysis quantified LVI and
LVD results from Chapter 3.7.2.1 (HR =2.56; 95% CI, 0.9-7.27). To assess if TB was
correlated to LVI, Pearson’s correlation was performed. TB and LVI are significantly
correlated within the training cohort (r = 0.69, p<0.0003) (Figure 65).
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Clinicopathological patient U nivariate M ultivariable
param eter
num ber
(n) HR 95% CI
P
value HR 95% CI
P
value
low er upper low er upper
T um ourBudding 5.76 2.38 13.8 0.0005 2.56 0.9 7.27 0.08
High 13
L ow 37
Table 10. Univariate and multivariable Cox regression analysis on disease specific survival for tumour
budding within the training cohort.
Figure 65. Pearson’s correlation of tumour budding and occult LVI in the training cohort.
1.4.2.1.2 Kaplan-Meier survival curves
KM curves were plotted using TMA Navigator to assess the prognostic relevance of
TB in the full training cohort as well as across the stage II subpopulation (Figure 66A).
TB was significantly prognostic for poor outcome and shorter disease specific survival
times in both the full training cohort (p<0.0001) and within the stage II subpopulation





















above cut-off subgroup (> than 287 buds) was 7.7% compared to 76% in the low
budding subgroup for the training cohort and 10% compared to 73% in the stage II
subpopulation. Automated analysis allows the quick comparison of the size of the
tumour bud to the significance of prognosis. The TBA was further programmed to
segment, quantify and export the number of panCK positive objects within the stroma
which contained only 1-2 nuclei (small tumour buds) and also those which contained
over 5 nuclei (large tumour buds). Interestingly, the results reported identical survival
curves when quantifying buds with up to 2 nuclei and buds with 1-5 nuclei within the
training cohort. The quantification of large tumour buds (islands of tumour cells larger
than 5 cells but below 5000µm2) showed slightly less significant separation of survival
between high and low risk groups than when quantifying tumour buds (Figure 66B).
When examining the results from the stage II subpopulation identical results are shown
when comparing classical tumour buds with small tumour buds, however large tumour
buds report a slight improvement by identifying an additional poor prognosis patient
correctly stratified into the high budding group (Figure 66C).
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Figure 66. Kaplan-Meier curves for tumour budding across WSI; training cohort. A) Patients within the
full cohort (n=50) and the stage II (n=29) subpopulations were significantly stratified into high and low
risk of disease specific death through the quantification of classical TB. Both the quantification of small
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TB is a highly significant prognostic factor with the ability to significantly stratify the
training cohort into high and low risk of disease specific death. In order to validate
whether TB can stratify a larger stage II population of patients into high and low risk
of disease specific death we applied this methodology to the validation cohort. The
immunofluorescence, image acquisition methodology and image analysis was
identical to the training cohort study for WSI (section 4.4.2.1).
1.4.2.2.1 Cox-regression survival analysis
The training cohort cut-offs were applied to the exported automated image analysis
results from the 15 images per patient within the validation cohort. The corresponding
groups of patients were assessed for significance of prediction of survival by univariate
Cox-regression analysis. TB was a significant predictor of disease specific death in the
validation cohort (HR=2.49; 95% CI, 1.03-5.99) (Table 11). Similar to the occult LVI
results in chapter 3.7.3.1, both hazard ratio and significance are substantially reduced
from training cohort results. TB and Occult LVI were found to be significantly
correlated (r = 0.64, p<0.0001) within the validation cohort after a Pearson’s
correlation was calculated (Figure 67).
Clinicopathological patient U nivariate
param eter num ber(n) HR 95% CI P value
low er upper
Budding 2.49 1.03 5.99 0.04
High 44
L ow 90
Table 11.Tumour budding univariate Cox-regression analysisfordisease specificsurvivalw ithin the
validationset.
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Figure 67. Pearsons’ correlation of Tumour budding and Occult LVI within the validation cohort.
1.4.2.2.2 Kaplan-Meier survival curves
KM curves were plotted to assess survival times across low and high TB subgroups
after the training cohort cut-offs were applied to the validation cohort. TB was
significantly prognostic for poor outcome and shorter disease specific survival time in



















Figure 68. Kaplan-Meier curves for tumour budding within the validation cohort. Patients within the
validation cohort were significantly stratified into high and low risk of disease specific death through
the quantification of tumour budding.
1.4.2.3 Total Tumour Budding
The TBA was programmed to quantify TB as stated in the literature and the RCPath
guidelines; that is, tumour islands of 1-5 cells in size which are separated from tumour
glands at the invasive front. Although this parameter was successful at stratifying high
and low risk patients within the training cohort with high significance, its ability to
stratify stage II patients in a larger sequentially selected validation cohort was less
significant. Large tumour buds were also shown to hold prognostic significance in the
training cohort. A new combined parameter of the number of tumour buds and large
tumour buds across the 15 analysed images per patient was created which was termed
“Total budding”. This was exported from the TBA in an attempt to stratify high and
low risk stage II patients in the validation cohort at a higher significance. Monte Carlo
simulations reported the optimal cut-off for Total budding within the training cohort
to be 640 events across 15 images and to have a significance of p= 0.003. The training
cohort cut-off was applied to the validation cohort and survival analysis was performed
through Kaplan-Meier curves for both the training and validation cohorts (Figure 69).
No patients survived past 5.5 years in the high cut-off Total budding group in either
FDR correctedP = 0.04
















the full training cohort or its Stage II subpopulation. However, when the cut-off of 640
events was applied to the validation cohort there was no significant separation of risk
and this was therefore a poorer parameter for stage II patient stratification than tumour
buds alone.
Figure 69. Kaplan-Meier curves for total tumour budding (Total TB) within the training (n=50) A) and
validation cohort (n=134) B). Total TB was highly significant in stratifying patients within the training
cohort into high and low risk of disease specific death; however this parameter was not significant
within the validation cohort.
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1.4.3 Optimal Validation cohort cut-offs
As in Chapter 3.7.2.4, when plotting all possible cut-offs of the data against
significance there were large ranges of highly significant cut-offs for the exported TB
parameters; in this study those parameters were tumour buds and total budding. The
single optimal cut-off, selected from multiple significant cut-offs, and validated for the
training cohort by the X-tile software, may not in fact be the optimal cut-off for
subsequent validation cohorts representing the greater stage II CRC patient population.
This study assesses if one of the other highly significant tumour bud cut-offs from the
training cohort allowed more significant stratification of the validation cohort into high
and low risk of disease specific death. In order to do so all training cohort and
validation cohort TB and total budding cut-offs with associated p-values, determined
by KM curves, were plotted on the same graph (Figure 70A & 71A). A cut-off for each
parameter was selected which held mutual high significance within each cohort. This
new mutually significant cut-off was then utilised to stratify the validation set into high
and low risk groups. The new cut-off of 253 tumour buds and 341 total budding events
created highly significant separation of high and low risk patient survival over time of
p= 0.0009 and 0.001 respectively in the validation cohort (Figure 70B & 71B). The
training cohort significance remained high at p<0.0001 and 0.003 for tumour buds
and total buds respectively.
Univariate Cox-regression of Tumour buds (HR = 4.5; 95% CI, 1.8-11.2) and Total
buds (HR = 4.5; 95% CI, 1.7-11.9) show that both are strong, significant and near
identical predictors of disease specific death within the validation cohort (Table 12).
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Figure 70. Assessment of optimal cut-offs within the training and validation cohorts for tumour budding.
A) P values for all possible cut-offs within the training cohort and validation cohort were plotted on the
same graph. An optimal cut-off of 253 tumour buds was selected which reported significant values for
both cohorts (red line). The green lines mark the area containing 80% of the training cohort. B) The
optimal cut-off of 253 tumour buds was utilised to plot Kaplan-Meier curves which significantly
stratified the validation cohort into high and low risk of disease specific death.
Figure 71. Assessment of optimal cut-offs within the training and validation cohorts for total budding.
A) P values for all possible cut-offs within the training cohort and validation cohort were plotted on the
same graph. An optimal cut-off of 341 total buds was selected which reported significant values for
both cohorts (red line). The green lines mark the area containing 80% of the training cohort. B) The
optimal cut-off of 341 total buds was utilised to plot Kaplan-Meier curves which significantly stratified
the validation cohort into high and low risk of disease specific death.
FDR correctedP = 0.0009
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Clinicopathological patient U nivariate
param eters num ber(n) HR 95% CI P value
low er upper
O ptim alT um ourBud 4.5 1.8 11.2 0.002
High 47
L ow 87
O ptim alT otalBudding 4.5 1.7 11.9 0.002
High 57
L ow 77
Table 12. . Univariate Cox regression of TB and Total TB utilising optimal cut-offs on the Validation
cohort.
1.5 LVA & TBA combined image analysis algorithm
Both the LVA and TBA Developer XD algorithms utilise similar programming to
optimise the segmentation of panCK objects. Therefore it was possible to add the
additional coding from the TBA to the LVA and combine the two. The additional
coding which was merged from the TBA involved the quantification and assignment
of the number of nuclei within panCK objects as tumour bud classifications, as detailed
above in section 4.2.2. After panCK objects were classified as a tumour bud category
they were merged with the vessel analysis from the LVA allowing colocalising of the
tumour bud object classifications with vessels. This then allows the classification of
the epithelial objects invading the lymphatic vessels as “Tumour bud invasion” or
“Non-bud invasion”.
Non-bud invasion includes panCK objects which are classified as “bud with debris
nuclei” or “large tumour buds” and which colocalise within a vessel. “Tumour bud
invasion” refers to tumour buds which colocalise with D2-40 positive vessels.
The merged single image analysis algorithm has the capability to segment and quantify
multiple tumour bud categories, multiple LVI categories as well as LVD from a single
immunofluorescence labelled tissue section.
Full algorithm specifications and output parameters are listed in Appendix 9.
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1.6 Analysing heterogeneous subpopulations
through image analysis
Tumour subpopulations with differential nuclear morphometry and expression of
panCK were observed in the digitised pathology slides of both the training and
validation set. The majority of tumour buds and large tumour buds expressed high
intensity levels of panCK and large round nuclei with a low spatial density (Figure
72A). On the contrary, tumour glands prevalently contained lower panCK intensity
and smaller oval or columnar nuclei which were in extremely close proximity to each
other (Figure 72B). Specific tumour glands at the invasive front and in close proximity
to tumour buds were observed to have similar panCK intensities and nuclear properties
to tumour buds (Figure 72C). A hypothesis was formed that the tumour buds had
disassociated from these “bud like” glands and that both had picked up driver
aberrations making them more adaptable to invasion through the stromal ECM. These
glands were termed “budding stations”.
Figure 72. Heterogeneity of panCK intensity (green) and nuclear morphometry (Gray scale and blue)
within tumour subpopulations. Images from within the same tumour section show: A) tumour buds
containing large and round nuclei and expressing a high panCK intensity, B) neoplastic glands
containing columnar densely packed nuclei and expressing low panCK and C) neoplastic glands with
similar nuclear morphometry and panCK intensity as tumour buds. Images taken with a x 20 objective.
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1.6.1 Segmenting tumour buds and tumour glands for
heterogeneity analysis
Image analysis was employed across the training cohort in order to quantify the visual
observations detailed above. The TBA was adapted to quantify panCK intensity and
nuclear morphometry within set subpopulations. The algorithm is already pre-
programmed to quantify these subpopulations; ‘tumour gland’, ‘tumour bud’ and
‘large tumour bud’. Multiple nuclear morphometries and intensities were calculated at
single nucleus resolution and exported within the algorithm (Appendix 10). Each
nucleus associated parameter was meaned within one of the three pre-segmented
subpopulations: tumour gland, tumour bud or large tumour bud, and again across the
same 15 images captured at the invasive front as in section 4.3.2. This gave the mean
of the mean of each nuclear parameter within three distinct tumour subpopulations and
across 15 images per tissue section. The whole tissue section training cohort was
analysed using this image analysis methodology. Although there is considerable inter-
patient heterogeneity of panCK intensities across the training cohort, intensity was
consistently higher within the tumour buds and the large tumour buds than within the
tumour glands. This was the case for every patient tissue section analysed (Figure 73).
Only one out of seven patients with a mean tumour gland intensity above 80au
survived follow-up, suggesting that high panCK intensity is a poor prognostic factor
and associated with an more invasive phenotype.
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Figure 73. Mean panCK intensities within tumour subpopulations of patients within the training cohort.
Tumour gland panCK intensity (blue) was consistently lower than the intensity within either tumour
buds (red) or large tumour buds (green). Patients with a panCK intensity of above 80 au (dotted line)
had a poor prognosis.
The thirteen nuclear morphometric parameters, as detailed in Appendix 10, were
exported for each nucleus and averaged separately within either their tumour bud or
tumour gland subpopulations. Each parameter showed a trend of differential nuclear
morphometry between the glands and the buds. Nuclear area, roundness, border length
and width displayed the largest difference between the two subpopulations across the
tissue sections (Figure 74).
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Figure 74. Differential nuclear morphometric parameters within tumour glands (red) or tumour buds
(blue) of the training cohort.
Single parameters showed differential morphometry between the two subpopulations,
however by performing principal component analysis (PCA) on all the parameters
within each subpopulation it was possible to create a nuclear morphometric fingerprint
for each patient sample. Three components were exported from the PCA and plotted
in 3D to allow the visualisation of the nuclear morphometric fingerprint. This was
performed in order to analyse the differential nuclear signatures between tumour buds
and tumour glands.
Figure 75 shows that there is very little inter-patient heterogeneity in tumour gland
nuclear morphometry. The multi-parametric nuclear phenotypic fingerprint of each
tissue section’s tumour gland cluster tightly in statistical space thus representing little
variation across patients. In contrast, not only do the tumour bud nuclear
morphometrics clearly cluster away from those of the tumour glands, there is also
substantial inter-patient heterogeneity. There is no significant separation of tumour
bud or tumour gland nuclear morphometry across the TNM stages.
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Figure 75. PCA of nuclear phenotypic fingerprint for tumour buds vs tumour glands within the training
cohort (n=50). Stage I (blue), stage II alive (green), stage II dead (red) and stage III (orange) patient
nuclear morphometric phenotypic fingerprint for tumour buds (circle) and tumour buds (square) are
plotted.
1.6.2 Assessing mechanistic proteomic signatures across
heterogeneous subpopulations through image analysis.
Tumour buds, large tumour buds and tumour glands display differential panCK
intensities within the same tissue section. Tumour buds and tumour glands also show
differential nuclear morphometrics and nuclear spatial densities. This led to the
hypothesis that tumour subpopulations within the same tissue section express
differential proteomic signatures. These proteomic signatures may identify driver
mutations which confer on the tumour buds a more invasive phenotype or allow them
to disassociate from the tumour glands. Previous image analysis algorithms detailed in
this thesis segment nuclei within set subpopulations but do not allow the segmentation
of the cell. As certain proteins of interest are expressed in the membrane or cytoplasm
of tumour cells a new image analysis approach must be undertaken.
T um ourglandnuclearm orphom etrics
T um ourbudnuclearm orphom etrics
155
1.6.2.1 Subcellular segmentation through Tissue Studio
As with all of the immunofluorescence image analysis algorithms detailed so far within
this thesis the first step in analysis is to utilize Tissue Studio’s Composer machine
learning technology to teach the algorithm to segment the tissue into ‘Tumour’,
‘Stroma’ and ‘no tissue’ before optimising the segmentation. The second step is to
segment the nuclei across each image. Both of these steps are identical to those
explained in Chapter 3.
Post nuclear segmentation the algorithm next simulates the cell’s cytoplasm by
growing out from the nucleus, in all directions, into an area of panCK above a set
threshold until it meets the border of a neighbouring cell’s cytoplasm. Due to low
panCK background staining this threshold is also set low in order to capture cells
expressing low intensities of the cell marker. A typical cell size is set at 200µm2 to aid
the algorithm in cell segmentation. The algorithm now assigns a nuclear and
cytoplasmic compartment for each segmented cell. The final step of the Tissue studio
cell segmentation algorithm is to assign each cell to a classification of high, medium
or low panCK intensity. As a subpopulation of tumour glands expressed similar high
panCK intensities to tumour buds these were segmented within the image analysis
algorithm by assigning these cells to a high panCK intensity dependent classification
(Figure 76).
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Figure 76. Automated image segmentation of tumour subpopulations and associated biomarker
quantification. A) Raw composite image of a TMA core post immunofluorescence with DAPI (blue),
panCK (green) and the proliferation marker Ki67 (red). B) Automated tissue segmentation with
Composer technology. C) Digital zoom of raw composite image. D) Cellular (green line) and nuclear
(blue line) segmentation of tissue. E) Segmented cells are classified as high (maroon), medium (orange)
or low (yellow) for panCK intensity. F) Biomarker (Ki67) is quantified within either the nuclear or





1.6.2.2 Segmentation of subpopulations and biomarker quantification
through Developer XD.
The segmented and classified image from Tissue Studio® was imported into
Developer XD™ for optimization, creation of subpopulations and for proteomic
quantification. The first step of the algorithm is to optimize cellular segmentation by
growing each cell into neighbouring unclassified pixels which are above a panCK
threshold of 35au resulting in a more accurate tumour cell outline. False panCK
positive stromal cells were next excluded from tumour cell classifications. The false
classification occurs when a stromal cell neighbours a tumour gland or tumour bud.
Both cancer subpopulations contain positive panCK fluorescence, and this
fluorescence may become incorrectly segmented within the stromal cell’s cytoplasm,
resulting in the stromal cell being classified as a tumour cell (Figure 77 A).
Exclusion criteria for falsely classified stromal cells are composed of combinations of
cytoplasmic and nuclear morphometric, ‘border to’ neighbouring objects and panCK
intensity parameters (Figure 77 B). False nuclei and debris nuclei are excluded as in
Chapter 3. Tumour gland subpopulations were created by merging neighbouring
tumour cells, within the tumour ROI, of similar panCK intensity classification: “Cell
High”, “Cell Medium” or “Cell Low”. These merged regions within the Tumour ROI
were then classified as subpopulations: “Tumour High”, “Tumour Medium” and
“Tumour Low”. Within the stromal ROI all neighbouring tumour cells, irrespective of
panCk intensity classification, were also merged to create subpopulations. If these
stromal subpopulations of tumour cells contained 1-5 nuclei they were classified as a
tumour bud and if they contained more than 5 nuclei it was classified as a large tumour
bud. Enclosed spaces within each merged classified subpopulation were assigned to
that classification so that all tumour cell subpopulations were complete and segmented
correctly (Figure 78). Areas of adjacent TMA cores may be present within the image
due to capturing the image at 10x magnification. The algorithm ignored these on area
of tissue thresholding. Full algorithm settings are listed in Appendix 11.
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Figure 77. Automated correction of falsely classified stromal cells. A) & B) show a tumour bud with
neighbouring stromal cells (panCK: green, DAPI: blue). A) Inaccurate cellular and nuclear
segmentation within the Tissue Studio algorithm results in incorrectly classified stromal cells as
containing high (maroon) or medium (orange) panCK intensity B) Accurate tumour bud and stromal
cell segmentation correctly classifies the stromal cells and being negative for panCK. Images taken with
a x 20 objective.
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Figure 78. Tumour subpopulation creation and classification within the Tumour bud TMA. A) and B)
show two separate cores from the TMA. Top images show the raw composite image with DAPI (blue),
panCK (green) and Ki67 (red). The bottom images show the Developer algorithm mask where tumour
gland subpopulations have been classified dependent on their panCK intensity. Tumour buds and large
tumour buds were classified within the stroma. Arrow in B shows a section of neighbouring TMA core
being automatically excluded by the algorithm. Images taken with a x 10 objective
A B
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1.6.2.3 Quantification of protein expression within segmented
subpopulations
The subcellular mean intensity of a biomarker protein of interest within the cells of
distinct subpopulations of: Tumour high, Tumour medium, Tumour low, tumour bud
or large tumour bud, is exported by the algortihm. This allows the investigation of
heterogeneously expressed protein signatures across the tumour subpopulations within
the CRC invasive margin.
Two areas of high TB were identified, after image analysis, in each of 50 patient tissue
sections from the validation set. These areas, as well as two areas of high tumour gland
density, were marked onto H&E stained tissue sections which consequently were used
to mark the areas onto the original tissue blocks. A TMA was created containing cores
taken from high TB areas and high tumour gland areas. A panel of proteins was
selected with which to interrogate the TMA. This study was carried out to investigate
if TB subpopulations expressed differential protein signatures from tumour glands and
whether high panCK tumour subpopulations (representing our hypothetical budding
stations) expressed a bud-like protein signature or a tumour gland-like one.
This study was also carried out to identify the tumour bud’s mechanistic drivers and
to see if they expressed invasion like protein signatures. β-Catenin was selected to 
identify whether Wnt signaling was differentially activated in the subpopulations as
well as aberrant epithelial cell status. Ki67 was selected to identify if the
subpopulations underwent differing proliferation rates. Nanog, Sox2, Oct4, CD44 and
CD133 were selected to identify if the subpopulations contained stem-like cancer cells.
E-Cadherin, pan-Cadherin, Src, snail, EpCam, Vimentin and a panel of cytokeratins
were selected to identify whether the subpopulations underwent EMT. MMPs were
selected to identify if the subpopulations remodeled the ECM, whereas Scrib3 and
Pard3 were selected to identify if subpopulations exhibited a loss of polarity. The
antibodies utilised and their optimised dilutions are listed in Table 2 in Materials and
Methods. Although all antibodies had been previously validated through western blot
and IF in either the University of Edinburgh or the University of St Andrews
laboratories all underwent a further optimisation experiment to identify the optimal
dilution to be used. Optimisation experiments were carried out at three dilutions on a
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CRC optimisation TMA. A number of the antibodies failed this further validation step
and were not carried forward to be tested on the tumour bud TMA for subpopulation
expression evaluation. The mean intensity of each subpopulation was again averaged
across the four cores taken per patient sample (two cores from a high budding area and
two from a high tumour gland area).The value for each subpopulation within a patient
sample was then averaged across the subpopulations of each patient sample. This was
calculated to inform on patterns of differential protein expression common across the
patient cohort. A high level of inter-patient heterogeneity was found across all proteins.
1.6.2.3.1 Proliferation rates within tumour subpopulations – Ki67
The nuclear expression of Ki67 was automatically quantified across the tumour
subpopulations within each TMA core prior to data collation as described above.
Although there was a large amount of inter-patient heterogeneity of nuclear Ki67
intensities there was a trend for tumour buds to contain less proliferation cells than the
tumour gland subpopulations (Figure 79 A) suggesting that tumour buds have, on
average across all patient samples, a lower proliferation rate than tumour glands.
Figure 79 B shows the intensity profiles of cores taken from two different patient
samples. The expression levels of Ki67 differ greatly between the patient samples
across each subpopulation, demonstrating the high inter-patient heterogeneity. In both
patient samples the tumour buds and large tumour buds express less Ki67 than the
tumour subpopulations demonstrating intra-patient heterogeneity. This intra-patient
differential expression pattern suggests tumour bud subpopulations have a lower rate




Figure 79. Mean intensity of Ki67 within distinct tumour subpopulations: tumour buds (TB), large
tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM HIGH),
neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic gland
subpopulations with low panCK intensity (TUM LOW). A) Mean intensity of Ki67within tumour
subpopulations averaged across 50 patients. Standard deviation error bars represent the inter-patient
heterogeneity. B) Mean intensity of Ki67 within tumour subpopulations of 2 individual patients: Core
A and B.
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1.6.2.3.2 Mesenchymal signature within tumour subpopulations – Vimentin &
Snail
Cytoplasmic expression of Vimentin was quantified across the tumour subpopulations
within each TMA core. The mesenchymal marker Vimentin’s expression was on
average increased within the tumour bud and large tumour bud subpopulations
compared to the tumour gland subpopulations upon assessing all subpopulations
across 50 patient samples (Figure 80 A).
Figure 80 B shows the Vimentin intensity profiles of the subpopulations taken from
two different patient samples. The expression levels of Vimentin demonstrate high
inter-patient heterogeneity. In both patient samples the tumour buds and large tumour
buds express more Vimentin than the tumour gland subpopulations. This intra-patient
differential expression pattern suggests tumour buds may have taken on a more
mesenchymal cellular phenotype than the cells within the tumour glands.
Although Vimentin expression was increased in the tumour bud subpopulations a
second mesenchymal marker’s intensity, Snail, was on average slightly decreased in
the tumour buds and increased in panCk high tumour subpopulations (Figure 81 A).
There was, however, very high inter-patient heterogeneity for Snail expression. The
inter-patient heterogeneity is demonstrated in Figure 81 B and, although both patient
samples express differential Snail, it seems that the panCK high tumour
subpopulations express the highest level of Snail in both tissue sections.
1.6.2.3.3 ECM remodeling within tumour subpopulations – MMP9
The cytoplasmic expression of MMP9 was quantified across all subpopulations. There
was no expression of MMP9 within any subpopulations and intensity of MMP9 was
at baseline levels (Figure 82). The antibody was specific and stromal cell expression




Figure 80. Mean intensity of Vimentin within distinct tumour subpopulations: tumour buds (TB), large
tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM HIGH),
neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic gland
subpopulations with low panCK intensity (TUM LOW). A) Mean intensity of Vimentin within tumour
subpopulations averaged across 50 patients. Standard deviation error bars represent the inter-patient
heterogeneity. B) Mean intensity of Vimentin within tumour subpopulations of 2 individual patients:




Figure 81. Mean intensity of Snail within distinct tumour subpopulations: tumour buds (TB), large
tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM HIGH),
neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic gland
subpopulations with low panCK intensity (TUM LOW). A) Mean intensity of Snail within tumour
subpopulations averaged across 50 patients. Standard deviation error bars represent the inter-patient
heterogeneity. B) Mean intensity of Snail within tumour subpopulations of 2 individual patients: Core
A and B.
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Figure 82. Mean intensity of MMP9 within tumour subpopulations meaned across 50 patients: tumour
buds (TB), large tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM
HIGH), neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic
gland subpopulations with low panCK intensity (TUM LOW). Mean intensity of MMP9 within tumour
subpopulations averaged across 50 patients. Standard deviation error bars represent the inter-patient
heterogeneity.
1.6.2.3.4 Epithelial signature within tumour subpopulations – EpCam,
E-Cadherin, CK5/6/8/18, CK7 & CK20
Cytoplasmic expression of all epithelial markers was quantified across the tumour
subpopulations of all patient samples. Cytokeratin 7 expression was either present for
all tumour subpopulations or absent within the patient samples (Figure 2). There was
therefore inter-patient heterogeneity (Figure 83) but no intra-patient heterogeneity.
Tumour buds and large tumour buds, on average, expressed lower epithelial markers
than the tumour glands. This was true for antibodies against EpCam (Figure 84), E-
Cadherin (figure 85), CK20 (Figure 86) and the combined CK5/6/8/18 antibody
(Figure 87). In some patient cores, for all antibodies except for E-Cadherin and CK 7,
the high panCK tumour subpopulations had similar low expression levels as the
tumour bud subpopulations, but this was however not the case for all patient samples.
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Subpopulation heterogeneity therefore differs across patient samples. A pattern of
lower expression of epithelial markers within the budding areas than the well
differentiated neoplastic glands suggests that tumour bud subpopulations partially lose
their epithelial phenotype. This, along with average increased Vimentin, may be
interpreted as an EMT by a more invasive tumour bud which has adapted to
disseminate from glands and migrate within the ECM.
Figure 83. Mean intensity of CK7 within tumour subpopulations averaged across 50 patients: tumour
buds (TB), large tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM
HIGH), neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic
gland subpopulations with low panCK intensity (TUM LOW). Mean intensity of CK7within tumour





Figure 84. Mean intensity of EpCam within distinct tumour subpopulations: tumour buds (TB), large
tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM HIGH),
neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic gland
subpopulations with low panCK intensity (TUM LOW. A) Mean intensity of EpCAM within tumour
subpopulations averaged across 50 patients. Standard deviation error bars represent the inter-patient
heterogeneity. B) Mean intensity of EpCAM within tumour subpopulations of 2 individual patients:




Figure 85. Mean intensity of E-Cadherin within distinct tumour subpopulations: tumour buds (TB),
large tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM HIGH),
neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic gland
subpopulations with low panCK intensity (TUM LOW. A) Mean intensity of E-Cadherin within tumour
subpopulations averaged across 50 patients. Standard deviation error bars represent the inter-patient
heterogeneity. B) Mean intensity of E-Cadherin within tumour subpopulations of 2 individual patients:




Figure 86. Mean intensity of CK20 within distinct tumour subpopulations: tumour buds (TB), large
tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM HIGH),
neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic gland
subpopulations with low panCK intensity (TUM LOW. A) Mean intensity of CK20 within tumour
subpopulations averaged across 50 patients. Standard deviation error bars represent the inter-patient





Figure 87. Mean intensity of CK5/6/8/18 within distinct tumour subpopulations: tumour buds (TB),
large tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM HIGH),
neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic gland
subpopulations with low panCK intensity (TUM LOW). A) Mean intensity of CK5/6/8/18 within
tumour subpopulations averaged across 50 patients. Standard deviation error bars represent the inter-
patient heterogeneity. B) Mean intensity of CK5/6/8/18 within tumour subpopulations of 2 individual
patients: Core A and B.
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1.6.2.3.5 Wnt signalling signature within tumour subpopulations– β-Catenin 
An increase in the nuclear to cytoplasmic ratio of β-Catenin is representative of its 
oncogenic role in CRC and aberrant Wnt signalling. Therefore β-Catenin was 
quantified within both the cytoplasm and the nucleus of each cell within all tumour
subpopulations. The mean nuclear to cytoplasmic ratio was then calculated for each
subpopulation within each core. Finally the mean nuclear to cytoplasmic ratio for each
subpopulation was calculated across each patient sample. There was high inter-patient
heterogeneity present across the cores. On average, there was a higher nuclear than
cytoplasmic sublocalisation of β-Catenin in all tumour subpopulations apart from the 
panCK low and well differentiated tumour glands (Figure 88 A). In some cores the
low panCK tumour subpopulations expressed higher cytoplasmic than nuclear β-
Catenin (Figure 88 B). This would indicate a loss of β-Catenin’s cell adhesion function 
and an increase in its oncogenic role in subpopulations containing higher panCK
intensity.
1.6.2.3.6 Stem-like cell marker expression within tumour subpopulations –
CD133 & CD44
Cytoplasmic expression of CD133 and CD44 was quantified within the subpopulations
across each patient core.
CD133 was either present in a tumour or absent and showed no intra-patient
heterogeneity. Only 3 patient samples expressed CD133 across their subpopulations.
A positive and negative sample is plotted in Figure 89.
There was inter- and intra-patient heterogeneous expression of CD44 within the
cohort. On average there was a slight increase of CD44 tumour bud expression than in
other subpopulations across the whole cohort (Figure 90 A). This was not the case for
all patient samples, as some showed an increased expression profile of CD44 in tumour
glands than tumour buds and some showed the opposite (figure 90 B).
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A) Mean nuclear to cytoplasmic ratio of β-Catenin intensity within tumour 
subpopulations meaned across 50 patients.
S ubpopulation M eanN uc/Cytratio
T B 1.44
L T B 1.53
T U M HIGH 1.51
T U M M ED 1.27
T U M L O W 1.02
B) Nuclear to cytoplasmic ratio of β-Catenin intensity within tumour 
subpopulations of 2 individual patients.
Figure 88. A) Mean intensity of nuclear or cytoplasmic β-Catenin within tumour subpopulations 
averaged across 50 patients. Nuclear to cytoplasmic ratio of β-Catenin intensity within distinct tumour 
subpopulations: tumour buds (TB), large tumour buds (LTB), neoplastic gland subpopulations with high
panCK intensity (TUM HIGH), neoplastic gland subpopulations with medium panCK intensity (TUM
MED) and neoplastic gland subpopulations with low panCK intensity (TUM LOW). The Mean nuclear
to cytoplasmic ratio across the 50 patient cohort is tabulated. B) Mean intensity of nuclear or
cytoplasmic β-Catenin within tumour subpopulations of an individual patient.
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Figure 89. Mean intensity of CD133 within tumour subpopulations: tumour buds (TB), large tumour
buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM HIGH), neoplastic gland
subpopulations with medium panCK intensity (TUM MED) and neoplastic gland subpopulations with




Figure 90. Mean intensity of CD44 within distinct tumour subpopulations: tumour buds (TB), large
tumour buds (LTB), neoplastic gland subpopulations with high panCK intensity (TUM HIGH),
neoplastic gland subpopulations with medium panCK intensity (TUM MED) and neoplastic gland
subpopulations with low panCK intensity (TUM LOW). A) Mean intensity of CD44 within tumour
subpopulations averaged across 50 patients. Standard deviation error bars represent the inter-patient




The initial aim of this study was to evaluate whether TB can be automatically
quantified through image analysis in a robust and reproducible manner. The image
analysis algorithm produced to quantify tumour buds was executed across a 50- patient
training set and a 134-patient validation set to assess the prognostic power of TB and
its ability to stratify stage II patients into high and low risk of CRC specific death.
When applying an optimal cut-off, which was highly significant over both cohorts, to
the clinically relevant Stage II CRC patient validation set, the hazard ratio for disease
specific death, with regard to TB, was 4.5 (95%CI;1.8-11.2). The result reported here
reflects multiple other studies which have shown TB to be associated with poor
survival, disease recurrence and lymph node metastasis in Stage II patients (91, 92,
265, 272, 307, 309, 312). Although there is a large body of evidence to support TB to
be a significant and independent prognostic parameter it is still not included in the
RCPath guidelines as a core data item(102). The main reason for this is a lack of
standardisation, both in quantification methodology as well as the cut-offs for high and
low risk patient stratification and variability of results across studies.
Although most researchers now define tumour buds as clusters of cells within the
stroma containing 5 or less cancer cells, as defined by Ueno(270), there is no general
consensus as to a standardised quantification methodology. Many studies adopt their
own magnification, sample area and cut-offs of what constitutes high grade budding.
Cut-offs have varied greatly and have been reported as 5 buds in a 20x field (272, 311)
through to 5 buds in a 40 x field (267, 272), however only a few have shown
statistically sound evidence for their cut-offs (20, 268, 310). Lugli’s laboratory has
recently proposed an average bud count across 10 fields at 40x objective which they
also compared to 7 other quantification methods and found their method to be the most
reproducible and the only one significant for stage II CRC patient outcome(92, 288).
Tumour bud counts have either been carried out in H&E(267, 270, 307) or cytokeratin
immunohistochemistry(92, 136, 311) studies which produce variable results
concerning the proportion of patients with high budding. A reason for these
discrepancies could be that tumour buds are easier to identify and therefore are more
accurately counted in cytokeratin labelled tissue sections. However observer
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variability has been shown, in some cases, to be similar in H&E based studies to those
who implement IHC(272).
Although some studies do show good observer concordance in TB count, all previous
studies have been undertaken in a semi-quantitative and manual way which can lead
to observer variability in reporting of TB. In spite of observer variability and a lack of
standardisation TB shows strong prognostic potential due to the majority of studies
showing high TB to be associated with a higher risk of CRC specific death or lymph
node metastasis(20, 136, 272). This study was carried out to provide methodology
which allows the standardisation of TB quantification through an image analysis
algorithm while negating observer variability. The image analysis algorithm
developed in this study quantified tumour buds and classified them as clusters of up to
5 cells within the stromal region of the invasive margin as defined by Ueno(270).
Unlike manual quantification studies in the literature, which quantify TB under
brightfield illumination, an IF approach was adopted with panCK and nuclear
counterstaining with DAPI. An IF approach allows a separate digital image to be
acquired for each fluorophore captured at a specific wavelength: panCK or DAPI.
Upon importing the separate images into the Definiens software, panCK positive
epithelial objects and DAPI positive nuclei can be segmented within their own image
layer resulting in no interference from each other. This was to ensure that nuclei were
not obscured by the panCK antibody, as was the case when image analysis was
performed on IHC with DAB visualisation. Merging of the two image layers allows
the image analysis algorithm to quantify the number of nuclei within each epithelial
panCk positive object within the stroma and consequently allows the classification of
a tumour bud as containing 1-5 cells.
Although most studies, as was done here, adopt Ueno’s definition of a tumour bud
being up to 5 cells in size, there is no proof of how this original cut-off was established.
Ueno has more recently proposed a novel grading system which quantifies the number
of poorly differentiated clusters (PDC) within the stroma with more than 5 nuclei(269)
and which he demonstrates has a higher significance on survival outcome than TB.
The image analysis algorithm developed in this study therefore also classified and
automatically quantified panCK objects within the stroma which fall outwith the 1-5
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cell TB classification. PanCK positive objects beneath 5000µm2 but with more than 5
associated nuclei were classified as “Large Tumour Buds” and their number
quantified, as were buds which only contained 1-2 nuclei. An area of 5000µm2 was
manually selected after observing the invasive front of tissue sections within the
training cohort. Above this area tumour clusters generally formed gland-like
structures. Patients from the training cohort were stratified by the classical TB, TB
with only 1-2 associated nuclei and Large Tumour Bud counts. KM curves were
plotted to assess CRC specific death over time between high and low budding cut-offs
in each bud category. The results from all categories in the Stage II subpopulation were
near identical. The sum of TB and LTB categories was classified as “Total Budding”
which was created to assess if this resulted in a more prognostic parameter than TB
alone. Although Total Budding (HR = 8.1; 95% CI, 3.3-19.8) was a more significant
prognostic parameter than TB (HR = 5.76; 95% CI, 2.38-13.8) in the training set it
reported near identical results to TB when the optimal cut-off for Total Budding was
applied to the clinically relevant Stage II validation set (HR = 4.5, p= 0.002). TB in
the training set was not an independent significant prognostic parameter when pT, pN,
Dukes, LVI, LVD were included in the model, however Total Budding is an
independent predictor of CRC specific death (HR = 4.5; 95% CI, 1.4-14.2). Further
large clinical trials will need to be performed to assess if Total Budding is a more
significant prognostic parameter than the classical TB classification. TB was also
correlated to LVI in both the training set (r = 0.69, p<0.0003) and the validation set (r
= 0.64, p< 0.0001), which mirrors similar results by Ohtsuki(265).
TB, as with all histopathological features, is a tissue sectioning artefact. In this study
we quantified tumour buds from 3µm thick tissue sections. In the 2D tissue section TB
is counted as clusters of 1-5 cells within the stroma of the invasive margin which
appear to be dissociated from the tumour glands. There is some proof that tumour buds
are in fact connected to neoplastic glands as spindle-like collective invasion when
serial sections are reconstructed in 3D(205, 310). If there is little single cell invasion
in reality, the size of the tumour bud may be based purely on the area the section is
taken from and may therefore be less important as a cut-off than, for example, the
morphometry and phenotype of the invading cells within the protrusions. Tumour buds
irrespective of their original 3D morphology take on a differential phenotypic and
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morphometric change from well-differentiated tumour glands. This study was able to
quantify these changes through automated image analysis. The tumour bud nuclear
morphometric fingerprint clustered apart from the tumour gland fingerprint within
each patient sample from the training set. Tumour gland morphometrics showed
relatively little inter-patient heterogeneity however tumour bud inter-patient
heterogeneity was pronounced. Tumour buds within each patient sample were larger
and rounder than those within the tumour glands. Although this is the first study to
show tumour bud morphometry to be differential to tumour gland morphometry,
Hamilton showed this to be the case between normal and CRC adenocarcinoma within
the same patient(325). Later Deans showed that nuclei in poorly differentiated glands
were rounder than those in well differentiated glands and nuclei with a larger diameter
were associated with tumours containing an infiltrative growth pattern(326). As
tumour buds are associated with a poor outcome these results reflect past studies and
have shown nuclear area and shape to be correlated to prognosis(167) as well as a
correlation to tumours which have metastasised or contain LVI; which contain larger
nuclei(166, 327). Other studies showed no correlation of nuclear morphometry to
patient outcome (165, 326).
Nuclear morphometry could act as a surrogate for EMT as it tends to occur at the
invasive edge of CRC where poorly differentiated cell clusters are located. TB has also
been associated with cancer stem cells and a decreased expression in
proliferation(328). These phenotypes would confer an evolutionary advantage for
metastasising cancer cells. Although cytokeratin expression is usually associated with
epithelial cells(329), TB and LTB showed an increase in panCK intensity compared
to the glands from the same patients. This could imply that a full EMT has not occurred
in TB and the cells have retained some epithelial characteristics. A decrease in cell
adhesion molecules such as E-Cadherin and β-Catenin have, however, been shown to 
occur in TB(330, 331) which are considered to be essential early markers of EMT(18).
An image analysis algorithm was developed to assess if subpopulations of tumour
glands (with similar nuclear morphometry and high panCK expression to TB and
which were termed ‘budding stations’, TB and LTB had undergone EMT or expressed
stem cell-like phenotypes. The algorithm segmented TB, LTB within the stroma and
further subpopulations within tumour glands to assess intra-patient heterogeneity. The
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gland subpopulations were segmented by panCK intensity. The algorithm then
measured biomarker expression within the tumour subpopulations. The quantification
of protein expression through image analysis with IF has advantages over semi-
quantitative brightfield quantification. These include full continuous data-sets across
the dynamic range of the intensity profile (instead of a subjective 1+, 2+. 3+ count),
and a decrease in reporter variability.
Similar to other studies of EMT in TB, this study found that, E-Cadherin (331) and
EpCam (317) showed a trend of decreased expression in TB and LTB across the patient
samples. A further EMT-like phenotype of nuclear β-Catenin expression was seen in 
TB and LTB which suggests a higher degree of aberrant Wnt signalling and oncogene
transcription. Although panCK is increased within the TBs, this is not due to an over-
expression of CK7, as previously reported(332, 333), and CK5, 6, 8, 18 and 20 are in
fact decreased in TB and LTB which is correlates with the EMT theory. Further proof
of an EMT within TB and LTB is the increase in the mesenchymal marker
Vimentin(334) although Snail was shown to be decreased in TB and LTB which is in
conflict with the EMT theory. Although TB have shown an increase in uPAR(328) and
MMP9(322) expression, to allow remodelling of the ECM, the only antibody which
showed specificity in this study was MMP9 and no tumour subpopulation expressed
this protein, although stromal cells did. The proteins Lgr5, Nanog, Sox2, Oct4, CD133,
CD44 and EpCAM have been associated with cancer stem cell and tumour
progression(335-337). CD133 showed no intra-patient heterogeneity in the tumour
subpopulations when analysed in this study and patient cores either expressed CD133
in all subpopulations or none. CD44 showed a general trend of increased expression
in TB but in some patients this was the opposite. There was large inter-patient
heterogeneity in the expression of all of the proteins studied which may have masked
the trend of subpopulation differential expression when the patient data was
accumulated across the samples; however when observing single patient data most
followed the trends described above.
Inter-patient heterogeneity in tumour bud morphometrics leads to the hypothesis that
there is intra-patient heterogeneity even within the same subpopulations e.g. tumour
buds which express a more stem-like or invasive phenotype than others within the
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same patient sample. Dawson et al suggested that tumour buds were a heterogeneous
population when examining proliferation and apoptosis markers(319) and this is
probably also the case in our study. This source of heterogeneity could stem from a
mechanistic artefact of the tumour block cutting process where some TB in a tissue
section are simply the edge of a cross section of a tumour gland and therefore does not
display EMT or invasive phenotypes. The inclusion of these tumour bud artefacts in a
TB count may decrease the prognostic significance of TB. Some tumour buds within
the tissue sample may not have developed invasive driver mutations, although they
have undergone EMT. To investigate this further, single cell data coupled with spatial
heterogeneity statistics, and not subpopulation mean data, would need to be exported
from the image analysis algorithm. Tumour buds which display EMT, stem-like or
invasive signatures could subsequently be included in the tumour bud count while the
rest are discarded. The counting of more “aggressive” TB could potentially increase
TB’s significance as a prognostic marker. If these aggressive buds can be further
correlated to a nuclear or cellular morphology this morphometric signature could be
utilised as a surrogate marker for the aggressive budding. Utilising a morphometric
surrogate for aggressive budding would discard the need for multiple serial sectioning
and the associated IHC to identify EMT and stem cell protein biomarkers. TB
heterogeneity, in this manner, could explain the inter-patient heterogeneity within the
nuclear morphometrics described within this study. Future TB proteomic and
morphometric studies could therefore serve two purposes: 1) to identify the
mechanism of invasion for novel drug targets and 2) to identify a subpopulation of
tumour buds which are in fact invasive and are responsible for poor prognosis. The
identification of tumour subpopulations through Tissue Phenomics may also allow the
purification of the subpopulations for further omics-based studies to elucidate novel
drug targets or mechanisms of cancer progression.
In summary, TB has been shown in this study to be a significant prognostic parameter
capable of stratifying stage II CRC patients into high and low risk of CRC specific
death. Image analysis allows the standardisation of TB count while negating observer
variability. Further validation studies utilising the TB image analysis algorithm could
overcome the obstacles preventing the parameter from being included in clinical core-
data sets.
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Chapter 5: Discovering Novel Prognostic
Features in Colorectal Cancer through Tissue
Phenomics
1.1 Introduction
As discussed in Chapters 3 and 4, digital pathology coupled with image analysis has
the ability to quantify histopathological features, segment tumour subpopulations and
quantify biomarkers across digitised immunofluorescence labelled tissue sections.
This methodology transforms pathological scoring from a traditionally semi-
quantitative science into a fully quantifiable one while allowing the standardisation of
reporting. Automated quantification may additionally free up a pathologist’s valuable
time and reduce observer variability. However, it does not perform a task which a
pathologist could not do themselves and there still remains scepticism of automated
methodologies. Quantitative image analysis within clinical pathology research may
only take hold and be widely adopted when the technology has the power to perform
tasks and calculations which are outwith the scope of manual quantification.
Histopathology is not solely the compilation of a set of recommended
histopathological features into a prognosis based on institutional guidelines. The field
of pathology recognises the rich data source which lies within the tissue section (338).
The pathologist takes into account the entire heterogeneous and heterotypic
microenvironment and its interactions across the tissue section. Through experience
they are able to process this complex, sometimes subtle information, and translate it in
order to aid their diagnostic or prognostic conclusion. Research pathologists also apply
this methodology to evaluate novel or significant prognostic features such as the
tumour differentiation or invasive morphology at the invasive front(236, 269, 304) or
immune response within the microenvironment(339) (340, 341). Although the
tumour’s microenvironment is becoming more evidently important in a cancer’s
progression, where complex immune cell infiltrate and its spatial distribution can be
quantified by image analysis(298, 342), a simple measurement such as the percentage
of stroma at the invasive front has also been shown to be prognostic(343-345).
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The empirical science of pathology can be difficult to standardise and quantify due to
the inter- and intra-heterogeneous nature of the tumour microenvironment. Automated
image analysis based segmentation of digitised tissue sections has the ability to
quantify and standardise complex and subtle morphological features or signatures in a
continuous data capture manner. The emerging field of Tissue Phenomics allows us to
perform such datafication of the tissue phenome from computationally segmented
tissue sections. This image analysis methodology quantifies and profiles the complex
phenome of the tumour’s microenvironment in an a priori “measure-everything big-
data” approach. This is performed in an attempt to identify and quantify novel
clinically relevant histopathological objects from large exported image based multi-
parametric data sets. These objects may represent single or combinations of
morphometrically quantifiable histological features, which may be subtle or difficult
to reproducibly quantify and therefore go unreported under manual observation, but
which could prove prognostic or predictive. Beck et al demonstrated this technique in
breast cancer and found the stromal microenvironment to be specifically relevant to
prognosis (192). This study details the development of a novel methodology allowing
the identification of novel histopathological features through the implementation of a
Tissue Phenomics pipeline. The Tissue Phenomics pipeline consists of performing
unbiased image analysis prior to data export and multi-parametric statistical analysis.
Initially a sophisticated image analysis solution is required to allow multi‐parametric
data export and the quantification and extraction of multiple histological features while
also capturing the morphometry of the tumour microenvironment. Here, the
methodology is demonstrated through profiling the phenome of the invasive front of
the CRC microenvironment on immunofluorescence labelled tissue sections, resulting
in a phenotypic fingerprint for each patient; the phenotypic fingerprint is created from
the hierarchical multi-parametric data exported post image analysis. As tumour
morphometry, the tumour microenvironment and the lymphatic vasculature within the
microenvironment have been shown to be prognostic in the literature (20, 259, 260,
267, 295), as well as in previous chapters within this thesis, the phenotypic fingerprint
within this study includes morphometric and intensity parameters of all tumour
subpopulations, such as neoplastic glands and tumour buds as well as the lymphatic
vasculature. Nuclear morphometric and fluorophore intensity parameters across the
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digitised images were therefore quantified and nuclei assigned to their appropriate
subpopulations to retain their heterogeneity. The image segmentation and image
analysis algorithm was based on the combined LVI and Tumour bud quantification
algorithm as described in Chapter 4.5. In addition to the parameters exported in
previous chapters, over one hundred intensity and morphometric parameters were
exported across the microenvironment resulting in a phenotypic fingerprint created
from all segmented objects. After post processing of the exported phenotypic
fingerprint, multi-parametric ensemble and decision tree learning methods were
performed in the Tissue Phenomics pipeline in order to undertake a data mining
approach to identify a novel prognostic histopathological feature with the ability to
stratify Stage II CRC patients into high and low risk of disease specific death.
The study in this chapter applied the Tissue Phenomics pipeline to the image analysis
of the CRC invasive front through the triple immunofluorescence multiplex labelling
of panCK, D2-40 and DAPI as implemented in previous chapters. The Tissue
Phenomics pipeline developed here is not, however, exclusive to this single
multiplexed immunofluorescence assay. The Tissue Phenomics pipeline can be
utilised to identify, for example, predictive or prognostic histopathological features,
spatial density signatures, intensity and texture profiles, in situ biomarker
quantification and expression levels from other image analysis segmented digital
pathology images. The pipeline may also be utilised, after small additions, to integrate
multi-omics data into the multiparametric fingerprint. The decision tree statistics allow





The initial step of every immunofluorescence algorithm within this project is to
segment the tumour glands from the stroma. This step is done through machine
learning with Definiens Composer™ technology. Previously this step was undertaken
to identify histopathological features within the stromal ROI while the tumour ROI
was excluded from further quantification. In order to assess whether specific tumour
morphometric parameters were prognostic the Tissue Studio image segmentation
algorithm was further programmed to quantify and export individual tumour gland
morphometrics as well as the percentage area of the image of each ROI
(Necrosis/Lumen, Stroma and Tumour). Fifteen tumour ROI morphometric
parameters were selected for export within the Tissue Studio® custom export feature
(Table 13). The updated tissue segmentation algorithm was run over the 15 images
captured across the invasive front of the WSI training cohort and which were utilized
in Chapter 3.7.2.1 The export parameters, as listed in Table 13, were collated across
the 15 images by calculating the mean of each parameter in order to create a single
row of data per tissue section. Each parameter was imported into the X-tile software
where optimal cut-offs were calculated and p values corrected through Miller-
Siegmund false discovery statistics. All percentage ROI parameters were highly
significant for stratifying the training cohort patients into high and low risk of disease
specific survival over 14 years of follow up (Table 13 and Figure 91). Of the tumour
gland morphometry parameters, eight were shown to be significant if no p value
correction was applied and only ‘Relative border to stroma’ (p = 0.004) and
‘Perimeter’ (p = 0.04) were significant after stringent Miller-Seigmund false discovery







% Lumen/Necrosis 1.9 <0.0001 0.0005
% Stroma 67.2 <0.0001 0.0008
% Tumour 25 <0.0001 0.0016
Border Index 1.7 0.002 0.06




Length (µm) N/A Non-significant
Width (µm) 130 0.01 0.24
Border to Stroma (µm) 1072 0.04 0.4
Relative Border to Stroma 0.8 0.0001 0.0035
Perimeter (µm) 1036 0.002 0.04
Circularity N/A Non-significant
Ellipticity N/A Non-significant
Elliptic Fit N/A Non-significant
Rectangular Fit 0.8 0.05 0.5
Asymetry 0.6 0.004 0.08
Table 13. Prognostic significance of percentage ROI and tumour morphometry calculated from the
training cohort. Optimal cut-offs for each parameter are calculated from KM curves and uncorrected or
Miller-Siegmund false discovery rate corrected p values are tabulated. Parameters in bold were deemed
to be significant (MS corrected <0.05).
TMA Navigator software was utilised to plot the KM curves of the significant
parameters to assess their ability to stratify patients on survival over time. Patients are
split into above or below cut-off groups prior to plotting the curves (Figure 91).
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Figure 91. Kaplan-Meier curves for ROI percentage of image and significant tumour morphometrics,
Training cohort. Disease specific survival of above and below cut-off categories for each significant
percent area ROI and tumour morphometric parameters. Patients categorised in Group 1(green) are
below cut-off and Group 2 (orange) above cut-off for each parameter.
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A number of the tumour gland morphometrics showed some promise in stratifying
patients into high and low risk of disease specific death, although after stringent false
discovery rate (FDR) statistics, most fell below significant levels. A combination of
these parameters may increase their prognostic significance and therefore the next
phase of this study is to create a Tissue Phenomics pipeline to export a multi-
parametric phenotypic fingerprint which incorporates a large number of image based
analysis parameters, including the tumour gland morphometrics. The fingerprint will
be interrogated for significant single or combinations of parameters.
1.2.2 Tissue Phenomics pipeline
The Tissue Phenomics pipeline was constructed to identify novel histopathological
features or combinations of features from large multi-parametric image-based data sets
(Figure 92). The Tissue Phenomics pipeline was performed on the 50 patient whole
tissue section training cohort. The same 15 immunofluorescence labelled (panCK, D2-
40, DAPI) images captured across the invasive front of each patient tissue section, as
utilised in Chapter 3.7.2.1, were the input for the Tissue Phenomics pipeline. The
digital image was segmented through the Definiens XD™ image analysis software
suite using the modified Tissue Studio® ROI segmentation ruleset as described in 5.2.1
and the IHA Developer XD™ image analysis algorithm. The algorithm was
augmented to allow morphometric, intensity and texture parameters to be calculated
and exported for each segmented object to create a Tissue Phenomics Algorithm
(TPA). Full algorithm settings for the TPA are listed in appendix 12. The multi-
parametric data export was collated across the 15 images to ensure one row of data per
tissue section creating a phenotypic fingerprint for each patient. This high dimensional
data was analysed through multiple multi-parametric statistical methods. The first of
these methods which was applied to the data was Principal Component Analysis
(PCA). PCA allowed the graphical visualisation, in 2D, of the phenotypic signature
and the evaluation of the fingerprint’s ability to stratify high and low risk patients.
Regression tree analysis was subsequently applied to the multi-parametric data in order
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to identify the significant parameters within the fingerprint. The next step in the
pipeline was therefore to perform a Random Forest regression tree model on the
phenotypic fingerprint. The parameters were ranked in order of significance through
the Random Forest modelling and their associated Gini score. The significant
parameters were the input for a Classification and Regression tree analysis (CART)
model to identify the optimal significant parameters, within the regression tree, along
with associated cut-offs to stratify patients into high and low risk of disease specific
death.
Figure 92. Tissue Phenomics pipeline. A) Digitised images are segmented with image analysis software
and resultant objects quantified. B) Associated hierarchical multi-parametric data is exported and
collated. C) PCA is performed to visualise the multi-parametric signature and to assess its prognostic
value. D) Significant parameters are identified through Random forest. E) The resultant significant
parameters act as input to a CART model for prognostic feature identification and cut-off analysis.
Multiparametric Image segmentation
Data Handling:














1.2.2.1 Image segmentation and data export
The first essential step that a Tissue Phenomics approach requires is to segment the
tissue through image analysis (Figure 92A). This quasi-unbiased multi-parametric
image feature capture is utilised to discover novel prognostic phenotypic fingerprints
and histopathological features. This study aimed to quantify the number of each
resultant segmented object as well as multiple morphological, texture and intensity
parameters from tumour cell subpopulations as well as the lymphatic vasculature in
order to identify novel prognostic features which enable the stratification of stage II
CRC patients into high and low risk of disease specific death.
Within this study immunofluorescence was utilised to label epithelial cells, lymphatic
endothelial cells and to counterstain the nuclei. The labelling of the tissue enables the
TPA to segment every labelled object within the image including tumour glands,
smaller invasive tumour bodies within the stroma or within vessels, epithelial debris
and lymphatic vessels. Once segmented the TPA allows the quantification and export
of morphometric, density and fluorescence intensity and texture measurements (Figure
93).
Spatial information, such as neighbouring and colocalising of objects is further
captured and used to further sub-classify objects, such as vessels bordering tumour
glands or tumour cells bordering vessels (Figure 94).
Nuclei within the stroma, the tumour glands and the tumour buds contain
heterogeneous and differential intensity, morphometric and texture phenotypic
features (Figure 95). The algorithm segments nuclei within set subpopulations on a
cell by cell basis. An individual nucleus may therefore only belong to a single region
of interest; such as a tumour gland or stroma, or an object of interest, such as a tumour
bud or vessel invading tumour cell (Figure 93B). This is performed to retain the
heterogeneity of nuclei across the tumour microenvironment and within certain
histological features. The multi-parametric single object and nucleus by nucleus data
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are exported from the TPA and subsequently collated through averaging or summing
the parameter data across the 15 images analysed per tissue section. This ensures a
single row of data per parameter for each patient sample (Figure 91B). A full list of
the 123 parameters exported from the image analysis algorithm and their collation
method can be found in appendix 13.
Figure 93. Examples of multi-parametric data export from the Tissue Phenomics Analyser. A) Left
panel shows a composite image of panCK:green & DAPI: blue. Right panel shows the algorithm mask
which classifies objects within the image. Multiple parameters are exported from each classified object
as is the percentage of each ROI within each image. B) Nuclei are subdivided dependent on the
hierarchical objects they belong to e.g. within tumour glands (green arrow), stroma (red arrow) or
tumour buds (blue arrow). Nuclear morphometric and intensity parameters are exported from within


























Figure 94. The quantification of spatial relationships of neighbouring objects. Left panel show
composite images of PanCK: green, DAPI: blue and D2-40: red. Right panels show corresponding
algorithm mask. Further multi-parametric data is exported from the spatial relationships of objects.
Colocalised and bordering objects are exported in a hierarchical manner. Top right panel: tumour bud
(white mask) which is also bordering to a vessel (pink mask). Bottom right panel: a vessel (yellow
mask) which is also bordering to a tumour gland (purple mask).
Figure 95. Examples of heterogeneous nuclear morphometry within three microenvironment
subpopulations: Stroma, tumour bud and tumour gland.
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1.2.2.2 Phenotypic fingerprint analysis
The resultant collated 123 parameters per patient sample make up the patient’s multi-
parametric phenotypic fingerprint. This raw data is difficult to utilise as a prognostic
tool due to its complexity and high dimensionality. To enable the visualisation of the
phenotypic fingerprint in a 2D scatter plot a PCA was performed. The data from the
first 2 principal components was exported as an x and y coordinate for each patient
sample (Figure 96). The 2 principal components capture and explain 72% variance in
the data set. Visualising the data by performing PCA allows us to evaluate the
effectiveness of the phenotypic fingerprint to stratify all patients within the cohort into
high or low risk of disease specific death as well as the Stage II subpopulation.
Figure 96. Visualisation of the phenotypic fingerprint through PCA. The data from a 2D principal
component analysis is plotted in a scatter plot for the full training cohort (A) and for the stage II
subpopulation (B). Patients who died specifically of CRC are plotted as triangles and patients who
survived follow up are plotted as circles. The phenotypic fingerprint allows the significant stratification
of good and poor prognosis patients.
Those patients who had a poor outcome, namely died of disease specific CRC during
follow up, cluster in the lower right section of the scatter plots while the majority of
those with a good outcome cluster within the top left section of the graph. In the Stage
II subpopulation there is only one outlier patient with good outcome which clusters in











the poor outcome section and no patients with poor outcome cluster with those with
good outcome. The clustering of the phenotypic fingerprint allows the robust patient
stratification across the whole cohort with 100% specificity, 76.7% sensitivity and an
area under the receiver operator curve (ROC) curve of 0.89. The sensitivity increased
to 92.85% when stratifying the stage II subpopulation (Table 14). The PCA based
clustering of the full exported parameter set is an excellent quality control checkpoint
within the Tissue Phenomics pipeline. It allows the user to ascertain if the data
captured allows meaningful patient clustering, with regards to his/her hypothesis,
before performing parameter reduction statistics.
Method
Method Comparison






Phenotypic fingerprint (PCA) 100% 76.7% 0.89 100% 92.85% 0.94
ALTB (CART) 96.3% 82.6% 0.90 100% 93.75% 0.96
Table 14. Comparison of full phenotypic fingerprint and ALTB patient stratification. ALTB reports
more accuracy in stage II patient stratification into good and poor prognosis categories than the full
phenotypic fingerprint. ALTB is also amenable to translation into the clinic due to being a single
parameter with an associated absolute cut-off calculated from continuous data.
1.2.2.2.1 Exclusion of fluorescence parameters
As with all immunofluorescence experiments there is a high likelihood of batch
variation when carrying out the experiment over multiple days. There are several
sources for the batch variation in fluorescence intensities and it can originate in
discrepancies in reagents (volume, shelf-life or exposure to light) or imaging
equipment (bulb and optics lifetimes). Although there are statistical methods to allow
for batch variation, the most robust method to ensure no variation in intensities is to
exclude all fluorescence intensity parameters from the phenotypic fingerprint. The
remaining shape, texture and spatial density measurements will remain a constant
across all batch processing. PCA was performed again after excluding all fluorescence
parameters from the training set’s phenotypic fingerprint. There was no change in the
results from the data and the clustering of each patient’s fingerprint was identical from
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when the full parameter set was utilised which allows the conclusion to be drawn that
fluorescence does not factor significantly in the PCA results (Figure 97).
Figure 97. Visualisation of the phenotypic fingerprint through PCA after exclusion of fluorescence
based parameters. The data from a 2D principal component analysis is plotted in a scatter plot for the
full training cohort and for the stage II subpopulation. Patients who died specifically of CRC are plotted
as triangles and patients who survived follow up are plotted as circles. The phenotypic fingerprint allows
the significant stratification of good and poor prognosis patients. There is no alteration in significance
of patient stratification upon the removal of fluorescence based parameters.
1.2.2.3 The identification of significant parameters through decision
tree models.
1.2.2.3.1 Random Forest parameter reduction
Although the multi-parametric phenotypic fingerprint allows the significant clustering
of good and poor outcome patient subgroups, there may be parameter redundancy
within the model and it is not possible to ascertain which of the parameters are most
significant from the PCA analysis. To allow the elimination of redundant parameters,
while retaining a robust stratification model, RF was performed (Figure 92D). The RF
analysis also ranks the parameters by associated Gini score which is based on variable











importance and the extent to which each variable contributes to optimal separation of
good and poor outcome patients.
The 123 parameters (listed in Appendix 13) utilised to create the prognostic phenotypic
fingerprint are the input for the RF analysis. The fluorescence parameters were
included to assess their significance in the model. After analysis the 123 parameters
were ranked by their associated Gini score and the least significant parameter was
removed from the phenotypic fingerprint. This process was performed iteratively until
the removal of a parameter affected the statistical significance of the model for the
worse. The method resulted in a set of 37 parameters (Appendix 13) which had the
ability to stratify the patients within the training cohort into high and low risk of CRC
disease specific death with the same statistical significance as the full parameter set
(100% specificity, 76.7% sensitivity, area under the ROC curve of 0.89). The top 20
parameters are listed in Table 15. Of these parameters 9 were involved in LVI, 7 were
involved in tumour budding and all 3 parameters involved in the relative area of tumor
ROIs (Necrosis/Lumen, Stroma, Tumour) within the images were present. No
fluorescence associated parameters were in the top 20 significant parameters and only
6 were present in the 37 most significant parameters while 5 of these were in the
bottom 7 parameters. This confirms that immunofluorescence parameters do not
feature highly when stratifying the patient cohort through decision tree modelling.
Table 15. Top 20 most significant parameters exported from Random Forest analysis. Blue circle:
parameters associated with tumour budding. Red circle: parameters associated with the lymphatic
vasculature. Green circle: parameters associated with percentage area of each ROI within an image.






















Random Forest analysis is a very robust method in which to perform parameter
reduction, as the model builds 5000 decision trees within the ‘forest’ and out of the
bag validation is performed across the model.
1.2.2.3.2 Identification of a novel histopathological feature through CART
modelling
The resultant 37 most significant parameters from the RF were used as input for
Classification And Regression Tree analysis (CART) to construct the decision tree
model. The CART decision tree reports optimal cut-offs and parameters which best
explain or stratify the data (Figure 92E).
In this study, only a single parameter was exported as the optimal terminal node.
Therefore one parameter alone can optimally and significantly stratify the patient
subpopulation into high and low risk of disease specific death. This parameter was the
“sum area of large tumour buds” (ALTB) across each tissue section (Figure 98) and is
measured in digital pixels (number of pixels within an object).
ALTB was also the most significant parameter reported from the Random Forest
model. This single parameter has the ability to robustly stratify patients from the
training cohort into good or poor outcome with a specificity of 96.3%, a sensitivity of
82.6% and an area under the ROC of 0.9. When analysing the Stage II subpopulation
the results become even more significant with a specificity of 100%, a sensitivity of
93.75% and an area under the ROC of 0.96 (Table 14). The CART model performs a
10 fold self-test validation on the data-set using the optimal cut-off reported from the
original data (self-test specificity 83.3%, sensitivity 75%, ROC 0.8).
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Figure 98. Examples of large tumour buds (LTB). The composite raw images (panCK: green, DAPI:
blue) of two examples of tissue containing large tumour buds at the invasive front of the cancer and the
associated algorithm mask. LTBs are classified with a blue object mask. The area of each LTB is
calculated in pixels for each object and summed across the 15 images taken per patient sample.
Composite image Composite image
Algorithm mask Algorithm mask
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The CART terminal node provides the optimal cut-off from the continuous data
captured within the parameter ALTB (Figure 99). For the parameters ALTB the
optimal cut-off was 161482 pixels.
Figure 99. CART terminal node and cut-off and Area under ROC for full training cohort. A) CART
terminal branch point and optimal cut-off. All patients represented in the full training cohort are
assigned to class 1 or 2 dependent on their ALTB cut-off (161482 pixels) (enclosed by top blue box).
Terminal node class 1 (left red box) contains patients with low ALTB (n= 27) of which 96.3%
experienced disease free survival. Terminal node class 2 (right red box) contains patients with high
ALTB (n= 23) of which 82.6% died specifically of CRC. B) Area under the receiver operator curve on
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Using the exported cut-off of 161482 pixels, it is possible to categorise patients into
groups of high and low risk of disease specific death which allows Kaplan-Meier
curves to be plotted to visualise the stratification and calculate the significance of the
outcome of patients over time. ALTB is a predictor of poor survival and shorter disease
specific survival times in both the training cohort (p<0.0001) and the Stage II
subpopulation (p<0.0001) (Figure 100). In the Stage II subpopulation no patients in
the below cut-off group die of CRC specific disease.
Figure 100. Kaplan-Meier curves for ALTB within the full training cohort and the stage II
subpopulation. Group 1 patients are below cut-off and Group 2 patients are above cut-off for ALTB
(161482 pixels). ALTB was highly significant in stratifying patients within the full training cohort and
the stage II subpopulation into high and low risk of disease specific death.
1.2.3 Validation of ALTB as a prognostic parameter
1.2.3.1 Stratification of validation set utilising the training set cut-off
The Tissue Phenomics pipeline reported a highly significant and novel
histopathological feature from the multi-parametric phenotypic fingerprint. In order to
validate the prognostic significance of ALTB, the training set cut-off of an area of
161482 pixels was applied to the validation cohort results for the parameter. The
patients were separated into categorical groups of either above or below the 161482
pixels ALTB and disease specific survival statistics were calculated.
Training cohort Stage II subpopulation



























FDR corrected P < 0.0001 FDR corrected P < 0.0001
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1.2.3.1.1 Cox-regression analysis
Univariate Cox-regression analysis was performed on the validation cohort results to
assess the hazard ratio and associated significance in survival prediction of ALTB. The
analysis reported the novel histopathological feature to be a significant predictor of
disease specific death (HR = 4; 95% CI, 1.5 – 11.1) (Table 16). The novel parameter
of the ALTB had a higher hazard ratio with more significance associated (p = 0.007)
than the literature based histopathological parameters of LVI (p = 0.05) and TB (p =
0.04).
Clinicopathological patient Univariate
Parameters number (n) HR 95% CI P value
lower upper
Area large tumour buds 4 1.5 11.1 0.007
High 65
Low 69
Table 16. Univariate Cox-regression for ALTB across the validation cohort utilising the CART exported
training cohort cut-off of 161482 pixels.
1.2.3.1.2 Kaplan-Meier survival analysis
Kaplan-Meier (KM) curves were plotted through TMA Navigator and patients in the
high cut-off group for ALTB had significantly shorter survival times than patients in
the low cut-off group (p = 0.0026) (Figure 101). Applying the training cohort cut-off
directly to the validation cohort showed that this parameter is more significant in KM
patient stratification than the two prognostic parameters of LVI (p = 0.05) and TB (p
= 0.04) which are both reported in the literature.
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Figure 101. Kaplan-Meier curves for ALTB across the validation cohort utilising the training set cut-
off of 161482 pixels. Group 1 patients are below cut-off and Group 2 patients are above cut-off for
ALTB. ALTB significantly stratified the validation cohort into high and low risk of disease specific
death.
1.2.3.2 Stratification of validation cohort utilising optimal cut-off for
ALTB
Plotting all possible cut-offs of the training cohort and their associated p values
reported a large range of highly significant (p = 0.001 or less) cut-offs within the
training cohort. The cut-off exported from the CART analysis, although being highly
significant for the training cohort, may not have been the optimal cut-off for
subsequent validation cohort. Similar to results in Chapters 3 and 4 the entire range of
validation cohort cut-offs and p values were plotted alongside those of the training
cohort to identify a cut-off which was highly significant for both. The mutually
significant cut-off for the stratification of patients based on ALTB was found to be
195806 pixels. By applying the new optimal cut-off to the validation cohort and
plotting the results as a KM curve there was only a slight increase in the stratification
of patients into high and low risk of disease specific death and the significance of
patient survival over time (training cohort cut-off; p = 0.002 and optimised cut-off; p
= 0.001) (Figure 102).
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Univariate cox-regression results for the optimal cut-off increased the prediction of
disease specific survival when applying the optimal cut-off compared to the training
cohort cut-off (HR = 5.6; 95% CI, 2 – 15.5 and HR = 4; 95% CI, 1.5 – 11.1
respectively) (Table 17). The increase in significance from the training cohort cut-off
to the optimal cut-off was less than when this methodology was applied to LVI or TB
parameters, suggesting that the training cohort cut-off calculated from CART analysis
was an extremely effective and significant one. Applying the optimal cut-off to the
novel parameter ALTB places it higher in significance in disease specific death
prediction compared to classical T stage (HR = 4.26; 95% CI, 1.76 – 10.33).
Figure 102. Assessment of optimal cut-offs within the training and validation cohorts for ALTB. A) p
values for all possible cut-offs within the training cohort and validation cohort were plotted on the same
graph. An optimal cut-off of 195806 pixels was selected which reported significant values for both
cohorts (red line). The green lines mark the area containing 80% of the training cohort. B) The optimal
cut-off of 195806 was utilised to plot Kaplan-Meier curves which significantly stratified the validation
cohort into high and low risk of disease specific death.
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parameters number (n) HR 95% CI P value
lower upper
Area large tumour buds 5.6 2 15.5 0.001
High 56
Low 78
Table 17. Univariate Cox-regression for ALTB utilising the optimal cut-off on the validation cohort.
1.3 Discussion
Morphometry is not a new science; nuclear morhpometry and tumour grade have been
shown to be prognostic not only in colorectal cancer(167, 304, 346) but renal(347),
ovarian(348) and bladder(349) cancer. Similarly, CRC tumour gland morphology and
phenotype have been utilised to subtype an individual’s cancer into clinical categories
such as signet cell, serrated adenoma and mucinous as well as the assessment of the
invasive edge’s morphology, whether infiltrating and containing tumour buds or a
pushing border(68). Recently there is growing evidence for the prognostic value of
quantifying the stromal morphometric and phenotypic cellular and histological make
up -- from quantifying vessel density(292), stromal cell types(350) and immune
infiltrate(49, 50) as well as their spatial distribution(339, 351). After taking all of the
above features into consideration, the resultant cancer tissue milieu is a complex mix
of multiple histopathological features and their interactions, some easy to quantify and
others not so. Although some of these histological features may be mentioned within
the colorectal pathology report(237, 241) they do not regularly factor in final
prognostic and treatment decisions(102). The reason for this is due to the difficulty in
manually quantifying even a handful of these features in a reproducible and robust
manner. In addition, assessing multiple serial sections, each stained specifically for a
host or tumour cell or phenotype, is a drain on both lab resource and analysis time.
In this study, digitised tumour tissue is segmented from the stroma through image
based machine learning which allows the automated measurement of multiple tumour
gland associated morphometric parameters. The tumour gland morphometric
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parameters were tested for significance by KM analysis across the 50-patient whole
slide imaging training cohort. The two morphometric parameters which were
significant for disease specific death were ‘Perimeter’ (M-S corrected p =0.04) and
‘Rel. border to stroma’ (M-S corrected p =0.004). These parameters are associated
with, and could reflect, an infiltrative invasion pattern as suggested by Jass(68) (2007).
Infiltrating extensions of tumour would increase the surface area, or perimeter, of the
tumour gland as well as the relative border of the gland to the stroma. The prognostic
relevance of stroma and tumour density percentages reflect results published in the
literature(343, 344). It would be expected that there was a higher percent of stroma in
images which contained a high volume of tumour buds compared to a high volume of
tumour glands and so could reflect an infiltrative invasive pattern. A factor to highlight
in all stroma percentage calculation is observer bias and variability with regard to
sample area. Mesker and Hujbers(343, 344) manually identify an area of high
infiltrative pattern at the invasive front in which to manually score tumour and stroma
percentages. Although our methodology endeavours to image the entire invasive
margin and quantify those with highest tumour budding, there is still scope for
variability of image collection. A higher percentage of lumen and dirty necrosis was
also significantly associated with better survival in the training set. Larger areas of
lumen could be representative of a well-differentiated tumour which correlates with
better survival(304) (Compton 1999) while a higher percentage of necrosis could
represent a tumour under attack by the host immune system or within an unfavourable
microenvironment; such as a hypoxic one.
The tissue phenomics approach adopted in this study employs an unbiased “measure
everything” approach to data capture. Each object within the tissue is segmented and
quantified with no a priori knowledge of which feature is prognostic. This is
performed in order to build up a phenotypic fingerprint of the invasive front of the
tumour for each patient. Data mining techniques are then employed to identify the
significant parameters captured and to calculate robust cut-offs for novel
histopathological features for patient stratification. Tissue phenomics may also add
further complexity to its multi-parametric data by the quantification of in situ
biomarkers although this was not undertaken in the present study. The novel
methodology presented in this study can be utilised in combination with any image
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analysis based segmented tissue to identify significant phenotypic parameters from the
exported big-data fingerprint. This study utilises immunofluorescence to aid tissue
segmentation, though various tissue markers coupled with image capture
methodologies may be employed to create a multi-parametric phenotypic fingerprint
amenable to the tissue phenomics pipeline showcased here.
For post capture and export of the multi-parametric phenotypic fingerprint one needs
to employ bioinformatics to mine the big-data. Data collation is the first step toward
biomarker discovery. Single cell and subcellular level segmentation creates a wealth
of data per tissue section. This data must be collated before the relevant bioinformatics
can be employed. Dependent on the parameter’s nature this study summed or averaged
each parameter to ensure a single row of data per patient. This approach is simplistic
and it can be argued that heterogeneity, such as stromal cell morphometrics, is lost,
however, in in vitro high content assays the mean of parameters has proven to be an
accurate method to analyse single cell data(148, 352). It is further possible to export
the multi-parametric intensity, texture and morphometric data alongside their ‘x, y’
coordinates within the image for each single segmented object. Although this would
create a complete heterogeneous map of each nucleus and subpopulation object it
would simultaneously create an extremely large and complex data set which would
need cutting-edge spatial and heterogeneity statistics to analyse. Researchers have
begun to map the spatial heterogeneity of the microenvironment(197) and employed
image analysis techniques from astronomy(353) to analyse protein expression in
TMAs, however the full potential to integrate astro-physics’ statistics to explain big-
data sets remains unexplored. Spatial density and patterns of the proximity and
interaction of objects could yield exciting results and create another layer of
complexity to the image-based big-data field. Additional cell type specific markers can
be introduced to segment the heterotypic milieu of the stromal microenvironment. The
combination of extra stromal or cancer markers coupled to spatial statistics could allow
the capture of the complexity of the tumour micoenvironment and the cellular
interactions between host and tumour thereby providing further data to input into a
systems pathology mode.
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Principal component analysis effectively clustered high and low risk CRC subgroups
based on their phenotypic fingerprint, and allowed the evaluation of the robustness of
the model through area under ROC calculations. PCA is, however, not amenable to
clinical translation and does not inform on which parameters are significant or which
are redundant in the model. Therefore each new patient would need to be analysed
against the growing historical cohort in order to evaluate to which cluster they match
the closest. To overcome this shortfall we employed decision tree ensemble models to
identify the significant parameters in the model.
Random Forest (RF) is performed to rank and reduce the parameters according to their
Gini score and significance in the model. Random Forest is extremely robust as it
performs 5000 decision trees within the forest and validates each tree with out of the
bag bootstrapping. RF is utilised to discard the non-significant parameters from the
model, however it is still not applicable to a clinical prognostic score as it does not
inform on cut-offs or combinations of parameters which yield the optimal output to
stratify patients into high and low risk. On the contrary CART produces a single
regression tree, and so is less robust than RF, however it provides optimal cut-offs for
each parameter at each decision point within the model and is therefore amenable to
the identification of a novel clinical histopathological marker. The CART model
becomes much more efficient if only significant parameters are used for input and
therefore the RF step is essential for the exclusion of non-significant parameters. In
this experiment a single parameter (ALTB) and thus a single CART decision point was
needed to optimally stratify the patient population. Future tissue phenomic
experiments could be made up of several decision points resulting in a combination of
parameters to optimally stratify patients on a predictive or prognostic query.
Large poorly differentiated cancer clusters disseminated from tumour glands are
generally ignored by the majority of tumour bud researchers who have historically
stated that tumour buds must be 1-5 cells in size(270). There is no obvious data within
the literature which evidences the significance of tumour budding having a cut-off of
1-5 cells in size. Ueno et al have, however, more recently analysed the prognostic
significance of larger undifferentiated tumour clusters >5 cells in size(90, 259, 269).
The majority of previous studies in TB have concentrated on their count(288, 313,
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354) and not the area of budding clusters, although Ueno has also proposed that the
area of poor differentiation may play a prognostic role(269, 355). This measurement
could be difficult to standardise and observer variability is bound to be great as it relies
on the observer’s judgement of the area containing the poorest differentiation within
the tumour section. Our methodology can accurately quantify the area of specifically
segmented objects through computer based analysis.
Ueno et al (269, 355) do not calculate the area of individual budding clusters but the
general area of poor differentiation and show it is an independent prognostic
parameter. They showed that poorly differentiated clusters, which they describe as
similar to the large tumour buds reported here, were more significant at stratifying
patients’ outcome than the tumour bud count. They attribute this fact to the easier
identification of larger islands of cells in H&E than TB which therefore results in a
lower observer variability and higher quantification rates. Interestingly their results
mirror those reported in this chapter in that the ALTB (HR = 5.6; 95% CI, 2-15.5) is a
more significant predictor of disease specific death in the stage II patient validation
cohort than tumour bud count (HR =4.5; 95% CI, 1.2-11.2). This result will need to be
verified through large and independent validation cohorts. Ueno et al’s findings may
not be due to the lower observation rate of buds but to the significance of
histolopathological feature itself.
A further advantage of automated image analysis is the capture of continuous feature
data from a field which historically relied on manual semi-quantitative categorical
clustering of histological features. Continuous data capture allows more accurate cut-
offs to be applied to novel histopathological features identified through tissue
phenomics as well as more robust quantification applied during validation testing due
to the lack of observer variability associated with categorical manual classifications.
This study has attempted to create a tissue phenomics pipeline which is amenable to
most research labs without the need for bespoke bioinformatics solutions for each
image based assay. Random Forest and CART can, for example, both be run in open
source software such as R (http://www.statmethods.net/advstats/cart.html) and the
multi-parametric input can be exported from any image analysis software such as open
source Image J (http://imagej.nih.gov/ij/) or Cell Profiler
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(http://www.cellprofiler.org/). Furthermore the methodology reported here is not
solely limited to image based morphometrics but is amenable to a systems pathology
and integrated pathology approach(191, 356, 357). Multi-modal omics data may be
added to the multi-parametric patient fingerprint in order to identify novel prognostic
or predictive signatures.
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Chapter 6: Integrative pathology
1.4 Introduction
Novel image based quantification techniques will more than likely not replace classical
pathology, at least in the near future, but rather add to the value which is already
present within the established clinical guidelines or along with biomarkers reported in
the literature. Combining omics based data with classical pathology, into a modern
pathology toolbox, could create more significant multi-parametric prognostic or
predictive signatures. The integrative signature theory is that this methodology should
be capable of more accurate and significant patient stratification than single parameters
or the gold standard TNM staging. Patient stratification can take the form of high and
low risk of disease specific death or inform the oncologist on personalised medical
regimens.
Medical research is already beginning to embrace big-data science especially in the
form of genomics, transcriptomics and proteomics(189, 190, 358, 359). A novel gene
expression signature for a rectal cancer recurrence score, for example, was developed
by integrating a 12 gene model to predict recurrence and disease specific
survival(360). The big-data disciplines are also being integrated(361) and being input
into systems medicine models(362, 363). There is less literature integrating disparate
omics or emerging histopathological data strands along with the original classical core
clinical pathology data items; although the value of clinical and omics integration is
beginning to be recognised(364, 365). Foulis’ group recently implemented a more
classical pathology integrative approach to stratify high and low risk CRC patients.
They integrated the manual quantification of BVI through elastic staining with T stage
and found a small increase in prognostic power for early stage CRC patients than TNM
staging alone(280). Similarly Japanese researchers of PDC have also integrated this
novel grading system with a desmoplastic reaction score from manually semi-
quantified classically H&E stained CRC tissue sections(27).
Although the general consensus of systems pathology is that it must include dynamic
computational modelling, another definition states that integrative systems pathology
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is the inclusion of data from multiple strands: proteomic, transcriptomic, genomic,
epigenetic and tissue phenomic, into a mathematical model which selects those
parameters, which when combined, infer optimal information to the pathologist or
oncologist about the treatment or prognosis of individual patients. This definition
(which still allows for the inclusion of dynamic modelling) of systems pathology was
set out by Saidi et al(366);
Systems Pathology seeks to integrate all levels of functional
and morphological information into a coherent model that
enables the understanding of perturbed physiological systems
and complex pathologies in their entirety.
Although this allows for a more simplistic view of systems pathology it has the
potential to include robust and clinically transferable methods of analysing data from
multiple streams of tissue datafication.
This integrative pathology method is demonstrated in this chapter by combining novel
histopathological features, discovered within this study through tissue phenomics and
image analysis, with parameters exported from the original clinical pathology reports
into a prognostic integrative model. The model informs on which individual
parameters, when combined, add value to the significance of the prediction of disease
specific death in the stage II CRC patient validation cohort. These parameters are then
included in a novel prognostic signature and its significance is tested across the stage
II validation set.
This study will test two approaches in selecting the optimal individual image-based
and core clinical data-set parameters for incorporation into the integrative model. The
integrative model will be tested on the validation set (n=134) due to its clinical
relevance consisting of sequential stage II CRC patients collected across 2 full years.
The first method will incorporate the main image-based parameters which were
significant in the validation cohort and which were reported in each of the previous
chapters: Occult LVI, TB and ALTB.
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The second method will select the top three most significant parameters reported from
the Random Forest model which were ranked according to their Gini score. These
three parameters are: ‘ALTB’, ‘Area of LVI’ and ‘Area of occult LVI.
1.5 Results.
A summary of all the individual parameters, and their corresponding hazard ratios, to
be investigated in this chapter are listed in Table 18 A & B.
Clinicopathological Univariate Training set cut-off Univariate Optimal cut-off
parameters HR 95% CI P value HR 95% CI P value
lower upper lower upper
Area large tumour buds*§ 4 1.5 11.1 0.007 5.6 2 15.5 0.001
Tumour Budding* 2.49 1.03 5.99 0.04 4.5 1.8 11.2 0.002
Occult LVI* 2.46 1 6.05 0.05 2.9 1.2 7.1 0.02
Area LVI§ 1.8 0.74 4.41 0.2 2.15 0.9 5.2 0.08
Area Occult LVI§ 1.4 0.45 4.09 0.57 2.48 1.03 5.99 0.04
Parameters utilised in method one annotated with *
Parameters utilised in method two annotated with §
Table 18 A. Significant image-based parameters.
Clinicopathological Univariate
parameters HR 95% CI P value
lower upper
pT 4.26 1.76 10.33 0.001
Differentiation 2.17 1.14 4.13 0.02
Table 18 B. Significant clinical pathology report parameters.
1.5.1 Method 1: Integrating TB, Occult LVI, ALTB, T stage and
Differentiation
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This method incorporated the significant parameters quantified from Chapter 3 (TB),
Chapter 4 (Occult LVI) and Chapter 5 (ALTB) with the two significant parameters
located within the clinical pathology report (pT stage and Differentiation).
To identify which parameters add value to the prediction of disease specific death they
were added into a forward step-wise conditional Cox-regression model. This
calculation adds, in a step-wise fashion, parameters which add significance to the
model and discards those parameters which do not. The model was executed across
the validation cohort for both the training set cut-offs and the optimal cut-offs for each
image-based parameter. The significant and non-significant parameters within the
model were the same when using the training set cut-offs and for the optimal cut-offs,
although significance was improved upon in the latter. The three parameters which
added significance to the model of CRC specific death in the stage II clinical validation
cohort were: ALTB (training set cut-off p = 0.03, optimal cut-off p = 0.004), pT stage
(training set cut-off p = 0.03, optimal cut-off p = 0.04), and differentiation (training-
set cut-off p = 0.05, optimal cut-off p = 0.04), (Table 19). The parameters of TB
(training set cut-off p = 0.84, optimal cut-off p =0.4), and Occult LVI (training set cut-
off p = 0.85 optimal cut-off p =0.9), were discarded as they did not add significance to
the final predictive model (Table 19).
Training set cut-off Optimal cut-off
Variables in the equation HR 95% CI P value HR 95% CI P value
lower upper lower upper
ALTB 3.3 1.1 9.5 0.03 4.7 1.6 13.6 0.004
pT stage 2.8 1.1 7.3 0.03 2.7 1.1 6.9 0.04
Differentiation 2.2 1 4.9 0.05 2.3 1 5 0.04
Variables not in the equation
TB 0.84 0.4
Occult LVI 0.85 0.9
Table 19.Forward cox-regression results for method 1. Parameters which do or do not add significant
value to the integrative prognostic signature in method 1 are listed. Parameters were reported by
executing forward step-wise Cox-regression on the validation cohort after categorising the patients by
applying the training cohort or optimal cut-offs.
1.5.2 Method 2: Integrating ALTB, Area LVI, Area Occult LVI,
T stage and Differentiation
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The input parameters for the integrative forward conditional Cox regression model in
method 2 were selected from the top 3 significant parameters reported from the RF
result in Chapter 5 (ALTB, Area Occult LVI and Area LVI) alongside the significant
parameters from the clinical core data-set (pT stage and Differentiation).
As in method 1, the model was executed across the data from the validation set after
applying the training set cut-off and the optimal cut-off. Method 2 reported the same
three significant parameters which added value to the prediction of disease specific
death as in Method 1: ALTB (training set cut-off p = 0.03, optimal cut-off p = 0.004),
pT stage (training set cut-off p = 0.03, optimal cut-off p =0.04), and Differentiation
(training set cut-off p = 0.05, optimal cut-off p = 0.04), while Area of occult LVI
(training set cut-off p = 0.6, optimal cut-off p =0.75) and Area LVI (training set cut-
off p = 0.73, optimal cut-off p =0.88) added no significant value (Table 20).
Training set cut-off Optimal cut-off
Variables in the equation HR 95% CI P value HR 95% CI P value
lower upper lower upper
ALTB 3.3 1.1 9.5 0.03 4.7 1.6 13.6 0.004
pT stage 2.8 1.1 7.3 0.03 2.7 1.1 6.9 0.04
Differentiation 2.2 1 4.9 0.05 2.3 1 5 0.04
Variables not in the equation
Area Occult LVI 0.6 0.75
Occult LVI 0.73 0.88
Table 20. Forward Cox-regression results for method 2. Parameters which do or do not add significant
value to the integrative prognostic signature in method 2 are listed. Parameters were reported by
executing forward step-wise Cox-regression on the validation cohort after categorising the patients by
applying the training cohort or optimal cut-offs.
1.5.3 Creation of an Integrative Pathology Signature
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The three significant parameters within the forward conditional model were compiled
into a final novel integrative prognostic signature (IPS). Patients with an above cut-off
score in two or more of the three significant parameters within the IPS were classified
as a “high-risk” group and the remainder of the patients were classified with a “low-
risk” score. The IPS was the only significant parameter to predict disease specific death
(training cut-off HR = 7.5; 95% CI, 3 – 18.5, p = 0.00001, optimal cut-off HR = 7.8;
95% CI, 3.2 – 19.2, p = 0.00001) when it is entered into a multivariate forward
conditional Cox regression model along with its composite parts (Table 21). The
composite parameters added no individual significance to the regression model in their
own right: ALTB (training set cut-off p = 0.21, optimal cut-off p =0.26), pT stage
(training set cut-off p = 0.49, optimal cut-off p =0.66) and differentiation (training set
cut-off p = 0.62, optimal cut-off p =0.72). The IPS prognostic prediction of CRC
specific death is an improvement on classical TNM staging (HR = 4.26; 95% CI, 1.76
– 10.33, p = 0.001) within this stage II CRC patient cohort.
Training cut-off Optimal cut-off
Variables in the equation HR 95% CI P value HR 95% CI P value
lower upper lower upper
IPS 7.5 3 18.5 0.00001 7.8 3.2 19.2 0.000008
Variables not in the equation
ALTB 0.2 0.3
pT stage 0.5 0.9
Differentiation 0.6 0.4
Table 21.Forward cox-regression results upon inputting the IPS and its composite parameters into the
model. Parameters were reported by executing forward step-wise Cox-regression on the validation
cohort after categorising the patients by applying the training cohort or optimal cut-offs.
Kaplan-Meier curves were plotted to assess the significance of the IPS in patient
survival over time (Figure 103). The IPS significantly stratifies stage II CRC patients
with a high risk of CRC specific death over an 11.5 year follow up. An IPS which
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consisted of either the parameters with the training set cut-off (Figure 103 A) or
optimal cut-off (Figure 103 B) were tested and both the final results had a high
significance in patient stratification (p < 0.00001).
Figure 103 A) Kaplan-Meier survival curve for IPS with parameters categorised by the training set cut-
offs (green: below cut-off, orange: above cut-off. The IPS was highly significant in stratifying the stage
II CRC validation cohort into high and low risk of disease specific death.















Training set cut-off Integrative prognostic signature (n=134)
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Figure 103 B) Kaplan-Meier survival curve for IPS with parameters categorised by the optimal cut-offs.
The IPS was highly significant in stratifying the stage II CRC validation cohort into high and low risk
of disease specific death.
1.6 Discussion
Pathology is now adept at creating large and complex data sources from across the
omics fields and more recently including histopathology morphometrics and spatial
heterogeneity(186, 191, 197). The challenge ahead is how to incorporate this
integrated data into models which can identify the optimal combinations of parameters
to answer clinical questions in a robust manner(367). TNM staging of CRC has long
been the gold-standard to predict disease progression and stratify high risk sub-groups.
Although many biomarkers and histopathological features have been reported in the
literature none have improved upon classical pathology and replaced TNM staging or
the core clinical data-set(102). Therefore it would seem pertinent to include the
pathological reporting which already exists into novel integrative models. In this
chapter the significant parameters from the original pathology report were added
alongside the significant parameters quantified through image analysis from previous
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chapters into a step-wise regressional model. Two separate methods were tested to
identify which image based parameters added value to the prediction of disease
specific death. Both models reported the same significant parameters: ALTB,
differentiation and pT stage. The three significant parameters were then integrated to
form a novel prognostic signature which reported the highest hazard ratio and
significance (HR = 7.8; 95% CI, 3.2 – 19.2, p = 0.00001) compared to its composite
parts and improved upon classical TNM staging (HR = 4.26; 95% CI, 1.76 – 10.33, p
= 0.001).
Although the parameters of the percent of stroma and percent of tumour per image
were highly significant in the training cohort and validation cohort (Table 13) they
were not in the top 3 RF parameters and therefore not included in the selection of
parameters to integrate. Further investigation may be beneficial in identifying the
optimal model to identify which parameters are used as input for the regression
analysis. There is some question on the reproducibility of the percent ROI in each
image due to manual selection of the invasive front, as discussed in Chapter 5. This
manual selection is open to observer variability and bias. Some impartiality is included
in image selection as it was endeavoured to image the entire invasive front and only
select the images with highest tumour budding for further analysis. It would be
prudent, therefore, to exclude these parameters from any integrative model until an
automated method of identifying the invasive front through image analysis can be
programmed and thereby standardising the sample area.
Differentiation has been shown to be an independent variable in multiple studies(254)
however it also shows a high degree of observer variability(368). Furthermore some
studies show it to be non-significant(369). High observer variability and non-
standardised reporting may result in a higher proportion of moderate differentiation
being input to the patient database as extremely low and high grade cancers are easier
to classify. To overcome this, a two-tiered grading system is proposed by CAP which
involves either low grade or high grade(370). In the validation cohort of this study
81.4% of patients had moderately differentiated cancer whereas only 16.4% had poor
and 2.2% well differentiated cancer. This small percentage of cancers at either
spectrum of the grading system will account for the inclusion of differentiation as an
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independently significant parameter. Implementing the two tiered system proposed by
The College of American Pathologists (CAP) may improve on this parameter’s
prognostic significance.
TB and LVI have been shown to be significant predictors of disease specific death in
univariate analysis, however, they both fall out of significance and add no extra
prognostic value when the model is altered for pT stage, differentiation and ALTB.
The novel parameter of ALTB therefore holds the highest prognostic significance of
all image segmented objects at the invasive front and this is reflected by the output of
both the Random Forest and CART decision tree models within chapter 5.
The integrative prognostic signature reported here includes information on the depth
of local invasion (pT stage), the morphometry and architecture of gland formation and
the invasive pattern at the tumour-stroma interface. These parameters describe the
cancer’s aggressiveness within the primary neoplastic site as well as giving insight into
the dynamic nature of its progression. Integration of molecular profiles of the invasive
subpopulations at the invasive front, such as the large tumour buds, could add to the
knowledge of an individual cancer’s invasive mechanism and lead to drug targets at
the personalised level. The future of pathology and its holistic and integrative nature
should move prognosis and prediction away from population statistics and towards P4
medicine(207).
This study adds proof to the theory that combining novel pathological parameters with
classical pathology returns more significant results than either the single novel
parameter or classical parameter individually, although this methodology must be
further validated in large inter-institutional cohorts.
220
Chapter 7: Conclusion
Translational research must always start with a clinical question. The clinical question
in this thesis is how to sub-stratify stage II CRC patients. Although TNM classification
is the gold standard of CRC prognosis, it is not able to successfully stratify stage II
patients into high and low risk of disease recurrence and disease specific death(102,
235). On average ~30% of Stage II CRC patients experience poor outcome and there
is therefore a clinical need to be able to identify these patients(243, 244, 295). Whether
chemotherapy will significantly increase disease free survival is yet to be
determined(242, 247, 295). The hypothesis of this thesis is that stage II CRC patients
can be stratified into high and low risk of disease specific death through automated
image analysis.
Although there is increasing evidence of lymphatic vessel invasion and tumour
budding being significantly associated with lymph node metastasis and disease
specific death, they have not been included in core clinical guidelines, due to a lack of
standardisation and poor reproducibility(20, 102, 238, 250, 257, 258, 270, 284). These
rare and sometimes obscure events are difficult to observe in classical H&E stained
tissue sections. Utilising specific antibodies through immunofluorescence coupled
with automated image analysis allows the standardisation of quantification of these
histopathological features. Upon applying this methodology to a training and
validation set of CRC patients, the stage II patients could be significantly stratified on
risk of death from CRC. Image analysis does not only segment histopathological
features for quantification, but allows us to profile molecularly these heterogeneous
subpopulations, such as tumour glands at the centre of a tumour and tumour buds at
the invasive edge. In doing so tumour buds in some patients were found to lose certain
epithelial markers such as E-Cadherin, decrease their proliferation index and show an
increase in the mesenchymal protein Vimentin.
The invasive edge of CRC holds a wealth of prognostic information within, amongst
other features, the tumour’s invasive pattern(90, 91, 265) and the vasculature(250, 258,
262, 276, 279, 368). Although pathologists are good at identifying histopathological
patterns between patients, it is a difficult task to accurately quantify each feature within
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the invasive front without the use of automated image analysis. Image analysis was
employed to identify the most significant of these parameters, for stage II prognosis,
from this complex and heterogeneous interface. All objects within
immunofluorescence images of the invasive front were segmented and multiple
morphometric and texture parameters extracted for each. These parameters built up a
hierarchical phenotypic fingerprint for each patient sample. The phenotypic fingerprint
was mined through ensemble decision tree models to identify which parameters best
predicted disease specific death. It was discovered that a single parameter was optimal
at stratifying the stage II CRC patient population. This parameter was the sum area of
the large tumour buds (ALTB) across 15 images captured at the invasive front of the
CRC tissue section. Image analysis, in the form of tissue phenomics, not only
identified this novel feature but allows its robust and standardised quantification in
future validation studies. This standardised quantification also makes the methodology
highly transferable to clinical practice.
As previously mentioned, TNM staging is utilised for the prognosis of CRC and has
stood the test of time since no other biomarker has yet to replace it. Therefore image
analysis and modern pathological data extraction techniques should aim to augment
this classical staging rather than replace it. The only two parameters significantly
associated with disease specific death from the original clinical report were
differentiation and pT stage. Integrating the novel parameter ALTB with these two
classical parameters was found to be the most significant prognostic signature captured
across all parameters quantified within this thesis. This signature therefore reports on
the depth of local invasion (pT stage), the morphometry and architecture of gland
formation and the invasive pattern at the tumour-stroma interface. Implementing this
signature allowed the significant prediction of disease specific death for a clinically
relevant stage II CRC patient cohort (n=134).
In conclusion image analysis can standardise the quantification of histopathological
features and probe their molecular profile. Novel image analysis methodology can also
discover novel prognostic features and integrate these to augment classical clinical
pathology.
Potential impact of Thesis:
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The IPS improved upon current clinical staging by almost 1.5 fold. Large international
validation cohorts must be applied to ensure that this result is reproducible. A major
advantage of image analysis is the objective quantification of histopathological
features which negates observer variability. Observer variability and poor
reproducibility is a major roadblock in the translation of candidate prognostic features
into the clinic. Once further validated the IPS is highly translatable to the clinic upon
where high risk Stage II CRC patients may be identified more accurately than current
practice. This would impact patient care as high risk Stage II patients would be
assigned more detailed follow up and intervention in an attempt to extend their disease
free survival and possibly prevent disease specific death.
Implementation to the clinic:
In order to implement the IPS into routine clinical practice it must, as previously stated,
be further validated. Digital pathology is becoming common place in laboratory
medicine although image analysis has been slower in its adoption. Studies such as this
are needed to validate image analysis for clinical practice and will overcome the
scepticism of the technology which currently exists. Once a digital pathology IT
infrastructure is in place it would be a simple alteration to bolt on image analysis
processing workstations to automatically quantify the ALTB in a standardised fashion.
The full Tissue Phenomics pipeline would be difficult to implement but it is in fact not
needed in a clinical setting. The research aspect of this study, and for other future
studies, would identify the most significant parameters and their optimal cut-offs to
answer the clinical question. Once these are identified only a far more simplistic assay
and image analysis solution would be required. In this case an image analysis
algorithm would only need to report a single parameter: ALTB. This end result is
readily transferable to the clinic and would require little training once the
immunofluorescence kit and algorithm was rolled out as a fully automated packaged.
The first two aims and objectives of the thesis were successfully mapped to the results
by the development of image analysis algorithms which:
1. Quantified the histopathological features of tumour budding, lymphatic
vasculature invasion and density in a standardised manner and the result of
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which allowed the significant stratification of high risk of disease specific
death Stage II CRC patients.
2. Automatically segmented and exported a multi-parametric image-based data
set captured in an unbiased manner and which formed part of a pipeline which
employed decision tree models to identify the most significant parameter to
stratify high risk of disease specific death Stage II CRC patients. Once
identified this novel parameter (ALTB) was able to significantly categorise a
validation cohort of 134 Stage II CRC patients into high and low risk of disease
specific death.
The final aim and objective was completed by identifying the significant parameters
in the clinical pathology report of the validation cohort patients through univariate
Cox-regression. The significant clinical and image-based parameters were entered into
a forward step-wise Cox-regression model to identify which added value to a novel
Integrative Pathology Signature (IPS). The IPS improved upon conventional clinical
staging and was more significant at identifying high risk of disease specific death Stage
II CRC patients.
Future work:
1. Validate the integrative prognostic signature in large international cohorts.
2. Profile the immune response at the invasive front through image analysis.
Calculate the spatial heterogeneity of the heterotypic immune cells with
tumour histopathological features and the cancer microenvironment.
3. Incorporate multi-omics data to the hierarchical clinical and phenotypic
signature so as to capture a holistic and complex data-set for CRC prognosis
and drug prediction enabling a systems pathology approach to be applied
(Figure 104). In doing so the field of pathology could move from population
statistics toward clinical decision making at the truly personalised level.
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Figure 104 – Multi-omics integration into a systems pathology model.
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Chapter 9: Appendices
Appendix A. Royal College of Pathologists (RCPath) clinical data items
RCPath Core data items:
Macroscopic core data items:
 Site of tumour.
 Maximum tumour diameter.
 Distance to the nearer longitudinal resection margin.
 Tumour perforation.
 Relation of the tumour to the peritoneal reflection (rectal tumours only).
 Grade of the plane(s) of surgical excision (AR and APE specimens).
 Distance of the tumour from the dentate line (for APE specimens only).
Microscopic core data items:
 Histological tumour type.
 Histological differentiation.
 Maximum extent of local invasion (pT stage) and maximum distance of
extramural
 spread.
 Grade of tumour regression following pre-operative (neoadjuvant) therapy.
 Resection margins (longitudinal and circumferential margins).
 Lymph node status (number present, number involved, highest lymph node
status).
 Venous invasion.
 Histologically confirmed distant metastatic disease.
RCPath non-core data items:
 Nature of advancing margin (infiltrative versus expansive).
 Tumour budding.
 Lymphatic invasion.
 Extramural tumour nodules less than 3 mm in diameter.
 Perineural infiltration
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Appendix 1 Brightfield vessel detect algorithm settings
series_name Parameter Value
Setting 1 Action General Settings
Setting 2 Magnification 20
Setting 3 µm/pixel 0.43
Setting 4 Stain Combination IHC Brown chromogen (e.g. DAB)
Setting 5 IHC Marker Cytoplasm
Setting 6 ROI Subset Export TRUE
Setting 7 Stitch Tiles FALSE
Setting 8 Analyze % of tissue 100
Setting 9 Action Manual ROI Selection (Select Segments)
Setting 10 Resolution (x) 0.88
Setting 20 Magnification 10
Setting 30 Action Vessel Detection
Setting 31 IHC Threshold 0.14
Setting 32 Gap to close (µm) 4
Setting 37 Action Vessel Classification
Setting 38 IHC Threshold 0.14
Setting 39 Select Feature Area (µm²)
Setting 40 Threshold Small/Medium 100
Setting 41 Threshold Medium/Large 300
Setting 53 Action Custom Export
Setting 54 Class Vessel
Setting 55 Per Single Objects FALSE
Setting 56 Per Single Objects FALSE
Setting 57 Standard Deviaion TRUE
Setting 58 Minimum FALSE
Setting 59 Maximum FALSE
Setting 60 Sum FALSE
Setting 61 Number TRUE
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Vessel with lumen density (1/mm²)
# Vessel
# Vessel with Lumen
Average vessel size (µm²)
Average vessel with lumen size
(µm²)







% Vessel with Lumen Small
% Vessel with Lumen Medium
% Vessel with Lumen Large
# Vessel with Lumen Small
# Vessel with Lumen Medium
# Vessel with Lumen Large





Stain Combination IHC Brown chromogen (e.g. DAB)
IHC Marker Cytoplasm
ROI Subset Export TRUE
Stitch Tiles FALSE
Analyze % of tissue 100
Action Manual ROI Selection (Select




Action Initialize Cellular Analysis
Analyze ROI 1 TRUE
Analyze ROI 2 FALSE
Analyze ROI 3 FALSE
Analyze ROI 4 FALSE
Analyze ROI 5 FALSE
Analyze ROI 6 FALSE
Analyze ROI 7 FALSE




Typical Nucleus Size (µm²) 55
Action Nucleus Morphology and Filter
Use Exclusion TRUE
Condition 1 Length/Width >= 3
Condition 2 Hematoxylin Intensity <= 0.0001
Condition 2 Area < 50
Remove Excluded Nuclei TRUE
Action Vessel Detection
IHC Threshold 0.14
Gap to close (µm) 8
Action Nucleus Classification
Select Feature Area (µm²)
Threshold Small/Medium (µm²) 60
Threshold Medium/Large (µm²) 110
Action Vessel Classification
IHC Threshold 0.14




Condition 1 Hematoxylin Intensity >= 0.2
Condition 2 Circularity < 0.1
Remove excluded vessels FALSE
Action Default Export
ROI: Screenshot 1 Overlay
ROI: Screenshot 2 Overlay with Outlines
ROI Statistics TRUE
Cellular Analysis: Screenshot 1 Original
Cellular Analysis: Screenshot 2 Overlay with Outlines
Cellular Analysis Statistics TRUE




Per Single Objects FALSE




























Use Layers CK, D240, DAPI,




Condition 1 Area < 5000
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Condition 1 Mean Layer 1 >= 7.7
Condition 2 Roundness <= 1
Interrupt on Server FALSE
Appendix 5. IF Vessel Detect algorithm settings
Parameter Value
Action Initialize Cellular Analysis
Analyze Tumour TRUE
Analyze ROI 2 FALSE
Analyze Necrosis FALSE
Analyze ROI 4 FALSE
Analyze Stroma TRUE
Analyze ROI 6 FALSE
Analyze ROI 7 FALSE






Typical Nucleus Size (µm²) 47
Export a Screenshot TRUE
Action Nucleus Morphology and Filter
Use Exclusion TRUE
Condition 1 Mean PanCK < 50
Condition 2 Area < 5




Gap to close (µm) 4
Export a Screenshot TRUE
Action Nucleus Classification





Export a Screenshot FALSE
Action Vessel Classification
Select Feature Area (µm²)
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Export a Screenshot TRUE
ROI Statistics TRUE
Cellular Analysis Statistics TRUE
Action Custom Export
Class Nucleus Positive
Per Single Objects TRUE






Appendix 6. IF Marker Area algorithm settings
Action Initialize Cellular Analysis
Analyze ROI 1 FALSE
Analyze ROI 2 FALSE
Analyze ROI 3 FALSE
Analyze ROI 4 FALSE
Analyze Stroma TRUE
Analyze ROI 6 FALSE
Analyze ROI 7 FALSE
Analyze ROI 8 FALSE
Magnification 20






Minimum Area (µm²) 11
Export a Screenshot FALSE
Action Default Export
Export a Screenshot TRUE
ROI Statistics TRUE
Cellular Analysis Statistics TRUE




Per Single Objects TRUE







Class Markers 1 and 2
Per Single Objects TRUE



























Use Layers CK, D240, DAPI,
Action Composer: Create Region
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Select Class Tumour
Select Distance (µm) 2
Simple Region Grow TRUE




Condition 1 Area < 5000
Action Composer: Reclassify Region
Source Class no tissue
Target Class stroma
Use Condition TRUE
Condition 1 Circularity > 0.7
Condition 2
Rel. Border to Image Border
= 0
Interrupt on Server FALSE











Action Tissue - Background Separation
Use Autothresholds TRUE








Condition 1 Area < 5000
Action ROI Correction
Interrupt on Server FALSE
Store ROI classification FALSE
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Action Initialize Cellular Analysis
Analyze ROI 1 FALSE
Analyze ROI 2 FALSE
Analyze ROI 3 FALSE
Analyze Lumen TRUE
Analyze ROI 5 FALSE
Analyze Stroma TRUE
Analyze Tumour TRUE




Typical Nucleus Size (µm²) 56.65982157
Action Marker Area Detection
Threshold Marker 0.76
Minimum Area (µm²) 8
Action Marker Area Classification




Remove Excluded Areas FALSE
Action Default Export
ROI: Screenshot 1 Original
ROI: Screenshot 2 Overlay with Outlines
ROI Statistics TRUE
Cellular Analysis: Screenshot 1 Original
Cellular Analysis: Screenshot 2 Overlay with Outlines
Cellular Analysis Statistics TRUE
Appendix 9. IHA algorithm settings (Developer LVI, LVD & TB)
optimisation of tumour bud and LVI
reset
delete map: on tumour bud map : delete map
delete map: on vessel map : delete map
delete map: on copy of main : delete map
delete map: on LVI colocalisation map : delete map
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delete map: on ROI and bud map : delete map
copy map: copy map to 'tumour bud map'
copy map: copy map to 'vessel map'
remove all objects but marker one on tumour bud
on tumour bud map
delete image object level: delete 'NucleusLevel'
remove objects: loop: Marker 2 at MarkerLevel: remove objects into
unclassified (merge by shape)
assign class: Markers 1 and 2 at MarkerLevel: Marker 1
merge region: Marker 1 at MarkerLevel: merge region
assign class: Marker 2 at MarkerLevel: unclassified
convert image objects: at MarkerLevel: convert image objects ->
Connected 2D
merge region: unclassified at MarkerLevel: merge region
assign class: Marker 1 with Existence of super objects Tumour (1) = 1 at
MarkerLevel: marker 1 in tumour
assign class: Marker 1 with Existence of super objects necrosis (1) = 1 at
MarkerLevel: marker 1 in tumour
assign class: Marker 1 with Existence of super objects no tissue (1) = 1
at MarkerLevel: marker 1 in no tissue
copy image object level: at TissueLevel: copy creating
'CopyofTissueLevel' above
assign class: with Classified as no tissue = 0 at CopyofTissueLevel:
_TempClass1
convert image objects: at CopyofTissueLevel: convert image objects ->
Connected 2D
merge region: _TempClass1, Tumour at CopyofTissueLevel: merge
region
distance map: at CopyofTissueLevel: distance to no tissue(distance map)
delete image object level: delete 'CopyofTissueLevel'
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convert to sub-objects: at TissueLevel: convert to sub-objects
assign class: with Existence of sub objects Marker 1 (1) = 1 at
TissueLevel: Marker 1
convert image objects: at TissueLevel: convert image objects ->
Disconnected (fusion up)
convert image objects: at TissueLevel: convert image objects ->
Connected 2D
update variable: Marker 1 at TissueLevel: distance to no tissue = Mean
distance map
assign class: Marker 1 with distance to no tissue <= 50 at TissueLevel:
edge effect
assign class: Marker 1 with Area <= 55 µm² at TissueLevel: necrotic
debris
remove all objects but marker two on vessel map
on vessel map
delete image object level: delete 'NucleusLevel'
remove objects: loop: Marker 1 at MarkerLevel: remove objects into
unclassified (merge by shape)
assign class: Markers 1 and 2 at MarkerLevel: Marker 2
pixel-based object resizing: loop: on vessel map Marker 2 at
MarkerLevel: grow into unclassified where D240>=40
find enclosed by class: on vessel map at MarkerLevel: enclosed by
Marker 2: Marker 2 +
merge region: on vessel map Marker 2 at MarkerLevel: merge region
assign class: Marker 1 at MarkerLevel: unclassified
convert image objects: at MarkerLevel: convert image objects ->
Connected 2D
merge region: unclassified at MarkerLevel: merge region
assign class: Marker 2 with Existence of super objects Tumour (1) = 1 at
MarkerLevel: marker 2 in tumour
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assign class: Marker 2 with Existence of super objects necrosis (1) = 1 at
MarkerLevel: marker 2 in tumour
assign class: Marker 2 with Existence of super objects no tissue (1) = 1
at MarkerLevel: marker 2 in no tissue
copy image object level: at TissueLevel: copy creating
'CopyofTissueLevel' above
assign class: with Classified as no tissue = 0 at CopyofTissueLevel:
_TempClass2
convert image objects: at CopyofTissueLevel: convert image objects ->
Connected 2D
merge region: _TempClass2, Tumour at CopyofTissueLevel: merge
region
distance map: at CopyofTissueLevel: distance to no tissue(distance map)
delete image object level: delete 'CopyofTissueLevel'
convert to sub-objects: at TissueLevel: convert to sub-objects
assign class: with Existence of sub objects Marker 2 (1) = 1 at
TissueLevel: Marker 2
convert image objects: at TissueLevel: convert image objects ->
Disconnected (fusion up)
convert image objects: at TissueLevel: convert image objects ->
Connected 2D
update variable: Marker 2 at TissueLevel: distance to no tissue = Mean
distance map
assign class: Marker 2 with distance to no tissue <= 50 at TissueLevel:
edge effect
assign class: on vessel map Marker 2 at TissueLevel: D240
evaluate tumour buds
fill holes in buds and evaluate nuclei in buds
pixel-based object resizing: on tumour bud map Marker 1 at
TissueLevel: grow into Stroma
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find enclosed by class: on tumour bud map at TissueLevel: enclosed by
Marker 1: _TempClass1 +
grow region: on tumour bud map Marker 1 at TissueLevel: <-
_TempClass1
merge region: on tumour bud map Marker 1 at TissueLevel: merge
region
pixel-based object resizing: on tumour bud map Marker 1 at
TissueLevel: shrink using Stroma
convert image objects: at TissueLevel: convert image objects ->
Connected 2D
merge region: on tumour bud map Stroma at TissueLevel: merge region
copy image object level: on tumour bud map at TissueLevel: copy
creating 'Nucleus level' below
synchronize map: on main at NucleusLevel: synchronize map 'tumour
bud map'
assign class: on tumour bud map Nucleus with Area < 16 µm² at
Nucleus level: Nucelar debris
assign class: on tumour bud map Nucleus with Standard deviation DAPI
< 6 and Mean DAPI < 40 at Nucleus level: false nucleus
assign class: on tumour bud map Marker 1 with Mean CK <= 50 at
TissueLevel: Non specific CK
assign class: on tumour bud map Marker 1 with Standard deviation CK
<= 10 at TissueLevel: Non specific CK
assign class: on tumour bud map Marker 1 with Number of sub objects
Nucleus (1) > 5 at TissueLevel: too big buds
assign class: on tumour bud map Marker 1 with Number of sub objects
Nucelar debris (1) >= 1 and Existence of sub objects Nucleus (1) < 1 at
TissueLevel: bud with debris nulceus
remove irrelevant marker 1 areas
assign class: on tumour bud map Marker 1 with Existence of sub objects
Nucleus (1) < 1 at TissueLevel: irrelevant marker
remainder of marker 1 = tumour bud
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on tumour bud map
assign class: Marker 1 at TissueLevel: tumour bud
create ROI and Tumour bud map and calculate distance to tumour
copy map: on tumour bud map : copy map to 'ROI and bud map'
on ROI and bud map
delete image object level: on ROI and bud map : delete 'Nucleus level'
copy image object level: at TissueLevel: copy creating 'vessel level'
below
synchronize map: on vessel map at TissueLevel: synchronize map
'ROI and bud map'
delete layer: delete image layer 'distance map'
copy image object level: at TissueLevel: copy creating
'CopyofTissueLevel' above
assign class: with Classified as Tumour = 0 at CopyofTissueLevel:
_TempClass1
convert image objects: at CopyofTissueLevel: convert image objects
-> Connected 2D
merge region: _TempClass1 at CopyofTissueLevel: merge region
distance map: _TempClass1 at CopyofTissueLevel: distance to
Tumour(distance map)
delete image object level: delete 'CopyofTissueLevel'
LVI and colocalisation
convert to sub-objects: at TissueLevel: convert to sub-objects
assign class: Stroma with Existence of sub objects D240 (1) = 1 at
TissueLevel: D240
assign class: tumour bud with Existence of sub objects D240 (1) =
1 at TissueLevel: Markers 1 and 2
assign class: bud with debris nulceus, irrelevant marker, too big
buds with Existence of sub objects D240 (1) = 1 at TissueLevel: non bud invasion
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assign class: tumour bud with Existence of D240 (0) = 1 at
TissueLevel: tumour bud border to marker 2
assign class: bud with debris nulceus, irrelevant marker, too big
buds with Existence of D240 (0) = 1 at TissueLevel: tumour border to marker 2
assign class: D240 with Existence of Markers 1 and 2 (0) = 1 at
TissueLevel: vessel border to bud invasion
convert image objects: at TissueLevel: convert image objects ->
Disconnected (fusion up)
convert image objects: at TissueLevel: convert image objects ->
Connected 2D
assign class: D240 with Existence of Tumour (0) = 1 at
TissueLevel: vessel border to tumour mass
calculate bud distance to tumour
on ROI and bud map
update variable: on ROI and bud map bud with debris nulceus, D240,
irrelevant marker, Markers 1 and 2, too big buds, tumour border to marker 2, tumour
bud, tumour bud border to marker 2, vessel border to bud invasion at TissueLevel:
distance to tumour = Mean distance map
update variable: D240 mean distance to tumour = 0
compute statistical value: on ROI and bud map D240 at TissueLevel:
D240 mean distance to tumour = mean(distance to tumour)
update variable: M1&2 mean distance to tumour = 0
compute statistical value: on ROI and bud map Markers 1 and 2 at
TissueLevel: M1&2 mean distance to tumour = mean(distance to tumour)
update variable: bud mean distance to tumour = 0
compute statistical value: on ROI and bud map tumour bud at
TissueLevel: bud mean distance to tumour = mean(distance to tumour)
update variable: debris bud mean distance to tumour = 0
compute statistical value: on ROI and bud map bud with debris
nulceus at TissueLevel: debris bud mean distance to tumour = mean(distance to
tumour)
update variable: irrelevant mean distance to tumour = 0
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compute statistical value: on ROI and bud map irrelevant marker at
TissueLevel: irrelevant mean distance to tumour = mean(distance to tumour)
update variable: big bud mean distance to tumour = 0
compute statistical value: on ROI and bud map too big buds at
TissueLevel: big bud mean distance to tumour = mean(distance to tumour)
update variable: tumour border to D240 mean distance to tumour = 0
compute statistical value: on ROI and bud map tumour border to
marker 2 at TissueLevel: tumour border to D240 mean distance to tumour =
mean(distance to tumour)
update variable: vessel border to bud invasion mean distance to
tumour = 0
compute statistical value: on ROI and bud map vessel border to bud
invasion at TissueLevel: vessel border to bud invasion mean distance to tumour =
mean(distance to tumour)
update variable: bud border to D240 mean distance to tumour = 0
compute statistical value: on ROI and bud map tumour bud border to
marker 2 at TissueLevel: bud border to D240 mean distance to tumour =
mean(distance to tumour)
statistical export of invasive eptihelial bodies
export object statistics: on ROI and bud map bud with debris nulceus,
D240, irrelevant marker, Markers 1 and 2, tumour bud, tumour bud border to marker
2, vessel border to bud invasion at TissueLevel: export object statistics
export object statistics: on ROI and bud map vessel border to tumour
mass at MarkerLevel: export object statistics
export object statistics: on tumour bud map bud with debris nulceus,
irrelevant marker, too big buds, tumour bud at TissueLevel: export object statistics
export object statistics: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: export object statistics
export object statistics: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 0 and Existence of super objects Stroma (1) = 1 at
Nucleus level: export object statistics
export object statistics: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: export object statistics
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calculate colocalisation stat
update variable: sum of area bud and vessel coloc = 0
compute statistical value: on ROI and bud map Markers 1 and 2 at
TissueLevel: sum of area bud and vessel coloc = sum(Area)
update variable: sum of area non-bud and vessel coloc = 0
compute statistical value: on ROI and bud map non bud invasion at
TissueLevel: sum of area non-bud and vessel coloc = sum(Area)
update variable: number of marker 1 and 2 = 0
compute statistical value: on ROI and bud map Markers 1 and 2 at
TissueLevel: number of marker 1 and 2 = number
update variable: number of non bud invasion = 0
compute statistical value: on ROI and bud map non bud invasion at
TissueLevel: number of non bud invasion = number
calculate tumour bud stat
update variable: number of buds = 0
compute statistical value: on tumour bud map tumour bud at TissueLevel:
number of buds = number
update variable: no. of big buds = 0
compute statistical value: on tumour bud map too big buds at TissueLevel:
no. of big buds = number
update variable: bud with <=2 nuc = 0
compute statistical value: on tumour bud map tumour bud with Number of
sub objects Nucleus (1) <= 2 at TissueLevel: bud with <=2 nuc = number
update variable: bud with >=3 nuc = 0
compute statistical value: on tumour bud map tumour bud with Number of
sub objects Nucleus (1) >= 3 at TissueLevel: bud with >=3 nuc = number
update variable: sum area of buds = 0
calculate vessel stat
update variable: number of vessels = 0
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compute statistical value: on vessel map D240 with Existence of Stroma (0)
= 1 at TissueLevel: number of vessels = number
update variable: sum area of vessels = 0
compute statistical value: on vessel map D240 at TissueLevel: sum area of
vessels = sum(Area)
update variable: on vessel map D240 at TissueLevel: Individual vessel area
= Area
export project statistics: on ROI and bud map : export project statistics
export project statistics: on tumour bud map : export project statistics
calculate LVD and export vessel stats
export project statistics: on vessel map : export project statistics
export object statistics: on vessel map D240 at TissueLevel: export object
statistics
Appendix 10. Nuclear morphometric export parameters
tumour subpopulation parameter
nuc in bud_asymmetry











































Average CK Intensity (Tumour Area) (mean)
Layer mean of CK tumour bud (mean)
Layer mean of CK Large tumour buds (mean)
Appendix 11. TMA Tumour subpopulation algorithm settings

















































Layer 4 Layer 4
Layer 5 Layer 5
Layer 6 Layer 6
Layer 7 Layer 7
Layer 8 Layer 8
Layer 9 Layer 9
Layer 10 Layer 10
Layer 11 Layer 11
Layer 12 Layer 12
Production Mode FALSE
Action Tissue - Background Separation








Use Layers panCK, B-Cat, DAPI,
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Action Composer: Create Region
Select Class Tumour
Select Distance (µm) 2
Simple Region Grow TRUE




Condition 1 Area < 3500
Action ROI Correction
Interrupt on Server FALSE
Store ROI classification TRUE
Action Initialize Cellular Analysis
Analyze ROI 1 FALSE
Analyze ROI 2 FALSE
Analyze ROI 3 FALSE
Analyze Necrosis TRUE
Analyze no tissue TRUE
Analyze Stroma TRUE
Analyze Tumour TRUE






Typical Nucleus Size (µm²) 60
Export a Screenshot TRUE
Action Cell Simulation
Simulation Mode Simulate inside cytoplasmic stain
Select Cytoplasm Layer panCK,
Marker Threshold 44.87
Typical Cell Size (µm²) 132
Export a Screenshot TRUE
Action Cell Classification







Remove Excluded Cells FALSE
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Export a Screenshot TRUE
Action Default Export
Export a Screenshot FALSE
ROI Statistics TRUE
Cellular Analysis Statistics TRUE
Part 2. Developer XD tumour subpopulation creation and biomarker
quantification.
Process: Main:
Creation of CK subpopulations
reset
delete map: on subpopulation map : delete map
delete map: on false cell map : delete map
copy map: copy map to 'subpopulation map'
copy map: copy map to 'false cell map'
negate stromal cells from buds
grow cytoplam into CK areas
delete image object level: on false cell map : delete 'CellLevel'
pixel-based object resizing: loop: on false cell map Cytoplasm at
NucleusLevel: grow into unclassified where CK>=35
clean up false CK positive cells
assign class: Nucleus with Rel. border to Cytoplasm <= 0.3 and Existence
of super objects Stroma (1) = 1 at NucleusLevel: Negative Nucleus
assign class: Nucleus with Mean CK <= 16 and Existence of super objects
Stroma (1) = 1 at NucleusLevel: Negative Nucleus
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assign class: Nucleus with Existence of super objects Stroma (2) = 1 and
Area <= 60 µm² at NucleusLevel: tempclass02
assign class: tempclass02 with Mean CK <= 40 at NucleusLevel:
tempclass4
assign class: tempclass4 with Rel. border to Cytoplasm >= 0.4 at
NucleusLevel: Nucleus
assign class: tempclass02 with Rel. border to Cytoplasm >= 0.45 at
NucleusLevel: Nucleus
assign class: tempclass02 at NucleusLevel: Negative Nucleus
assign class: tempclass4 at NucleusLevel: Negative Nucleus
merge maps together for correct cell segmentation
delete image object level: delete 'NucleusLevel'
copy image object level: at CellLevel: copy creating 'NucleusLevel' below
synchronize map: on false cell map at NucleusLevel: synchronize map
'subpopulation map'
assign class: Cell Stained Subclasses (excl. Negative) with Existence of sub
objects Negative Nucleus (1) = 1 and Existence of sub objects Nucleus (1) = 0 at
CellLevel: Cell Negative
grow cells into CK areas
pixel-based object resizing: loop: on subpopulation map Cell Stained
Subclasses (excl. Negative) at CellLevel: grow into all where CK>=35
find enclosed by class: loop: unclassified at CellLevel: enclosed by Cell
High: Temp class01 +
grow region: loop: Cell High at CellLevel: <- Temp class01
find enclosed by class: loop: on subpopulation map unclassified at
CellLevel: enclosed by Cell Medium: Temp class01 +
grow region: loop: Cell Medium at CellLevel: <- Temp class01
find enclosed by class: loop: on subpopulation map unclassified at
CellLevel: enclosed by Cell Low: Temp class01 +
grow region: loop: Cell Low at CellLevel: <- Temp class01
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find enclosed by class: loop: on subpopulation map unclassified at
CellLevel: enclosed by Cell Negative: Temp class01 +
grow region: loop: Cell Negative at CellLevel: <- Temp class01
clean up false nuclei
assign class: on subpopulation map Nucleus with Area <= 14 µm² at
NucleusLevel: debris nucleus
assign class: Nucleus with Mean Layer 3 <= 40 and Standard deviation
Layer 3 <= 6 at NucleusLevel: false nucleus
\\ Merge panCk positive cells to create subpopulations in stroma and in tumour
depending on low, medium and high CK intensity
merge subpopulations
merge stromal subpopulations
copy image object level: at CellLevel: copy creating 'subpop level' above
merge region: Cell Stained Subclasses (excl. Negative) with Existence of
super objects Stroma (1) = 1 at subpop level: merge region
assign regions on subpopulation map
assign class: Cell Stained Subclasses (excl. Negative) with Number of
sub objects Cell (1) <= 5 and Existence of super objects Stroma (1) = 1 at subpop
level: tumour bud
assign class: Cell Stained Subclasses (excl. Negative) with Number of
sub objects Cell (1) >= 6 at subpop level: BigTumour bud
merge tumour subpopulations
merge region: Cell High with Existence of super objects Tumour (1) = 1
at subpop level: merge region
merge region: Cell Low, Cell Negative with Existence of super objects
Tumour (1) = 1 at subpop level: merge region
merge region: Cell Medium with Existence of super objects Tumour (1)
= 1 at subpop level: merge region
assign class: Cell High with Existence of super objects Tumour (1) = 1
at subpop level: Tumour high CK
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assign class: Cell Medium with Existence of super objects Tumour (1) =
1 at subpop level: Tumour medium CK
assign class: Cell Low, Cell Negative with Existence of super objects
Tumour (1) = 1 at subpop level: Tumour low CK
Export results
export nuclear morphometry in subpops
export object statistics: Nucleus with Existence of super objects tumour
bud (2) = 1 at NucleusLevel: export object statistics
export object statistics: Nucleus with Existence of super objects
BigTumour bud (2) = 1 at NucleusLevel: export object statistics
export object statistics: Negative Nucleus with Existence of super objects
Cell Negative (2) = 1 at NucleusLevel: export object statistics
export object statistics: Nucleus with Existence of super objects Tumour
high CK (2) = 1 at NucleusLevel: export object statistics
export object statistics: Nucleus with Existence of super objects Tumour
medium CK (2) = 1 at NucleusLevel: export object statistics
export object statistics: Cytoplasm with Existence of super objects
Tumour low CK (2) = 1 at NucleusLevel: export object statistics
calculate mean nuclear stats in stroma
update variable: nuc in stroma_meanTarget = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 and Existence of super objects
Stroma (3) = 0 at NucleusLevel: nuc in stroma_meanTarget = mean(Mean Layer 2)
update variable: Cyto in stroma_meanTarget = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects Cell Negative (2) = 1 and Existence of super objects
Stroma (3) = 0 at NucleusLevel: Cyto in stroma_meanTarget = mean(Mean Layer
2)
update variable: nuc in stroma_meanCK = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_meanCK = mean(Mean CK)
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update variable: cyto in stroma_meanCK = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects Cell Negative (2) = 1 and Existence of super objects
Stroma (3) = 1 at NucleusLevel: cyto in stroma_meanCK = mean(Mean CK)
update variable: nuc in stroma_meanDAPI = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_meanDAPI = mean(Mean Layer 3)
update variable: nuc in stroma_mean_stdev_CK = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_stdev_CK = mean(Standard deviation CK)
update variable: nuc in stroma_mean_stdev_D240 = 0
compute statistical value: on subpopulation map Negative Nucleus,
Nucleus with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc
in stroma_mean_stdev_D240 = mean(Standard deviation Layer 2)
update variable: nuc in stroma_mean_stdev_DAPI = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_stdev_DAPI = mean(Standard deviation Layer 3)
update variable: nuc in stroma_mean_Ratio_CK = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_Ratio_CK = mean(Ratio CK)
update variable: nuc in stroma_mean_Ratio_D240 = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_Ratio_D240 = mean(Ratio Layer 2)
update variable: nuc in stroma_mean_Ratio_DAPI = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_Ratio_DAPI = mean(Ratio Layer 3)
update variable: nuc in stroma_mean_Area = 0
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compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_Area = mean(Area)
update variable: nuc in stroma_mean_borderlength = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_borderlength = mean(Border length)
update variable: nuc in stroma_mean_length = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_length = mean(Length)
update variable: nuc in stroma_asymmetry = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_asymmetry = mean(Asymmetry)
update variable: nuc in stroma_border index = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_border index = mean(Border index)
update variable: nuc in stroma_mean_lengthwidth = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_lengthwidth = mean(Length\Width)
update variable: nuc in stroma_mean_perimeter = 0
compute statistical value: on Screenshot Negative Nucleus with
Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_perimeter = mean(Perimeter)
update variable: nuc in stroma_mean_width = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_width = mean(Width)
update variable: nuc in stroma_mean_circularity = 0
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compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_circularity = mean(Circularity)
update variable: nuc in stroma_mean_compactness = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_compactness = mean(Compactness)
update variable: nuc in stroma_mean_density = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_density = mean(Density)
update variable: nuc in stroma_mean_Ellipticity = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_Ellipticity = mean(Ellipticity)
update variable: nuc in stroma_mean_Roundness = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_Roundness = mean(Roundness)
update variable: nuc in stroma_mean_Shape index = 0
compute statistical value: on subpopulation map Negative Nucleus
with Existence of super objects Cell Negative (2) = 1 at NucleusLevel: nuc in
stroma_mean_Shape index = mean(Shape index)
calculate mean intensities tum buds
update variable: nuc in tumourbud_meanTarget = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects tumour bud (2) = 1 at NucleusLevel: nuc in
tumourbud_meanTarget = mean(Mean Layer 2)
update variable: Cyto in tumourbud_meanTarget = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects tumour bud (2) = 1 at NucleusLevel: Cyto in
tumourbud_meanTarget = mean(Mean Layer 2)
update variable: nuc in tumourbud_meanCK = 0
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compute statistical value: on subpopulation map Nucleus with
Existence of super objects tumour bud (2) = 1 at NucleusLevel: nuc in
tumourbud_meanCK = mean(Mean CK)
update variable: Cyto in tumourbud_meanCK = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects tumour bud (2) = 1 at NucleusLevel: Cyto in
tumourbud_meanCK = mean(Mean CK)
update variable: Nuc in tumourbud_meanDAPI = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects tumour bud (2) = 1 at NucleusLevel: Nuc in
tumourbud_meanDAPI = mean(Mean Layer 3)
calculate mean intensities large tum buds
update variable: nuc in BIGtumourbud_meanTarget = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects BigTumour bud (2) = 1 at NucleusLevel: nuc in
BIGtumourbud_meanTarget = mean(Mean Layer 2)
update variable: Cyto in BIGtumourbud_meanTarget = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects BigTumour bud (2) = 1 at NucleusLevel: Cyto in
BIGtumourbud_meanTarget = mean(Mean Layer 2)
update variable: nuc in BIGtumourbud_meanCK = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects BigTumour bud (2) = 1 at NucleusLevel: nuc in
BIGtumourbud_meanCK = mean(Mean CK)
update variable: Cyto in BIGtumourbud_meanCK = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects BigTumour bud (2) = 1 at NucleusLevel: Cyto in
BIGtumourbud_meanCK = mean(Mean CK)
update variable: nuc in BIGtumourbud_meanDAPI = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects BigTumour bud (2) = 1 at NucleusLevel: nuc in
BIGtumourbud_meanDAPI = mean(Mean Layer 3)
calculate mean intensities tumour HIGH
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update variable: nuc in TumHIGH_meanTarget = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects Tumour high CK (2) = 1 at NucleusLevel: nuc in
TumHIGH_meanTarget = mean(Mean Layer 2)
update variable: Cyto in TumHIGH_meanTarget = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects Tumour high CK (2) = 1 at NucleusLevel: Cyto in
TumHIGH_meanTarget = mean(Mean Layer 2)
update variable: nuc in TumHIGH_meanCK = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects Tumour high CK (2) = 1 at NucleusLevel: nuc in
TumHIGH_meanCK = mean(Mean CK)
update variable: Cyto in TumHIGH_meanCK = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects Tumour high CK (2) = 1 at NucleusLevel: Cyto in
TumHIGH_meanCK = mean(Mean CK)
update variable: nuc in TumHIGH_meanDAPI = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects Tumour high CK (2) = 1 at NucleusLevel: nuc in
TumHIGH_meanDAPI = mean(Mean Layer 3)
calculate mean intensities tumour MED
update variable: nuc in TumMED_meanTarget = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects Tumour medium CK (2) = 1 at NucleusLevel: nuc in
TumMED_meanTarget = mean(Mean Layer 2)
update variable: Cyto in TumMED_meanTarget = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects Tumour medium CK (2) = 1 at NucleusLevel: Cyto in
TumMED_meanTarget = mean(Mean Layer 2)
update variable: nuc in TumMED_meanCK = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects Tumour medium CK (2) = 1 at NucleusLevel: nuc in
TumMED_meanCK = mean(Mean CK)
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update variable: Cyto in TumMED_meanCK = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects Tumour medium CK (2) = 1 at NucleusLevel: Cyto in
TumMED_meanCK = mean(Mean CK)
update variable: nuc in TumMED_meanDAPI = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects Tumour medium CK (2) = 1 at NucleusLevel: nuc in
TumMED_meanDAPI = mean(Mean Layer 3)
calculate mean intensities tumour LOW
update variable: nuc in TumLOW_meanTarget = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects Tumour low CK (2) = 1 at NucleusLevel: nuc in
TumLOW_meanTarget = mean(Mean Layer 2)
update variable: Cyto in TumLOW_meanTarget = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects Tumour low CK (2) = 1 at NucleusLevel: Cyto in
TumLOW_meanTarget = mean(Mean Layer 2)
update variable: nuc in TumLOW_meanCK = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects Tumour low CK (2) = 1 at NucleusLevel: nuc in
TumLOW_meanCK = mean(Mean CK)
update variable: Cyto in TumLOW_meanCK = 0
compute statistical value: on subpopulation map Cytoplasm with
Existence of super objects Tumour low CK (2) = 1 at NucleusLevel: Cyto in
TumLOW_meanCK = mean(Mean CK)
update variable: nuc in TumLOW_meanDAPI = 0
compute statistical value: on subpopulation map Nucleus with
Existence of super objects Tumour low CK (2) = 1 at NucleusLevel: nuc in
TumLOW_meanDAPI = mean(Mean Layer 3)
export subpopulation stats
export object statistics: Cell Negative at subpop level: export object
statistics
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export object statistics: tumour bud at subpop level: export object
statistics
export object statistics: BigTumour bud at subpop level: export object
statistics
export object statistics: Tumour high CK at subpop level: export object
statistics
export object statistics: Tumour medium CK at subpop level: export
object statistics
export object statistics: Tumour low CK at subpop level: export object
statistics
export cytoplasmic intensity in subpops
export object statistics: Cytoplasm with Existence of super objects
tumour bud (2) = 1 at NucleusLevel: export object statistics
export object statistics: Cytoplasm with Existence of super objects
BigTumour bud (2) = 1 at NucleusLevel: export object statistics
export object statistics: Cytoplasm with Existence of super objects Cell
Negative (2) = 1 at NucleusLevel: export object statistics
export object statistics: Cytoplasm with Existence of super objects
Tumour high CK (2) = 1 at NucleusLevel: export object statistics
export object statistics: Cytoplasm with Existence of super objects
Tumour medium CK (2) = 1 at NucleusLevel: export object statistics
export nuclear intensity in subpops
export object statistics: Nucleus with Existence of super objects tumour
bud (2) = 1 at NucleusLevel: export object statistics
export object statistics: Nucleus with Existence of super objects
BigTumour bud (2) = 1 at NucleusLevel: export object statistics
export object statistics: Nucleus with Existence of super objects Cell
Negative (2) = 1 at NucleusLevel: export object statistics
export object statistics: Nucleus with Existence of super objects Tumour
high CK (2) = 1 at NucleusLevel: export object statistics
export object statistics: Nucleus with Existence of super objects Tumour
medium CK (2) = 1 at NucleusLevel: export object statistics
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export mean nuc stats
export project statistics: on subpopulation map : export project statistics
Appendix 12. Tissue Phenomics Aanalyser algorithm settings
optimisation of tumour bud and LVI
reset
delete map: on tumour bud map : delete map
delete map: on vessel map : delete map
delete map: on copy of main : delete map
delete map: on LVI colocalisation map : delete map
delete map: on ROI and bud map : delete map
copy map: copy map to 'tumour bud map'
copy map: copy map to 'vessel map'
remove all objects but marker one on tumour bud
on tumour bud map
delete image object level: delete 'NucleusLevel'
remove objects: loop: Marker 2 at MarkerLevel: remove objects into
unclassified (merge by shape)
assign class: Markers 1 and 2 at MarkerLevel: Marker 1
merge region: Marker 1 at MarkerLevel: merge region
assign class: Marker 2 at MarkerLevel: unclassified
convert image objects: at MarkerLevel: convert image objects ->
Connected 2D
merge region: unclassified at MarkerLevel: merge region
assign class: Marker 1 with Existence of super objects Tumour (1) = 1 at
MarkerLevel: marker 1 in tumour
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assign class: Marker 1 with Existence of super objects necrosis (1) = 1 at
MarkerLevel: marker 1 in tumour
assign class: Marker 1 with Existence of super objects no tissue (1) = 1
at MarkerLevel: marker 1 in no tissue
copy image object level: at TissueLevel: copy creating
'CopyofTissueLevel' above
assign class: with Classified as no tissue = 0 at CopyofTissueLevel:
_TempClass1
convert image objects: at CopyofTissueLevel: convert image objects ->
Connected 2D
merge region: _TempClass1, Tumour at CopyofTissueLevel: merge
region
distance map: at CopyofTissueLevel: distance to no tissue(distance map)
delete image object level: delete 'CopyofTissueLevel'
convert to sub-objects: at TissueLevel: convert to sub-objects
assign class: with Existence of sub objects Marker 1 (1) = 1 at
TissueLevel: Marker 1
convert image objects: at TissueLevel: convert image objects ->
Disconnected (fusion up)
convert image objects: at TissueLevel: convert image objects ->
Connected 2D
update variable: Marker 1 at TissueLevel: distance to no tissue = Mean
distance map
assign class: Marker 1 with distance to no tissue <= 50 at TissueLevel:
edge effect
assign class: Marker 1 with Area <= 55 µm² at TissueLevel: necrotic
debris
remove all objects but marker two on vessel map
on vessel map
delete image object level: delete 'NucleusLevel'
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remove objects: loop: Marker 1 at MarkerLevel: remove objects into
unclassified (merge by shape)
assign class: Markers 1 and 2 at MarkerLevel: Marker 2
pixel-based object resizing: loop: on vessel map Marker 2 at
MarkerLevel: grow into unclassified where D240>=40
find enclosed by class: on vessel map at MarkerLevel: enclosed by
Marker 2: Marker 2 +
merge region: on vessel map Marker 2 at MarkerLevel: merge region
assign class: Marker 1 at MarkerLevel: unclassified
convert image objects: at MarkerLevel: convert image objects ->
Connected 2D
merge region: unclassified at MarkerLevel: merge region
assign class: Marker 2 with Existence of super objects Tumour (1) = 1 at
MarkerLevel: marker 2 in tumour
assign class: Marker 2 with Existence of super objects necrosis (1) = 1 at
MarkerLevel: marker 2 in tumour
assign class: Marker 2 with Existence of super objects no tissue (1) = 1
at MarkerLevel: marker 2 in no tissue
copy image object level: at TissueLevel: copy creating
'CopyofTissueLevel' above
assign class: with Classified as no tissue = 0 at CopyofTissueLevel:
_TempClass2
convert image objects: at CopyofTissueLevel: convert image objects ->
Connected 2D
merge region: _TempClass2, Tumour at CopyofTissueLevel: merge
region
distance map: at CopyofTissueLevel: distance to no tissue(distance map)
delete image object level: delete 'CopyofTissueLevel'
convert to sub-objects: at TissueLevel: convert to sub-objects
assign class: with Existence of sub objects Marker 2 (1) = 1 at
TissueLevel: Marker 2
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convert image objects: at TissueLevel: convert image objects ->
Disconnected (fusion up)
convert image objects: at TissueLevel: convert image objects ->
Connected 2D
update variable: Marker 2 at TissueLevel: distance to no tissue = Mean
distance map
assign class: Marker 2 with distance to no tissue <= 50 at TissueLevel:
edge effect
assign class: on vessel map Marker 2 at TissueLevel: D240
evaluate tumour buds
fill holes in buds and evaluate nuclei in buds
pixel-based object resizing: on tumour bud map Marker 1 at
TissueLevel: grow into Stroma
find enclosed by class: on tumour bud map at TissueLevel: enclosed by
Marker 1: _TempClass1 +
grow region: on tumour bud map Marker 1 at TissueLevel: <-
_TempClass1
merge region: on tumour bud map Marker 1 at TissueLevel: merge
region
pixel-based object resizing: on tumour bud map Marker 1 at
TissueLevel: shrink using Stroma
convert image objects: at TissueLevel: convert image objects ->
Connected 2D
merge region: on tumour bud map Stroma at TissueLevel: merge region
copy image object level: on tumour bud map at TissueLevel: copy
creating 'Nucleus level' below
synchronize map: on main at NucleusLevel: synchronize map 'tumour
bud map'
assign class: on tumour bud map Nucleus with Area < 16 µm² at
Nucleus level: Nucelar debris
assign class: on tumour bud map Nucleus with Standard deviation DAPI
< 6 and Mean DAPI < 40 at Nucleus level: false nucleus
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assign class: on tumour bud map Marker 1 with Mean CK <= 50 at
TissueLevel: Non specific CK
assign class: on tumour bud map Marker 1 with Standard deviation CK
<= 10 at TissueLevel: Non specific CK
assign class: on tumour bud map Marker 1 with Number of sub objects
Nucleus (1) > 5 at TissueLevel: too big buds
assign class: on tumour bud map Marker 1 with Number of sub objects
Nucelar debris (1) >= 1 and Existence of sub objects Nucleus (1) < 1 at
TissueLevel: bud with debris nulceus
remove irrelevant marker 1 areas
assign class: on tumour bud map Marker 1 with Existence of sub objects
Nucleus (1) < 1 at TissueLevel: irrelevant marker
remainder of marker 1 = tumour bud
on tumour bud map
assign class: Marker 1 at TissueLevel: tumour bud
create ROI and Tumour bud map and calculate distance to tumour
copy map: on tumour bud map : copy map to 'ROI and bud map'
on ROI and bud map
delete image object level: on ROI and bud map : delete 'Nucleus level'
copy image object level: at TissueLevel: copy creating 'vessel level'
below
synchronize map: on vessel map at TissueLevel: synchronize map
'ROI and bud map'
delete layer: delete image layer 'distance map'
copy image object level: at TissueLevel: copy creating
'CopyofTissueLevel' above
assign class: with Classified as Tumour = 0 at CopyofTissueLevel:
_TempClass1
convert image objects: at CopyofTissueLevel: convert image objects
-> Connected 2D
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merge region: _TempClass1 at CopyofTissueLevel: merge region
distance map: _TempClass1 at CopyofTissueLevel: distance to
Tumour(distance map)
delete image object level: delete 'CopyofTissueLevel'
LVI and colocalisation
convert to sub-objects: at TissueLevel: convert to sub-objects
assign class: Stroma with Existence of sub objects D240 (1) = 1 at
TissueLevel: D240
assign class: tumour bud with Existence of sub objects D240 (1) =
1 at TissueLevel: Markers 1 and 2
assign class: bud with debris nulceus, irrelevant marker, too big
buds with Existence of sub objects D240 (1) = 1 at TissueLevel: non bud invasion
assign class: tumour bud with Existence of D240 (0) = 1 at
TissueLevel: tumour bud border to marker 2
assign class: bud with debris nulceus, irrelevant marker, too big
buds with Existence of D240 (0) = 1 at TissueLevel: tumour border to marker 2
assign class: D240 with Existence of Markers 1 and 2 (0) = 1 at
TissueLevel: vessel border to bud invasion
convert image objects: at TissueLevel: convert image objects ->
Disconnected (fusion up)
convert image objects: at TissueLevel: convert image objects ->
Connected 2D
assign class: D240 with Existence of Tumour (0) = 1 at
TissueLevel: vessel border to tumour mass
calculate bud distance to tumour
on ROI and bud map
update variable: on ROI and bud map bud with debris nulceus, D240,
irrelevant marker, Markers 1 and 2, too big buds, tumour border to marker 2, tumour
bud, tumour bud border to marker 2, vessel border to bud invasion at TissueLevel:
distance to tumour = Mean distance map
update variable: D240 mean distance to tumour = 0
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compute statistical value: on ROI and bud map D240 at TissueLevel:
D240 mean distance to tumour = mean(distance to tumour)
update variable: M1&2 mean distance to tumour = 0
compute statistical value: on ROI and bud map Markers 1 and 2 at
TissueLevel: M1&2 mean distance to tumour = mean(distance to tumour)
update variable: bud mean distance to tumour = 0
compute statistical value: on ROI and bud map tumour bud at
TissueLevel: bud mean distance to tumour = mean(distance to tumour)
update variable: debris bud mean distance to tumour = 0
compute statistical value: on ROI and bud map bud with debris
nulceus at TissueLevel: debris bud mean distance to tumour = mean(distance to
tumour)
update variable: irrelevant mean distance to tumour = 0
compute statistical value: on ROI and bud map irrelevant marker at
TissueLevel: irrelevant mean distance to tumour = mean(distance to tumour)
update variable: big bud mean distance to tumour = 0
compute statistical value: on ROI and bud map too big buds at
TissueLevel: big bud mean distance to tumour = mean(distance to tumour)
update variable: tumour border to D240 mean distance to tumour = 0
compute statistical value: on ROI and bud map tumour border to
marker 2 at TissueLevel: tumour border to D240 mean distance to tumour =
mean(distance to tumour)
update variable: vessel border to bud invasion mean distance to
tumour = 0
compute statistical value: on ROI and bud map vessel border to bud
invasion at TissueLevel: vessel border to bud invasion mean distance to tumour =
mean(distance to tumour)
update variable: bud border to D240 mean distance to tumour = 0
compute statistical value: on ROI and bud map tumour bud border to
marker 2 at TissueLevel: bud border to D240 mean distance to tumour =
mean(distance to tumour)
statistical export of invasive eptihelial bodies
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export object statistics: on ROI and bud map bud with debris nulceus,
D240, irrelevant marker, Markers 1 and 2, tumour bud, tumour bud border to marker
2, vessel border to bud invasion at TissueLevel: export object statistics
export object statistics: on ROI and bud map vessel border to tumour
mass at MarkerLevel: export object statistics
export object statistics: on tumour bud map bud with debris nulceus,
irrelevant marker, too big buds, tumour bud at TissueLevel: export object statistics
export object statistics: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: export object statistics
export object statistics: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 0 and Existence of super objects Stroma (1) = 1 at
Nucleus level: export object statistics
export object statistics: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: export object statistics
calculate colocalisation stat
update variable: sum of area bud and vessel coloc = 0
compute statistical value: on ROI and bud map Markers 1 and 2 at
TissueLevel: sum of area bud and vessel coloc = sum(Area)
update variable: sum of area non-bud and vessel coloc = 0
compute statistical value: on ROI and bud map non bud invasion at
TissueLevel: sum of area non-bud and vessel coloc = sum(Area)
update variable: sum of area of vessel border to bud invasion = 0
compute statistical value: on ROI and bud map vessel border to bud
invasion at TissueLevel: sum of area of vessel border to bud invasion = sum(Area)
update variable: number of bordering bud and vessel = 0
compute statistical value: on ROI and bud map tumour bud border to marker
2 at TissueLevel: number of bordering bud and vessel = number
update variable: number of bordering tumour and vessel = 0
compute statistical value: on ROI and bud map tumour border to marker 2 at
TissueLevel: number of bordering tumour and vessel = number
update variable: number of vessel border to bud invasion = 0
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compute statistical value: on ROI and bud map vessel border to bud
invasion at TissueLevel: number of vessel border to bud invasion = number
update variable: number of marker 1 and 2 = 0
compute statistical value: on ROI and bud map Markers 1 and 2 at
TissueLevel: number of marker 1 and 2 = number
update variable: number of non bud invasion = 0
compute statistical value: on ROI and bud map non bud invasion at
TissueLevel: number of non bud invasion = number
calculate tumour bud stat
update variable: number of buds = 0
compute statistical value: on tumour bud map tumour bud at TissueLevel:
number of buds = number
update variable: no. of big buds = 0
compute statistical value: on tumour bud map too big buds at TissueLevel:
no. of big buds = number
update variable: bud with <=2 nuc = 0
compute statistical value: on tumour bud map tumour bud with Number of
sub objects Nucleus (1) <= 2 at TissueLevel: bud with <=2 nuc = number
update variable: bud with >=3 nuc = 0
compute statistical value: on tumour bud map tumour bud with Number of
sub objects Nucleus (1) >= 3 at TissueLevel: bud with >=3 nuc = number
update variable: sum area of buds = 0
compute statistical value: on tumour bud map tumour bud at TissueLevel:
sum area of buds = sum(Area)
update variable: on tumour bud map tumour bud at TissueLevel: Individual
bud area = Area
calculate vessel stat
update variable: number of vessels = 0
compute statistical value: on vessel map D240 with Existence of Stroma (0)
= 1 at TissueLevel: number of vessels = number
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update variable: sum area of vessels = 0
compute statistical value: on vessel map D240 at TissueLevel: sum area of
vessels = sum(Area)
update variable: on vessel map D240 at TissueLevel: Individual vessel area
= Area
calculate mean nuclear stats in stroma
update variable: nuc in stroma_meanD240 = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_meanD240 =
mean(Mean D240)
update variable: nuc in stroma_meanCK = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_meanCK =
mean(Mean CK)
update variable: nuc in stroma_meanDAPI = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_meanDAPI =
mean(Mean DAPI)
update variable: nuc in stroma_mean_stdev_CK = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_stdev_CK =
mean(Standard deviation CK)
update variable: nuc in stroma_mean_stdev_D240 = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_stdev_D240 =
mean(Standard deviation D240)
update variable: nuc in stroma_mean_stdev_DAPI = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_stdev_DAPI =
mean(Standard deviation DAPI)
update variable: nuc in stroma_mean_Ratio_CK = 0
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compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_Ratio_CK =
mean(Ratio CK)
update variable: nuc in stroma_mean_Ratio_D240 = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_Ratio_D240 =
mean(Ratio D240)
update variable: nuc in stroma_mean_Ratio_DAPI = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_Ratio_DAPI =
mean(Ratio DAPI)
update variable: nuc in stroma_mean_Area = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_Area =
mean(Area)
update variable: nuc in stroma_mean_borderlength = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_borderlength =
mean(Border length)
update variable: nuc in stroma_mean_length = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_length =
mean(Length)
update variable: nuc in stroma_asymmetry = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_asymmetry =
mean(Asymmetry)
update variable: nuc in stroma_border index = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_border index =
mean(Border index)
update variable: nuc in stroma_mean_lengthwidth = 0
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compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_lengthwidth =
mean(Length\Width)
update variable: nuc in stroma_mean_perimeter = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_perimeter =
mean(Perimeter)
update variable: nuc in stroma_mean_width = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_width =
mean(Width)
update variable: nuc in stroma_mean_circularity = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_circularity =
mean(Circularity)
update variable: nuc in stroma_mean_compactness = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_compactness =
mean(Compactness)
update variable: nuc in stroma_mean_density = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_density =
mean(Density)
update variable: nuc in stroma_mean_Ellipticity = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_Ellipticity =
mean(Ellipticity)
update variable: nuc in stroma_mean_Roundness = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_Roundness =
mean(Roundness)
update variable: nuc in stroma_mean_Shape index = 0
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compute statistical value: on tumour bud map Nucleus with Existence of
super objects Stroma (1) = 1 at Nucleus level: nuc in stroma_mean_Shape index =
mean(Shape index)
calculate mean nuclear stats in bud
update variable: nuc in bud_meanD240 = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_meanD240 =
mean(Mean D240)
update variable: nuc in bud_meanCK = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_meanCK =
mean(Mean CK)
update variable: nuc in bud_meanDAPI = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_meanDAPI =
mean(Mean DAPI)
update variable: nuc in bud_mean_stdev_CK = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_stdev_CK =
mean(Standard deviation CK)
update variable: nuc in bud_mean_stdev_D240 = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_stdev_D240 =
mean(Standard deviation D240)
update variable: nuc in bud_mean_stdev_DAPI = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_stdev_DAPI =
mean(Standard deviation DAPI)
update variable: nuc in bud_mean_Ratio_CK = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_Ratio_CK =
mean(Ratio CK)
update variable: nuc in bud_mean_Ratio_D240 = 0
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compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_Ratio_D240 =
mean(Ratio D240)
update variable: nuc in bud_mean_Ratio_DAPI = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_Ratio_DAPI =
mean(Ratio DAPI)
update variable: nuc in bud_mean_Area = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_Area =
mean(Area)
update variable: nuc in bud_mean_borderlength = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_borderlength =
mean(Border length)
update variable: nuc in bud_mean_length = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_length =
mean(Length)
update variable: nuc in bud_asymmetry = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_asymmetry =
mean(Asymmetry)
update variable: nuc in bud_border index = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_border index =
mean(Border index)
update variable: nuc in bud_mean_lengthwidth = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_lengthwidth =
mean(Length\Width)
update variable: nuc in bud_mean_perimeter = 0
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compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_perimeter =
mean(Perimeter)
update variable: nuc in bud_mean_width = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_width =
mean(Width)
update variable: nuc in bud_mean_circularity = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_circularity =
mean(Circularity)
update variable: nuc in bud_mean_compactness = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_compactness =
mean(Compactness)
update variable: nuc in bud_mean_density = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_density =
mean(Density)
update variable: nuc in bud_mean_Ellipticity = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_Ellipticity =
mean(Ellipticity)
update variable: nuc in bud_mean_Roundness = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_Roundness =
mean(Roundness)
update variable: nuc in bud_mean_Shape index = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects tumour bud (1) = 1 at Nucleus level: nuc in bud_mean_Shape index =
mean(Shape index)
calculate mean nuclear stats in tumour
update variable: nuc in tumour_meanD240 = 0
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compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_meanD240 =
mean(Mean D240)
update variable: nuc in tumour_meanCK = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_meanCK =
mean(Mean CK)
update variable: nuc in tumour_meanDAPI = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_meanDAPI =
mean(Mean DAPI)
update variable: nuc in tumour_mean_stdev_CK = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_stdev_CK =
mean(Standard deviation CK)
update variable: nuc in tumour_mean_stdev_D240 = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_stdev_D240 =
mean(Standard deviation D240)
update variable: nuc in tumour_mean_stdev_DAPI = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_stdev_DAPI =
mean(Standard deviation DAPI)
update variable: nuc in tumour_mean_Ratio_CK = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_Ratio_CK =
mean(Ratio CK)
update variable: nuc in tumour_mean_Ratio_D240 = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_Ratio_D240 =
mean(Ratio D240)
update variable: nuc in tumour_mean_Ratio_DAPI = 0
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compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_Ratio_DAPI =
mean(Ratio DAPI)
update variable: nuc in tumour_mean_Area = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_Area =
mean(Area)
update variable: nuc in tumour_mean_borderlength = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_borderlength =
mean(Border length)
update variable: nuc in tumour_mean_length = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_length =
mean(Length)
update variable: nuc in tumour_asymmetry = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_asymmetry =
mean(Asymmetry)
update variable: nuc in tumour_border index = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_border index =
mean(Border index)
update variable: nuc in tumour_mean_lengthwidth = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_lengthwidth =
mean(Length\Width)
update variable: nuc in tumour_mean_perimeter = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_perimeter =
mean(Perimeter)
update variable: nuc in tumour_mean_width = 0
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compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_width =
mean(Width)
update variable: nuc in tumour_mean_circularity = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_circularity =
mean(Circularity)
update variable: nuc in tumour_mean_compactness = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_compactness =
mean(Compactness)
update variable: nuc in tumour_mean_density = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_density =
mean(Density)
update variable: nuc in tumour_mean_Ellipticity = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_Ellipticity =
mean(Ellipticity)
update variable: nuc in tumour_mean_Roundness = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_Roundness =
mean(Roundness)
update variable: nuc in tumour_mean_Shape index = 0
compute statistical value: on tumour bud map Nucleus with Existence of
super objects Tumour (1) = 1 at Nucleus level: nuc in tumour_mean_Shape index =
mean(Shape index)
export LVI and bud stats
export project statistics: on ROI and bud map : export project statistics
export project statistics: on tumour bud map : export project statistics
export object statistics: on ROI and bud map Markers 1 and 2, non bud
invasion, tumour border to marker 2, tumour bud border to marker 2, vessel border to
bud invasion at TissueLevel: export object statistics
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export object statistics: on tumour bud map unclassified at Nucleus level:
export object statistics
export object statistics: on tumour bud map Stroma at Nucleus level: export
object statistics
calculate LVD and export vessel stats
export project statistics: on vessel map : export project statistics
export object statistics: on vessel map D240 at TissueLevel: export object
statistics
Appendix 13. Phenotypic fingerprint parameters


































































































































Parameters in bold and above the line are the 37 significant parameters reported from the Random
Forest model
7th  E D I T I O N
Primary Tumor (T)   
 TX  Primary tumor cannot be assessed
 T0  No evidence of primary tumor
 Tis  Carcinoma in situ: intraepithelial 
or invasion of lamina propria1
 T1  Tumor invades submucosa
 T2  Tumor invades muscularis propria
 T3  Tumor invades through the muscularis 
propria into pericolorectal tissues
 T4a  Tumor penetrates to the surface 
of the visceral peritoneum2
 T4b  Tumor directly invades or is adherent 
to other organs or structures2,3
Regional Lymph Nodes (N)4
 NX  Regional lymph nodes cannot be assessed
 N0  No regional lymph node metastasis
 N1  Metastasis in 1–3 regional lymph nodes
 N1a  Metastasis in one regional lymph node
 N1b  Metastasis in 2–3 regional lymph nodes
 N1c  Tumor deposit(s) in the subserosa, mesentery, 
or nonperitonealized pericolic or perirectal 
tissues without regional nodal metastasis
 N2  Metastasis in 4 or more regional lymph nodes
 N2a  Metastasis in 4–6 regional lymph nodes
 N2b  Metastasis in 7 or more regional lymph nodes
Distant Metastasis (M)
 M0  No distant metastasis
 M1  Distant metastasis
 M1a  Metastasis confined to one organ or site  
(for example, liver, lung, ovary, 
nonregional node)
 M1b  Metastases in more than one organ/site or  
the peritoneum
A N AT O M I C  S TA G E / P R O G N O S T I C  G R O U P S
Stage T N M Dukes* MAC*
0 Tis N0 M0 – –
I T1 N0 M0 A A
 T2 N0 M0 A B1
IIA T3 N0 M0 B B2
IIB T4a N0 M0 B B2
IIC T4b N0 M0 B B3
IIIA T1–T2 N1/N1c M0 C C1
 T1 N2a M0 C C1
IIIB T3–T4a N1/N1c M0 C C2
T2–T3 N2a M0 C C1/C2
T1–T2 N2b M0 C C1
IIIC T4a N2a M0 C C2
T3–T4a N2b M0 C C2
T4b N1–N2 M0 C C3
IVA Any T Any N M1a – –
IVB Any T Any N M1b – –
NOTE: cTNM is the clinical classification, pTNM is the 
pathologic classification. The y prefix is used for those 
cancers that are classified after neoadjuvant pretreatment 
(for example, ypTNM). Patients who have a complete 
pathologic response are ypT0N0cM0 that may be similar to 
Stage Group 0 or I. The r prefix is to be used for those cancers 
that have recurred after a disease-free interval (rTNM).
* Dukes B is a composite of better (T3 N0 M0) and worse  
(T4 N0 M0) prognostic  groups, as is Dukes C (any TN1 M0 and 
Any T N2 M0). MAC is the modified Astler-Coller classification.
Notes
1 Tis includes cancer cells confined within the glandular basement membrane (intraepithelial) or mucosal lamina propria (intramucosal) with no extension 
through the muscularis mucosae into the submucosa.
2 Direct invasion in T4 includes invasion of other organs or other segments of the colorectum as a result of direct extension through the serosa, as confirmed on 
microscopic examination (for example, invasion of the sigmoid colon by a carcinoma of the cecum) or, for cancers in a retroperitoneal or subperitoneal location, 
direct invasion of other organs or structures by virtue of extension beyond the muscularis propria (that is, a tumor on the posterior wall of the descending colon 
invading the left kidney or lateral abdominal wall; or a mid or distal rectal cancer with invasion of prostate, seminal vesicles, cervix, or vagina).
3 Tumor that is adherent to other organs or structures, grossly, is classified cT4b. However, if no tumor is present in the adhesion, microscopically, the classification 
should be pT1-4a depending on the anatomical depth of wall invasion. The V and L classifications should be used to identify the presence or absence of vascular 
or lymphatic invasion, whereas the PN site-specific factor should be used for perineural invasion.
4 A satellite peritumoral nodule in the pericolorectal adipose tissue of a primary carcinoma without histologic evidence of residual lymph node in the nodule may 
represent discontinuous spread, venous invasion with extravascular spread (V1/2), or a totally replaced lymph node (N1/2). Replaced nodes should be counted 
separately as positive nodes in the N category, whereas discontinuous spread or venous invasion should be classified and counted in the Site-Specific Factor 
category Tumor Deposits (TD).
Definitions
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